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Abstract 
 
In first part we have discussed about the pyrazoles, ring fused pyrazoles and their 
applications. Pyrazole derivatives display a broad spectrum of biological activities. In order to 
investigate new pyrazole derivatives, we have developed a simple regiocontrolled protocol of 
1,3-DC to get ring fused pyrazole derivatives. These pyrazole derivatives were synthesized using 
1,3-DC between nitrile imine and various dipolarophiles such as alkynes, cyclic α,β-ketones, 
lactones, thiocatones and lactums. The reactions were found to be highly regiospecific.  
When thio-actylenes were used, the reactions were found to be controlled by the 
oxidation state of the ‘S’ to give thienopyrazoles. ‘S’ in +2 state gives preference to 5-
regioisomer and in +6 state gives 4-regioisomer as major one. Reaction was also found to be 
affected by the use of a lewis acid catalyst like Sc(OTf)3, which leads to form  4-regioisomer as 
the prevalent isomer. This strategy was further used to synthesize a biologically active 
thienopyrazole molecule which showed some promising biological activity on nanomolar scale. 
When the cyclic α,β-ketones, lactones, thiocatones and lactams were used, reactions were 
found to be more substrate controlled as well. With small ring size we found the formation of 4-
regioisomer as major one with activated dipoles whereas with moderate or larger rings we found 
prevalence of 5-regioisomer. To demonstrate this reactivity we have developed a theoretical 
model which describes the trends in this type of reactions. Topological analysis further gave 
support to our assumption for existence of those theoretical models.  
In second part we have discussed about helicene, its properties, synthesis and applications 
as asymmetric catalyst. Helicenes are interesting carbocyclic compounds that involve ortho-
fused ring systems forming a helix.  Helicene compounds have numerous applications in modern 
chemistry, in biological systems and in molecular mechanics. Due to special structural 
arrangement they are chiral in nature. In this context of chirality, herein we have made an 
attempt to synthesize the helicene-thiourea based catalyst for asymmetric catalysis. The synthesis 
involved formation of two key intermediates viz, bromo-phenanthrene 5 and a vinyl-naphthalene 
10. The coupling of these two intermediates leads to formation of hexahelicene. We have 
described a simple route towards helicene synthesis.   
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Chapter 1 
1,3-Dipolar cylcoaddition (DC) reaction and Pyrazoles 
 
1.1   Introduction of 1,3-dipolar cycloadditon reactions: 
Cycloaddition is a pericyclic  reaction, in which "two or more unsaturated molecules (or 
parts of the same molecule) combine to form a cyclic adduct in which there is a net reduction of 
the bond multiplicity."1 The resulting reaction is a cyclization reaction. Many but not all 
cycloadditions are concerted. Cycloadditions are usually described by the backbone size of the 
participants. This would make the Diels-Alder reaction a (4 + 2) cycloaddition, the 1,3-dipolar 
cycloaddition a (3 + 2) cycloaddition and cyclopropanation of a carbene with an alkene a (2+1) 
cycloaddition. This type of reaction is non-polar addition reaction. 
1,3-dipolar cycloaddition reactions are those in which multiple unsaturated compounds 
combine to form a cyclic addition product. They combine 1,3-dipoles and dipolarophiles to form 
five-membered rings.2 The earliest 1,3-dipolar cycloadditions were described in the late 19th 
century to the early 20th century, following the discovery of 1,3-dipoles. Mechanistic 
investigation and synthetic applications were established in the 1960s, primarily through the 
work of Rolf Huisgen.3a Hence, the reaction is sometimes referred to as the Huisgen 
cycloaddition which involves the 1,3-dipolar cycloaddition between an organic azide and an 
alkyne to generate 1,2,3-triazole (Scheme 1.1). American chemist K. Barry Sharpless has 
referred to this cycloaddition as "the cream of the crop" of click chemistry.3bCurrently, 1,3-
dipolar cycloaddition is an important route to the regio- and stereoselective synthesis of five-
membered heterocycles and their ring-opened acyclic derivatives. 
 
Scheme 1.1: Huisgen cycloaddition between benzyl azide and (prop-2-yn-1-yloxy)benzene. 
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The first dipole methyl 2-diazo ester and its 1,3-DC with acrylate ester were discovered 
by Curtius3c and Buchner3d in 1880s.  The reaction product they found was pyrazoline compound 
(Scheme 1.2). 
 
Scheme1.2:  First 1,3-dipole and its 1,3-DC. 
 
This reaction has been developed into very general and useful method for synthesis of 
five-membered heterocycles and carbocycles. 
 
1.2  1,3-Dipoles and their properties: 
A 1,3-dipole is an organic compound. First 1,3-dipole, diazoacetic acid ester was 
discovered by Curtius3b in 1883 (Scheme 1.2). Then it was followed by series of invention of 
other dipoles viz. hydrazine (1887), hydrogen azide, nitrone (1890), nitrile oxide (1894), ozone 
(1903), nitrile imine (1934), azomethine imine (1958) azomethine ylide (1959), nitrile ylide 
(1960), carbonyl ylide (1965), azimine (1970) and thiocarbonyl ylide (1976). There are 18 well 
characterized 1,3-dipoles which forms a base for 1,3-DC reactions.   
 
They are divided into two categories, 
1.  Allyl anion type 
2. Propargyl/allenyl type zwitterionic octet/sextet structures.  
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The allyl anion type is bent and has four electrons in three parallel p-orbitals 
perpendicular to the plane of the dipole.3a There are a total of 12 allyl-type dipoles (Figure 1.1).  
 
Figure 1.1: Allyl anion 1,3-dipoles. 
 
The propargyl/allenyl anion type dipole is normally linear. The central atom is 
occasionally presented as hypervalent and is limited to nitrogen (Figure 1.2). The other dipole 
atoms can be carbon, oxygen and nitrogen. There are 6 number of propagyl/allenyl-type second-
row 1,3-dipoles (which consist of carbon, nitrogen and oxygen centers). 
 
Figure 1.2: Propargyl/allenyl type 1,3-dipoles. 
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1,3-Dipoles containing higher-row elements such as sulfur or phosphorus are also known, but are 
utilized less routinely. 
Resonance structures can be drawn to delocalize both negative and positive charges onto 
any terminus of a 1,3-dipole. A more accurate method to describe the electronic distribution on a 
1,3-dipole is to assign the major resonance contributor based on experimental or theoretical data, 
such as dipole moment measurements4 or computations.5 For example, diazomethane bears the 
largest negative character at the terminal nitrogen atom, while hydrazoic acid bears the largest 
negative character at the internal nitrogen atom (Scheme 1.3). This means that the termini of a 
1,3-dipole can be treated as both nucleophilic and electrophilic at the same time. The extent of 
nucleophilicity and electrophilicity at each terminus can be evaluated using the frontier 
molecular orbitals (FMO), which can be obtained computationally. In general, the atom that 
carries the largest orbital coefficient in the HOMO acts as the nucleophile, whereas that in the 
LUMO acts as the electrophile. The most nucleophilic atom is usually, but not always, the most 
electron-rich atom.6,7,8 
 
Scheme 1.3: Major resonance structures for diazomethane and hydrazoic acid. 
 
 
Dipolarophiles display less diversity than dipoles. The most commonly used 
dipolarophiles are substituted alkenes and alkynes. Double or triple bonds with heteroatoms like 
carbonyl, iminium and cyano groups can also be dipolarophiles. Other examples of 
dipolarophiles include fullerenes and nanotubes, which can undergo 1,3-dipolar cycloaddition 
with azomethine ylide in the Prato reaction. 
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1.3 Mechanism of 1,3-DC reactions: 
Originally it was thought to have two possible reaction mechanisms for 1,3-DC reactions, 
first one concerted reaction mechanism proposed by Rolf Huisgen10 and second one, stepwise 
reaction mechanism involving diradical intermediate proposed by Firestone11 (Scheme 1.4). In 
concerted mechanism, 1,3-DC involves 4 electrons from a dipole and 2 electrons from 
dipolarophile. According to the Woodward-Hoffmann rules,12 if 1,3-DC reaction proceeds via a 
concerted mechanism, three pz orbitals of 1,3-dipole and two pz  orbitals of a dipolarophile will 
combine suprafacially, symbolized as [  4s +   2s ] to give cycloadduct. 
 
Scheme 1.4: Concerted mechanism by Huisgen and diradical mechanism by Firestone. 
 
 
During the concerted reaction mechanism the stereochemistry of the reactants could be 
transferred to the product. For example, the 1,3-DC of diazomethane  with (Z)-methyl 2-
methylbut-2-enoate gave exclusively the trans-pyrazoline (Scheme 1.5).13 
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Scheme 1.5: Stereochemistry in 1,3-DC reaction. 
 
For those step-wise 1,3-DC involving some intermediates, the stereochemical 
information will be destroyed during these transformations. Therefore, after much debate the 
concerted mechanism is accepted, which is based on experimental evidances although there are 
some experimental evidances for the diradical mechanism as in above case (Scheme 1.5).14  
Concerted 1,3-DC can be interpreted by frontier molecular orbital theory (FMO).15 Based 
on FMO theory, three types of interactions are possible between the 1,3-dipole and dipolarophile 
(Figure 1.3).  
a. Type-I (Normal electron demand): In this type of FMO interaction, highest 
occupied molecular orbital (HOMO) of the dipole interact with the lowest unoccupied 
molecular orbital (LUMO) of the dipolarophile.  Here the dipole is considered as a 
nucleophilic dipole. Some e.g. of this type  includes azomethine ylide, carbonyl ylide, 
nitrile ylide, azomethine imine, carbonyl imine and diazoalkane. These dipoles add to 
electrophilic alkenes readily. Electron-withdrawing groups (EWG) on the 
dipolarophile would accelerate the reaction by lowering the LUMO, while electron-
donating groups (EDG) would decelerate the reaction by raising the HOMO (Figure 
1.3). e.g. Without any activation of either component, the reaction between an 
electron-rich dipole (e.g.TMS substituted carbonyl ylides) and an electron-deficient 
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dipolarophile (e.g.,dimethyl maleate)16  is dominated by the interaction between the 
dipole HOMO and the dipolarophile LUMO.    
 
Figure 1.3: FMO interaction in 1,3-DC. 
 
 
b. Type –II (Equal sharing): In this type HOMO of the dipole can pair with LUMO of 
the dipolarophile; alternatively, HOMO of the dipolarophile can pair with LUMO of 
the dipole. This two-way interaction arises because the energy gap in either direction 
is similar (Figure 1.3). A dipole of this class is referred to as a HOMO-LUMO-
controlled dipole or an ambiphilic dipole, which includes nitrile imine, nitrone, 
carbonyl oxide, nitrile oxide and azide. Any substituent on the dipolarophile would 
accelerate the reaction by lowering the energy gap between the two interacting 
orbitals i.e. EWG would lower the LUMO while EDG would raise the HOMO. 
c. Type-III (Inverse electron demand): These interactions are dominated by the 
reaction between the HOMO of the dipolarophile and the LUMO of the dipole. The 
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dipole has a low-lying LUMO which overlaps with HOMO of the dipolarophile. A 
dipole of this class is referred to as a LUMO-controlled dipole or an electrophilic 
dipole, which includes nitrous oxide and ozone. EWGs on the dipolarophile 
decelerate the reaction, while EDGs accelerate the reaction. Reaction between nitrile 
oxide and acetonitrile gives 1,2,4-oxadiazoles17 (Scheme1.6). 
 
Scheme 1.6: Example of Inverse electron demand. Reaction between nitrile oxide and nitrile. 
 
 
Even though some cases, like ozonolysis of olefins and addition of nitrile oxides to 
alkynes,18 proceed without additional promoters, many more substrate combinations result in no 
cycloadduct formation when dipole and dipoarophile are simply mixed. To accelerate those 
reactions, lewis acids like Scandium triflate are often used. 
 
1.4      Diazo dipole properties and synthesis: 
Diazo compounds are one of the reagents involved in 1,3-DC reactions for the synthesis 
of pyrazoles. In 1890’s, Buchner3c and Pechmann19 discovered the first [3+2] cycloaddition 
reaction using diazoacetate and diazomethane as dipole components respectively. After that, 
diazo compounds as well as azide compounds have been developed to be some of the most 
useful dipoles in organic synthesis over the past century. Diazo compounds are also used as 
precursors to carbenes, which are generated by thermolysis or photolysis, for example in the 
Wolff rearrangement. Certain diazo compounds can couple to form alkenes in a formal carbene 
dimerization reaction. Here the focus will be on use of diazo compounds as 1,3-dipoles in 1,3-
DC reactions to form pyrazoles. 
Several laboratory methods exist for synthesis of diazo compounds. Diazo compounds 
can be obtained by treatment of amine with nitrous acid, electrophilic substitution using 
diazomethyl compound with acyl halide but the major methods include diazo group transfer from 
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azides (Regitz diazo transfer reaction),20 dehydrogenation of hydrazones, alkaline cleavage of N-
alkyl-N-nitroso compounds (scheme1.7). 
 
Scheme 1.7: Synthesis of diazo compound. 
 
Diazo compounds reacts as 1,3-dipoles in diazoalkane 1,3-dipolar cycloadditions. In this 
reaction 1,3-dipole like diazomethane reacts with a dipolarophile (an alkene) to form a 
pyrazoline compound.21 The reaction product of a cycloaddition between diazomethane and 
trans-diethyl glutaconate is a 1-pyrazoline.22 This reaction is 100% regioselective because the 
diazo terminal nitrogen atom binds exclusively to the α-carbon of the ester. The reaction is also a 
syn addition, and the configuration in the dipolarophile is preserved. The 1-pyrazoline is unstable 
and isomerizes to the 2-pyrazoline due to favorable conjugation with the ester group (Scheme 
1.8). 
 
Scheme 1.8: 1,3-DC of diazomethane and trans-diethyl glutaconate. 
 
With phenyldiazomethane as the reactant, the regioselectivity is reversed and the reaction is 
extended further by oxidation of the 2-pyrazoline to the pyrazole.  
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The utility of 1,3-DC of diazo compounds has been expanded based on the investigation 
of novel dipolarophiles, such as functionalized carbon-carbon double and triple bonds, carbon-
hetereoatom double and triple bonds, and hetereoatom-hetereoatom double and triple bonds.2 
Among these dipolarophiles, alkenes and alkynes  have been extensively studied as 
cycloaddition partners for different types of diazo dipoles. Depending on the substitution of these 
two cycloaddition partners, the cycloaddition can yield dihydropyrazoles (pyrazolines) or, after 
1,2-elimination reaction, pyrazoles, while the treatment of the dipole with alkyne yields directly 
the pyrazole (Scheme 1.9). 
 
Scheme 1.9: 1,3-DC of diazo compounds. 
 
 
1.5      Pyrazoles background and properties: 
Pyrazole is a 5-membered heterocyclic diazole compound composed of three carbon 
atoms and two nitrogen atoms in adjacent positions. It is a prevalent scaffold in drug discovery 
programs. Being so composed and having pharmacological effects on humans, they are classified 
as alkaloids, even though they are rare in nature.  First natural pyrazole, 1-pyrazolyl-alanine was 
isolated in 1959 from seeds of watermelon23 (Figure 1.4).  Pyrazoles constitute an important 
class of biologically active compounds as they display broad spectrum of biological activities. As 
they are biologically important, they have applications in agrochemical and pharmaceutical 
industries as herbicides and active pharmaceuticals.  
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Figure 1.4: Pyrazole and first natural pyrazole 1-pyrazolyl-alanine. 
 
 
Derivatives of pyrazole are used for their anti-microbial,24 anti-inflammatory,25 
antipyretic,26 antiarrhythmic, tranquilizing, muscle relaxing, psychoanaleptic, anticonvulsant,27 
antibacterial28, anticancer,29 monoamineoxidase inhibiting, antidiabetic and selective enzyme 
inhibitory activities.30 The pyrazole ring is present as the core in a variety of leading nonsteroidal 
anti-inflammatory drugs (NSAIDs) and antihypertensive drugs. It has been found that these 
compounds have hypoglycemic activity, and are also known as inhibitors and deactivators of 
liver alcohol dehydrogenase and oxidoreductases.31 It has been shown in vivo that some of the 
pyrazole derivatives have appreciable antihypertensive activity.32 These compounds also exhibit 
properties such as cannabinoid hCB1 and hCB2 receptor, inhibitors of p38 Kinase, CB1 receptor 
antagonists.33  The 1-phenylpyrazole motif is present in several drug candidates for treatment of 
various diseases such as cyclooxygenase-2 (COX-2) inhibitors, IL-1 synthesis inhibitors, and 
protein kinase inhibitors etc. Similarly a few of the 1, 5 diarylpyrazole derivatives have been 
shown to exhibit non-nucleoside HIV-1 reverse transcriptase inhibitory activities along with 
Cox-2 inhibitor.34a Several substituted pyrazolo [3, 4-d] pyrimidine derivatives have xanthine 
oxidase inhibitor activity34b like allopurinol which was first synthesized by Robins in 1956 and is 
still the drug for the treatment of hyperuricemia and gouty arthritic disease.34c 
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Here are some of the representative examples of drugs containing pyrazole motif which 
are accounted for important biological activity (Figure 1.5). 
 
Figure 1.5: Some important drugs containing pyrazole moiety. 
 
 
1. Celecoxib (Celebrex): Celebrex35 is a sulfa non-steroidal anti-inflammatory drug 
(NSAID) and selective COX-2 inhibitor used in the treatment of osteoarthritis, 
rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to 
reduce numbers of colon and rectum polyps in patients with familial adenomatous 
polyposis and it is marketed by Pfizer. 
2. Viagra: Sildenafil citrate, sold as Viagra,36 Revatio and other trade names, is a drug used 
to treat erectile dysfunction and pulmonary arterial hypertension (PAH). It was originally 
developed by British scientists and then brought to market by the Pfizer. 
3. Lonazonac: Lonazolac is a non-steroidal anti-inflammatory drug. 
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4. Rimonabant : Also known as SR141716 sold with trade names Acomplia, Bethin, 
Monaslim, Remonabent, Riobant, Slimona, Rimoslim, Zimulti and Riomont. It is an 
anorectic antiobesity drug that has been withdrawn from the market. It is an inverse 
agonist for the cannabinoid receptor CB1.37 It’s main effect is reduction in appetite.  
 
5. Mepiprazole:  Mepiprazole (Psigodal) is a minor tranquilizer with a phenylpiperazine 
structure used in Spain for the treatment of anxiety neuroses.38 It acts as a 5-HT2A and α1-
adrenergic receptor antagonist,39 and has also been shown to inhibit the reuptake and 
induce the release of serotonin, dopamine, and norepinephrine to varying extents.[8][9] 
Similarly to other phenylpiperazines like trazodone, nefazodone, and etoperidone, 
mepiprazole produces mCPP as an active metabolite.40  
 
6. AS-19: AS-19 is a substance which acts as a potent agonist at the 5HT7 receptor, with an 
IC50 of 0.83 nM. It reverses the amnesia induced by drugs such as scopolamine and 
dizocilpine and improves long term memory acquisition, but inhibits short term memory 
formation.41 
 
Pyrazole derivative as anti-diabetic: 
Froesch E.E et.al.42 has reported anti-diabetic activity in the 5-methyl-1H-pyrazole-3-
carboxylic acid (Figure 1.6). 
 
Figure 1.6: Pyrazole derivative as anti-diabetic. 
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Pyrazole derivative as vasodilator: 
 Bruner H. R. et.al. 43 have reported vasodilator action in 4-(1-cyclohexyl-1H-
pyrazol-4-yl)pyridine (Figure 1.7). 
 
Figure 1.7: Pyrazole derivative as vasodilator. 
 
 
Pyrazole derivatives as hypoglycemic agents: 
Smith D. L. et. al.44 have reported that 1H-pyrrole-2,4-dicarboxylic acid  and 1,3,5-
trimethyl-1H-pyrazole exhibited hypoglycemic activity (Figure 1.8).  
 
Figure 1.8: Pyrazole derivatives as hypoglycemic agents. 
 
 
Pyrazole derivative as anti-inflammatory agents:  
Sarangan S. et.al.45 have synthesized number of derivatives of pyrazole- (3, 4-d) 
pyrimidine-4-6-diones (Figure 1.9) and reported the screening for C.N.S depression properties 
and anti-inflammatory activity. It was also reported that some derivatives showed anti- 
inflammatory properties equivalent to aspirin.  
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Figure 1.9: Pyrazole derivative as anti-inflammatory agents.  
 
 
Pyrazole derivative as anti-tumor agent: 
Peng-Cheng L.V. et. al.,46 synthesized a series of pyrazole derivatives. Following 1H-
pyrazole-1-carbothioamide shows high anti-proliferative activity against MCF-70 with IC50 0.08 
M (Figure 1.10). 
 
Figure 1.10: Pyrazole derivative as anti-tumor agent. 
N N
S
H2N
O
H3C
H3C
3-(3,4-dimethylphenyl)-5-(4-methoxyphenyl)-
4,5-dihydro-1H-pyrazole-1-carbothioamide
 
 
Pyrazole derivative as anti-microbial agent: 
 Samaail Radi et. al.47 synthesized pyrazole derivatives, which were found potent 
for anti-microbial activity (Figure 1.11).  
 
Figure 1.11: Pyrazole derivatives as anti-microbial agent. 
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1.6 Pyrazole synthesis: 
Owing to its biological significance, lot of efforts have been made for synthesis of 
pyrazoles and its analogues. The name “Pyrazole” was given by L. Knorr. In 1883, L. Knorr 
synthesized first pyrazole starting from a 1,3-dicarbonyl compound and a hydrazine derivative 
using a acid catalyst48 (Scheme 1.10).  
 
Scheme 1.10: Knorr synthesis of pyrazole. 
 
In this reaction depending on the substituents in the starting materials, two regioisomers 
may or may not form as shown in the above scheme. Following L. Knorr in 1898, German 
chemist Hans Von Pechmann49  developed another method for pyrazole synthesis in which he 
used acetylenes and diazomethane as starting materials (Scheme 1.11). 
 
Scheme 1.11: Pyrazole synthesis by Pechmann. 
 
Two general methods are known for the synthesis of pyrazoles. The first method is the 
standard reaction of hydrazines with 1,3-difunctional substrates such as 1,3-dicarbonyl 
compounds,48, 50 ynones51 or β-aminoacrolein.52 The second method involves the 1,3-dipolar 
cycloaddition  between alkynes and nitrile imines and it provides a direct access to pyrazoles,53 
but regioisomeric mixtures of pyrazoles are frequently obtained (Scheme 1.12). Moreover, 
during the last years new paths have emerged, like domino C-N coupling/hydroamination of 
enynes,54 azacyclization of elaborated structures55 and direct N-arylation of a 1H-pyrazole.56  
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Scheme 1.12: General methods for pyrazole synthesis. 
 
 
1.7 Recent literature on pyrazole synthesis: 
Jae Nyoung Kim et.al. reported57 the expeditious synthesis of 1, 3, 4 trisubstituted 
pyrazoles from Baylis-Hillman adducts (Scheme 1.13). 
 
Scheme 1.13: Synthesis of 1,3,4-trisubstituted pyrazoles. 
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H. Junjappa et.al. reported58 regioselective synthesis of 1-Aryl-3, 4-substituted/ 
annulated-5-(methyl thio) pyrazoles and 1-Aryl-3-(methyl thio)-4, 5-substituted/annulated 
pyrazoles (Scheme 1.14). 
 
Scheme 1.14: Synthesis of thio-substituted pyrazoles. 
 
A.Mori et.al.59 reported the pyrazole and isoxazole derivatives that are prepared by a 
palladium-catalyzed four-component coupling of a terminal alkyne, hydrazine (hydroxylamine), 
carbon monoxide under ambient pressure and an aryl iodide (Scheme 1.15). 
 
Scheme 1.15: Synthesis of pyrazole reported by A. Mori et. al.  
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Chapter 2 
1,3-DC of nitrile imines with sulfur substituted acetylenes and their 
application in synthesis of ring-fused thieno[2,3-c]pyrazoles 
 
2.1 Ring-fused pyrzoles properties and their biological importance: 
 Ring-fused pyrazoles are the compounds in which pyrazole ring is fused with other 
aromatic or carbocyclic ring forming a bicyclic or multicyclic structure. Synthesis of pyrazoles is 
well known but when it comes to ring-fused pyrazoles it seems to be challenging from the 
synthetic point of view. Ring fused pyrazoles are also important biological targets as they display 
a vast array of biological properties. There exists numerous examples of the ring fused pyrazoles 
which have shown promising biological activities (Figure 2.1).  
 
Figure 2.1: Ring fused pyrazoles. 
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 Pyrazolo[3,4-d]pyrimidines of type A show inhibition properties towards Src in a cell-
free assay, as well as antiproliferative activity towards the epidermoid (A431) and breast cancer 
(BC-8701) cell line.1 Pyrazolo-pyrimidines have also been tested in terms of inhibition of 
Abelson Kinase (Abl) enzymatic activity and antiproliferative properties towards human 
leukemic cells.2  Huang et.al. recently reported that a novel class of indazol-4-ones of type B 
exhibits low nanomolar antiproliferative potencies across multiple cancer cell lines.3 2,3-
Dihydropyran[2,3-c]pyrazoles of type C have been recently obtained through multicomponent 
microwave-assisted organocatalytic domino Knoevenagel/hetero Diels-Alder reaction and are 
potential anti-tubercular agents.4 Pyrazolo[1,5-C]quinazolines5 of type D are Gly/NMDA 
receptor antagonists while pyrazol-piperidines E and pyrazol-pyridines F are acorticotrophin-
releasing-factor (CRF-1) receptor antagonists and very promising for the treatment of depression 
and anxiety.6 
 In 2007, T. Gharbaoui et. al. synthesized series of pyrazole fused-ring derivatives, which 
showed promising activity as GPR109a agonist activity.7 F.D Boyer et.al. made a novel series of 
conformationally-restricted oxazolidinones which possess a fused pyrazole ring substituted with 
various alkyl, aryl and heteroaryl substituents. A number of analogs exhibited potent activity 
against both Gram-positive and fastidious Gram-negative organisms.8 Sheriff Rostom, 
synthesized some indeno[1,2-c]pyrazoles substituted with sulfonamide, thiourea 
pharmacophores. 9 They found that some of these compounds were cytotoxic and cytostatic. He 
further evaluated their antitumour activity against broad spectrum of cancer cells. In 2004, L. 
Bhat et. al. synthesized some steroid fused pyrazole derivatives for bile acid transporters (hIBAT 
and hLBAT). The selected pyrazole fused bile acids were further conjugated with drugs and drug 
surrogates. The annulated pyrazoles and their drug conjugates showed good aﬃnity for hLBAT 
as compared to hIBAT, and weak to moderate transport activity in hIBAT expressing oocytes.10 
Fused pyrazole-bearing systems have become well-recognized pharmacophores for numerous 
Chk1 inhibitors. These aminopyrazole cores have been reported by companies like Agouran 
Pharmaceuticals,11a Abott Laboratories.11b 
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2.2 Recent literature in synthesis of ring fused pyrzoles: 
Recently Mark Kruth et.al.12 have reported a facile syntheses of novel benzo- 1,3-
dioxolo-, benzothiazolo-, pyrido-, and quinolino-fused 5H-benzo[d]-pyrazolo[5,1-b][1,3]-
oxazines and 1H-pyrazoles (Scheme 2.1) by using  an easy and effective N,N-bond forming 
heterocyclization reaction. In doing so, the substrate scope of this heterocyclization reaction, 
which starts with o-nitroheterocyclic aldehydes, was expanded to provide several unique 
heterocyclic compounds for biological screening. 
 
Scheme 2.1: Ring-fused pyrazoles reported by Mark Kruth et.al. 
 
G. Hajós et.al.13 have reported synthesis of pyrazolo[3,4-b]pyrazines and pyrazolo[4,3-
c]pyridazines through ring closing reaction of 2-pyrazinyl and 3-pyridazinylketone 
arylhydrazones. These arylhydrazones were obtained by treatment of pyrazinyl ketones with aryl 
hydrazines. The aryl hydrazones were then subjected for the treatment with either 
EtOH/HCl/heating or DBU/heating followed by heating with 1,2-dichlorobenzene to yield the 
final compounds (Scheme 2.2). 
 
Scheme 2.2: Synthesis of pyrazolo[3,4-b]pyrazines and pyrazolo[4,3-c]pyridazines. 
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Recently M. Bakavoli et.al.14 have reported synthesis of pyrazolo [4,3-e][1,2,4]triazolo-
[4,3a]pyrimidine-4(5H)-imines over 4 steps (Scheme 2.3). This new route for the synthesis of 
pyrazolo[4,3-e][1,2,4]triazolo[4,3-a]pyrimidine4(5H)-imines has been delineated through 
heterocyclization of suitably functionalized pyrazoles with phenylisothiocyanate followed by 
methylation, nucleophilic displacement with hydrazine, and ﬁnally cyclocondensation with 
orthoesters. 
 
Scheme 2.3: Synthesis of pyrazolo [4,3-e][1,2,4]triazolo-[4,3a]pyrimidine-4(5H)-imines. 
 
 
In 1999, M. J. Kurth et. al.15 reported synthesis of pyrazolo[3,4-g] [2,1] 
dihydrobenzoisoxazole and pyrazolo[3,4-g] [2,1] dihydrobenzoisoxazoline through a 
intramolecular [3+2] - nitrile oxide cycloaddition. In this synthesis they started with ethyl 
acetoacetic ester, which was converted to a desired pyrazole derivative over 3 steps. The 
pyrazole thus obtained was formylated and this aldehyde was then converted to a nitrone which 
was subjected to an intramolecular [3+2] - nitrile oxide cycloaddition to yield the final ring fused 
pyrazole (Scheme 2.4). 
 
Scheme 2.4: Synthesis of pyrazolo [3,4-g] [2,1] dihydrobenzoisoxazol(in)e. 
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Narsidas J. Parmar et. al.16 have reported synthesis of benzopyran-annulated pyrano[2,3-
c]pyrazoles through tetrabutylammonium hydrogen sulfate mediated domino / Knoevenagel-
hetero-Diels–Alder reaction (Scheme 2.5). Angularly fused pyrazole derivatives are also of 
biological importance as they exhibit various biological activity specially with the core 
pyrano[2,3-c]pyrazole.  
 
Scheme 2.5: Synthesis of pyrano[2,3-c]pyrazoles. 
 
 
2.3  Thieno-pyrazoles: 
As pyrazole containing compounds display a broad spectrum of biological activity, there 
are numerous systems developed by organic chemists in order to obtain novel pyrazole fused 
ring compounds. Thieno-pyrazole is one of the classes of these compounds. 
Thieno-pyrazoles are the organic compounds in which one or more rings of pyrazole and 
thiophene are fused to form a single unit. Depending on the position of sulfur atom in the ring 
with respect to diazo group in pyrazole ring, there are 3 different types of regioisomers (Figure 
2.2). These compounds broadly exhibit the kinase inhibitor activity.  
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Figure 2.2: Structures of thieno[2,3-c]pyrazole, thieno[3,2-c]pyrazole, thieno[3,4-c]pyrazole. 
 
Thieno-pyrazole of type B and C have been extensively explored, whereas the type A is 
underexplored and scarcely reported in literature. 
 
2.4 Biological activity of thienopyrazoles: 
 Thieno-pyrazoles of type A is used for inhibiting PDE 7 selectively which is responsible 
for allergy, immunological diseases and inflammatory diseases.17 Several thienopyrazole analogs 
have been identified as inhibitors of KDR. Thieno-pyrazoles  of type B have ability to inhibit 
the protein kinase ITK (asthma). 
 Simona Bindi et.al.18 reported a series of thieno[3,2-c]pyrazoles (type B) to demonstrate 
their activity as a potent inhibitor for aurora kinase. They also discovered a representative 
compound (Figure 2.3), which showed low nanomolar inhibitory activity in the anti-
proliferation assay and was able to block the cell cycle in HCT-116 cell line. This compound 
demonstrated favorable pharmacokinetic properties. It showed good efficacy in the HL-60 tumor 
model and was able to induce significant TGI. 
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Figure 2.3: Thieno[3,2-c]pyrazole reported by Simona Bindi et.al. 
 
In 2006, Irini Akritopoulou-Zanze et.al.19 reported kinase targeted libraries based on 
thieno[2,3-c]pyrazole (type A) scaffold (Figure 2.4). Several analogs have been identified as 
submicro- molar inhibitors of KDR.  
 
Figure 2.4: Thieno[3,2-c]pyrazoles reported by A. Z. Irini et. al.  
 
 
2.5 Recent literature on synthesis of thieno[2,3-c]pyrazoles: 
 Although thieno[3,2-c]pyrazole (Type B) and  thieno[3,4-c]pyrazole (type C) are 
important biological targets we are going to focus our attention on synthesis of thieno[2,3-
c]pyrazoles as these are interesting biological targets and are scarcely reported in literature.  
 In 1998, Wang et.al.20 reported synthesis of thieno[2,3-c]pyrazoles starting with ethyl 
acetoacetate (Scheme 2.6). The ethyl acetoacetate ester I was treated with phenyl hydrazine to 
give pyrazolone II, which was then chlorinated and followed by formylation  using Vilsmeier-
Haak reaction to give pyrazolealdehyde III. This pyrazolaldehyde III was converted to alkene 
IV by Wittig reaction modified by Ogura, which in turn was converted to pyrazolacetate ester V 
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by using dry HCl. This pyrazolacetate ester was then finally treated with CS2 / KOH followed by 
R’X to give thieno[2,3-c]pyrazole VI. 
 
Scheme 2.6: Synthesis of thieno[2,3-c]pyrazoles reported by Wang et.al. 
 
 
 Later in 2008, Mohamed Akssira et.al.21 reported a synthesis of thieno[2,3-c]pyrazoles 
starting with functionalized pyrazoles (Scheme 2.7). Pyrazoloester VII was selectively 
brominated. This bromo-pyrazoloester VIII was then treated with  disodium sulfide at 100°C in 
DMF,  followed by addition of ethyl bromoacetate to give IX. The thio-pyrazoloester IX thus 
obtained was then subjected to base promoted ring closure using sodium ethoxide in ethanol 
which then subsequently aromatized by addition of acetic acid to yield the final thieno[2,3-
c]pyrazole X.  
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Scheme 2.7: Synthesis of thieno[2,3-c]pyrazoles as reported  by Akssira et.al. 
 
 
 In 2011, Garnet A. Eller et.al.22 devised a new route using sonogashira reaction. In this 
methodology they also started with functionalized pyrazoles (Scheme 2.8). Pyrazole XI was 
iodinated, the iodo-pyrazole XII, thus obtained was treated with phenylacetylene to get pyrazole 
XIII. This pyrazole 3 was then treated with disodium sulfide in dimethylformamide to yield 
desired thieno[2,3-c]pyrazole XIV. 
 
Scheme 2.8: Synthesis of thieno[2,3-c]pyrazoles reported by G. A. Eller et.al. 
 
 
We have recently developed a method for the regiocontrolled synthesis of pyrazoles 
based on the 1,3-DC of nitrile imines with functionalized acetylenes.23 As part of our group’s 
ongoing effort24 directed towards obtaining the pyrazole derivatives as multi-kinases inhibitors 
we decided to investigate the application of our methodology to the regiocontrolled synthesis of 
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thieno[2,3-c]-pyrazoles  (Type A), through a 1,3-DC of nitrile imines and sulphur-substituted 
acetylenes. 
Heteroatom-substituted acetylenes have been scarcely studied and reported in 1,3-DC 
reaction of nitrile imines as 1,3-dipoles. Only Zecchi reported the reaction of N-phenyl C-phenyl 
nitrile imine with alkynyl phenyl sulfones with yields in the range 15-71% and with the 
cycloadduct having the PhSO2 group in position 4 as the predominant or exclusive regioisomer 
(Scheme 2.9), 25 while alkynyl phenyl sulfides  have been never investigated in this 1,3-DC. On 
the other hand, this kind of dipolarophiles, and the possible control of the regiochemistry, could 
play an important role to install the ‘S’ atom in the correct position of the pyrazole ring which 
after synthetic elaboration can lead to the formation of ring-fused thienopyrazoles.  
 
Scheme 2.9: Zecchi’s synthesis of pyrazoles. 
 
 
2.6 Results and discussion: 
For primary investigation we decided to synthesize mono- 1 and di-functional 2 sulfones 
containing triple bond to extend Zecchi’s result with the more versatile and unreported C-
carboxymethyl-N-aryl-nitrile imines. Moreover, we present herein the sulfur acetylenes 3-4 in 
their general behaviour in 1,3-DC with nitrile imines derived from 5a-c (Figure 2.5).  
 
Figure 2.5: General sulphur acetylenes and nitrile imines. 
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 The starting acetylenes 1-4 were readily prepared according to literature procedures. The 
trimethylsilylethyne was treated with n-BuLi followed by treatment with S-Phenyl 
benzenethiosulfonate to give trimethyl(phenylthioethynyl)silane, which was then treated with 
tetrabutyl ammonium fluoride (1M solution in THF) to give acetylene 3. The intermediate 
trimethyl(phenylthioethynyl)silane was oxidised with m-CPBA followed by TMS deprotection 
using tetrabutyl ammonium fluoride (1M solution in THF) to give acetylene 1 (Scheme 2.10). 
 
Scheme 2.10: Synthesis of acetylenes 1 and 2. 
 
 
Acetylenes 2 and 4 were prepared in the same manner from ethyl propiolate (Scheme 2.11). 
 
Scheme 2.11: Synthesis of acetylene 3 and 4. 
 
 
While the selected hydrazonoyl chlorides 5a-c were prepared from corresponding 
aromatic amines by treating with nitrous acid forming a diazonium salt which was then treated 
with methyl 2-chloroacetoacetate to yield the desired  hydrazonoyl chloride 5a-c (Scheme 2.12). 
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Scheme 2.12: Synthesis of hydrazonoyl chlorides 5a-c. 
 
 
The cycloadditions of 1 and 2 with the C-carboxymethyl-N-aryl-nitrile imines derived 
from 5a-c were carried out in dry dioxane at 80°C for 24 hours using 2.5 equivalents of Ag2CO3, 
and 1-2 were used in stoichiometric amount with respect to the dipoles with yields ranging from 
35 to 63% (Scheme 2.13, Table 2.1, entries 1-6). 
 
Scheme 2.13: 1,3-DC of sulfone substituted acetylenes 1-2 and nitrile imines 5a-c.  
 
Cycloadducts 6-6’ were obtained in 35/65 ratio, 7-7’ in 40/60 ratio while 8-8c’ were 
isolated as balanced mixtures in a 54/46 ratio (entries 1-3). These results of regiochemistry fit 
with the data obtained for the N-phenyl-C-phenyl nitrile imines,25 and are due to the strong 
electron withdrawing effect of the sulfonyl group which determine a large LUMO coefficient at 
the β-carbon of the acetylene with a consequent HOMO (dipole)-LUMO (dipolarophile) 
interaction.  
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Table 2.1: 1,3-DC of sulfone substituted acetylenes 1-2 and nitrile imines 5a-c. 
Entry 
Dipolaro- 
phile 
1,3-
Dipole 
Y 
Cycload-
ducts 
Yield (%)a Ratioa Yield (%)b Ratiob 
1 1 5a H 6-6’ 49 35:65 38 12:88 
2 1 5b H 7-7’ 35 40:60 34 14:86 
3 1 5c H 8-8’ 58 54-46 39 14:86 
4 2 5a CO2Et 9-9’ 63 11-89 72 8:92 
5 2 5b CO2Et 10-10’ 65 20:80 67 15:85 
6 2 5c CO2Et 11-11’ 60 10:90 64 9:91 
[a] Without Sc(OTf)3 [b] With 10% Sc(OTf)3. 
 
The same reactions were repeated in the presence of scandium triflate catalyst for a 
possible control of the regiochemistry.23 As expected, the amount of the 4-isomer was higher 
under Sc(OTf)3 catalysis (entries 1-3), the 4-isomer increased to 12:88 for 6-6’ and to 14:86 for 
7-7’ and 8-8’, due to the possibility of a chelate transition state involving the CO2Me group and 
the sulfonyl group with scandium catalyst (Figure  2.6).23  
 
Figure 2.6: Possible mode of chelation of Sc(OTf)3 with 1,3 dipole and acetylene. 
 
Disubstituted-sulfone 2 gave good yields of cycloadducts (60-65%) with a higher 
quantity of the 4-isomer, ratio 11:89 for 9-9’, 20:80 for 10-10’ and 10:90 for 11-11’ (entries 4-6 
in Table 2.1), but in this case no significant improvement was observed in the ratio under 
scandium catalysis in favour of 4-isomer. This observation shows that this kind of 1,3-DC is 
substrate-controlled and does not take place under the control of the catalyst. Moving to the PhS-
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dipolarophile 3 and 4 a reversal in the regiochemistry in favor of the 5-substituted pyrazoles was 
observed. The C-carboxymethyl-N-aryl-nitrile imines derived from 5a-c with 3 and 4 gave only 
the regioisomers 12-17 with the PhS- group in position 5 with or without scandium catalysis 
(Scheme 2.14, Table 2.2). Satisfactory yields in the range 45-70% were achieved (entries 1-6). 
These results are in line with results obtained by us in 1,3-NED (normal electron demand) 
dipolar cycloaddition of nitrile imines with acetylene derivatives.26 
 
Scheme 2.14: 1,3-DC of sulfur substituted acetylenes 3-4 and nitrile imines 5a-c. 
 
The identification of the 5- and the 4-pyrazoles in the cycloadducts 6-8 and 12-14 was 
done by using 1H-NMR signals taking advantage from the fact that it is known that the CH signal 
on the C5 for the 4-substituted pyrazole resonates at about 8.0 ppm. This signal was absent in the 
NMR spectra of our cycloadducts.23 Furthermore, NOE experiments confirmed the formation of 
5-pyrazole. Similar was the case for compounds 9-11 and 15-17. 
 
Table 2.2: 1,3-DC of sulfur substituted acetylenes 3-4 and nitrile imines 5a-c. 
Entry Dipolarophile 1,3-Dipole Y Cycloadducts Yield (%) Regioisomeric Ratio 
1 3 5a H 12-12’ 70 >99:1 
2 3 5b H 13-13’ 57 >99:1 
3 3 5c H 14-14’ 67 >99:1 
4 4 5a CO2Et 15-15’ 50 >99:1 
5 4 5b CO2Et 16-16’ 45 >99:1 
6 4 5c CO2Et 17-17’ 67 >99:1 
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From these results we understood that sulphur or sulfone based functionalities controls 
the regiochemistry in the cycloaddition reaction. The electron-releasing property of the S atom 
together with the electron-withdrawing CO2Et group bring to a synergistic regiochemical effect 
that leads exclusively to one regioisomer, in contrast with the behaviour of the SO2 substituted 
triple bond. This regiochemistry is correct for the obtaining the ring-fused thienopyrazole of 
Type A.   
To apply this protocol for synthesis of ring-fused thieno-pyrazole we decided to 
synthesize properly substituted simple acetylene having a CH2- group at α position to the sulphur 
atom and on other side of the acetylene a carbonyl group like COOEt, as this was feasible with 
the literature procedure.27 For synthesis of this type of acetylene we started with with ethyl 
propyolate which was then treated with sodium hydride followed by addition of phenacyl 
mercaptan to yield disubstituted acetylene in good yield. When this disubstituted acetylene was 
treated with one of the nitrile imine 5a, the cycloadduct was formed together with a by-product 
oxathiine in the reaction (Scheme 2.15) which was due to presence of highly acidic H’s next to 
S. But when we tried to cyclise this cycloadduct using strong acidic and basic conditions we 
didn’t got any conversion in fact the cycloadduct got degraded.  
 
Scheme 2.15: Synthesis of disubstituted acetylene. 
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To overcome the fact that ester group was not reacting in the final step we decided to 
synthesise acetylene containing formyl group and less acidic functionality on S. In order to 
achieve this we planned to synthesize  acetal of phenacyl disulfide. We started with synthesis of 
diphenacyldisulfide 18, which was synthisized from readily available phenacyl chloride (Scheme 
2.16).27 The phenacyl chloride was treated with thiolacetic acid in pyridine at 85°C for 2 h to 
yield phenacylthioacetate. This intermediate phenacylthioacetate was then deacylated using 2N 
NaOH at RT in 91% yield, which was then subjected to dimerisation  using NaI / H2O2 in 
ethylacetate to give diphenacyldisulfide 18 with 93% yield. 
 
Scheme 2.16: Synthesis of diphenacyldisulfide. 
 
This diphenacyldisulfide 18 was then protected with ethylene glycol to yield dioxolane-
disulfide 19 with 81% yield. This dioxolane-disulfide 19 was then treated with TMS acetylene to 
give S-substituted acetylene, the acetylene 20 was obtained by reaction of 19 with lithium 
trimethylsilyl acetylene in THF at 0°C in 80% yield. The acetylene 20 was then desilylated using 
TBAF at 0°C, to give compound 21 in 93% yield (Scheme 2.17). 
 
Scheme 2.17: Synthesis of acetylene 21. 
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In the acetylene 21 the formyl group was introduced by reaction with LiHMDS in THF at 
-78°C followed by addition of a mixture of DMF and HMPA (Scheme 2.18). The disubstituted 
acetylene was not isolated but immediately treated with 5a-c in the usual conditions. The 
corresponding were obtained in good overall yields, 66% for 22a, 42% for 22b, 43% for 22c and 
fully characterized after chromatography on silica. Deprotection of the dioxolane in 22 and 
condensation to the thieno[2,3-c]pyrazole 23 was done in one step by reaction with 
trifluoroacetic acid in acetone in 20% overall yield. Similar results were obtained with using 6M 
HCl, but overall yields were very pure in the range of 10 to 11%. 
 
Scheme 2.18: General scheme for synthesis of ring-fused thieno[2,3-c]pyrazole 23a-c. 
 
 
When we tried to oxidise compound 20  using m-CPBA in order to get thieno[3,2-
c]pyrazole (Type B) we found in was getting oxidised but the on basic workup it was getting 
cyclised forming a 1,4-oxathiine. This is attributed to the fact that the molecule contains more 
acidic H’s next to carbonyl group making it more acidic which on basic workup gets enolized 
that subsequently attacks on one of the acetylenic carbon atom preferably forming a 6-membered 
structure (Scheme 2.19) which was also confirmed by 1H-NMR data.  
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Scheme 2.19: Formation of 1,4-oxathiine. 
 
 
2.7 Conclusion: 
In summary, an efficient multi-step synthetic sequence based on a 1,3-DC of C-
carboxymethyl-N-aryl-nitrile imines with sulfur-acetylenes has been developed and this 
methodology appears suitable for the regiocontrolled synthesis of thieno[2,3-c]pyrazoles of type 
A. With a particular interest there is the possible synthetic elaboration of the ester group that 
would allow the preparation of libraries of potentially active thienopyrazoles. Therefore, 
applications in medicinal chemistry call for other studies which will be reported in due course.  
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2.8 Experimental Section: 
 
2.8.1 Material and Methods:  
1H NMR and 13C NMR spectra were recorded using CDCl3 or CD3OD or DMSO-d6 
solutions at 300, 400 and 600 MHz for 1H and 75.46, 100.6 and 150.92 MHz for 13C. Chemical 
shifts (δ) are reported in ppm relative to CHCl3 (δ = 7.26 for 
1H and δ = 77.0 for 13C). J values 
are given in Hz. 1H NMR and 13C NMR spectral assignments were made by DEPT, gCOSY and 
gHSQC experiments. IR spectra were recorded in solvent as specified. Mass spectra (MS) were 
obtained with an electrospray ionization source (ESIMS). All the ESIMS spectra were performed 
using MeOH as the solvent. High Resolution Mass Spectra (HRMS) were recorded on a 
micromass LCT spectrometer using electrospray (ES+) ionisation techniques. Reactions were 
conducted in oven-dried (120°C) glassware under a positive Ar atmosphere. Transfer of 
anhydrous solvents or mixtures was accomplished with oven-dried syringes/septum techniques. 
THF was distilled from sodium/benzophenone just prior to use and stored under argon. Toluene 
was distilled from sodium. Et2O was distilled from phosphorus pentoxide. CH2Cl2 was passed 
through basic alumina and distilled from CaH2 prior to use. Other solvents were purified by 
standard procedures. Light petroleum ether refers to the fraction with bp 40-60°C. The reactions 
were monitored by TLC performed on silica gel plates (Baker-flex IB2-F). Column 
chromatography was performed with Merck silica gel 60 (70-230 mesh). Preperative TLC was 
carried out on glass plates using a 1 mm layer of Merck silica gel 60 Pf 254. All chemicals were 
used as obtained or purified as needed. 
 
 Ethynylsulfonylbenzene (1): To a stirred solution of 
trimethyl(phenylthioethynyl)silane (0.5 g, 2.4 mmol) in DCM (5 mL) was 
added solution of m-CPBA (77%, 1.34 g, 6.4 mmol) in DCM (5 mL). The reaction was 
vigorously stirred for 1-2 h. After completion, reaction was cooled to 0 oC and sat. NaHCO3 
solution (15 mL) was added with caution. Then reaction mixture was extracted with DCM (3 x10 
mL) and washed with water and brine. The DCM layer was dried on MgSO4 and evaporated. No 
purification was necessary as almost pure product was obtained as yellow oil (0.55 g, 96% 
yield). 1H (300MHz, CDCl3): δ 7.97–8.09 (d, J = 6 Hz, 2H), 7.55–7.75 (m, 3H), 0.22–0.25 (s, 
9H).  This oil (0.55 g, 2.3 mmol) was then dissolved in THF (10 mL) and cooled to 78oC and 
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then mixed with n-Bu4NF (1 M in THF, 0.7 mL, 0.7 mmol). The reaction was stirred for 2-3 h at 
same temperature. After completion of reaction sat NH4Cl solution (15 mL) was added and 
mixture was extracted with diethyl ether (3 x 10 mL). The combined ether extracts were washed 
with water (2 x 10 mL)  and brine and then dried over anhydrous Na2SO4. Ether layer was 
carefully evaporated in vacuo and crude product 1 (0.33 g, 87% yield) was kept as stock solution 
in diethyl ether (ca. 20%w/v) at 4 oC. The crude product was used as such for further reactions 
without purification. 
 
 Ethyl-3-(phenylsulfonyl)propiolate (2): To a stirred solution of 
ethyl-3-(phenylthio)propiolate 4 (0.77 g,  3.7 mmol) in DCM (10 mL) 
was added a solution of m-CPBA (77%, 2.1 g, 9.3 mmol) in DCM (10 
mL) and left to react at room temperature for 2 h. Afterwards, the solution was washed with 10%  
aq. Na2S2O4 solution (10 mL) and saturated aq. NaHCO3 solution (2 x 10 mL). The organic layer 
was dried over anhydrous Na2SO4, evaporated and the crude product was purified by 
chromatography on silica gel (EtOAc/Light Petroleum 1/5) to yield 0.59 g (68 %) of compound 2 
as a yellow oil. 1H NMR (300 MHz , CDCl3):δG 8.03 (d, J = 7.6 Hz, 2H), 7.76 (t, J = 7.6 Hz, 1H), 
7.63 (t, J = 7.6 Hz, 2H), 4.28 (q, J = 7.2 Hz, 2H), 1.31 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, 
CDCl3): δ 150.8, 139.6, 135.2, 129.6 (2CH), 127.9 (2CH), 79.7, 78.9, 63.5, 13.7;IR (CCl4): ν = 
3061, 2978, 2532, 1726, 1570, 1472, 1441, 1358, 1238, 1171, 1088 cm-1; [M+Na]+: 261; Anal. 
Calcd for C11H10O4S: C, 55.45; H, 4.23. Found: C, 55.48; H, 4.25. 
 
  Phenylthioacetylene (3): Trimethylsilylethyne (1 g, 10.2 mmol) was dissolved 
in dry THF (15 mL) at 0oC. A solution of n-BuLi (1.6 M in Hexane, 6.4 mL, 
10.2 mmol) was then added dropwise with stirring under argon at 0 oC. After 45 min. a solution 
of S-Phenyl benzenethiosulfonate (2.3 g, 9.2 mmol) in THF (10 mL) was introduced at 0 oC 
stirring was continued for 2 h and the reaction mixture was then quenched with sat. NH4Cl 
solution (20 mL). The reaction mixture was extracted with diethyl ether (3 x 15 mL) and organic 
layer was washed with water (2 x 15 mL) and brine. The ether layer was then dried over 
anhydrous Na2SO4 and evaporated in vacuo. The residue was purified by flash column 
chromatography using n-hexane as eluent to afford yellow oil (1.48 g, 70% yield). 1H NMR (300 
MHz, CDCl3): δ 7.50-7.55 (m, 2H), 7.42-7.49 (t, J = 7.5 Hz, 2H), 7.29-7.38 (tt, J = 7.5 and 1.5 
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Hz, 1H), 0.36-0.38 (s, 9H). This oil trimethyl(phenylthioethynyl)silane (1 g, 4.8 mmol) was then 
dissolved in THF (20 mL) and cooled to −78 oC and then mixed with n-Bu4NF (1M in THF, 1.45 
mL, 1.4 mmol). The reaction was stirred for 2-3 h at same temperature. After completion sat. 
NH4Cl (20 mL) was added and reaction mixture was extracted with diethyl ether (3 x 15 mL). 
The combined ether extracts were washed with water (2 x 15 mL) and brine and then dried over 
anhydrous Na2SO4. Ether layer was carefully evaporated in vacuo and crude product 3 (0.63 g, 
97% yield) was kept as stock solution in ether (ca. 20%w/v) at -4 oC. The crude product was used 
as such for further reactions without purification. 
 
 Ethyl-3-(phenylthio)propiolate (4): To a stirred solution of ethyl 
propiolate (0.4 mL, 4 mmol) in THF (8 mL) at -78 °C was added 
slowly a  solution of lithium bis(trimethylsilyl)amide (1 M in THF, 4 
mL, 4 mmol). After 30 minutes, a solution of S-Phenyl benzenethiosulfonate (1.0 g, 4 mmol) in 
THF (6 mL) was added at -78 °C and left to react at room temperature for 2 h. After completion 
of reaction, saturated NH4Cl solution (10 mL) was added and extracted with diethyl ether (2 x 10 
mL), then the combined organic layers were dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo to afford the product 4 as a yellow oil (0.77 g, 93% yield). 1H NMR (300 
MHz, CDCl3): δ 7.47 (d, J = 7.9 Hz, 2H),  7.39 (t, J = 7.9 Hz, 2H), 7.30 (t, J = 7.3 Hz, 1H), 4.27 
(q, J = 7.2 Hz, 2H), 1.33 (t, J = 7.2 Hz, 3H); 
13C NMR (100 MHz, CDCl3): δ 152.9, 129.6 (2CH), 
129.5, 127.9, 127.4 (2CH), 91.6, 79.8, 62.0, 14.1; IR (CCl4): ν = 3066, 2984, 2153, 1709, 1583, 
1479, 1444, 1366, 1232, 1037 cm-1; [M+Na]+: 229. 
 
2.8.1 General Procedure for 1,3 dipolar cycloaddition and analysis of cycloadducts:  
To a stirred solution of phenylthioacetylene (1 eq.) and 1,3- dipole (1 eq.) in freshly 
distilled dioxane (5 mL) was added silver carbonate (2.5 eq.) under argon atmosphere. Reaction 
was heated at reflux for overnight. After completion, reaction mixture was allowed to cool and 
filtered through bed of celite and washed with DCM (5 mL). The filtrate was then evaporated in 
vacuo to give dark red crude oil. The crude product was purified by column chromatography to 
give corresponding title compound/s. 
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Methyl 1-phenyl-5-(phenylsulfonyl)-1H-pyrazole-3-carboxylate (6) and Methyl 1-phenyl-4-
(phenylsulfonyl)-1H-pyrazole-3-carboxylate (6’): Compounds 6 and 6’ were obtained as a off 
white solids following the general procedure for the 1,3-DC and separated by chromatography on 
silica gel (EtOAc/hexane 2:8). 
 
 Methyl 1-phenyl-5-(phenylsulfonyl)-1H-pyrazole-3-carboxylate (6): 
m.p.= 154.8 oC; 1H NMR(300 MHz, CDCl3): δ 7.57–7.60 (s, 1H), 7.44-
7.57 (m, 4H), 7.32–7.42 (quartet, J = 7.9 Hz,  4H), 7.22–7.28 (m, 2H), 
3.92–3.98 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 161.2, 144.0, 142.7, 
138.7, 137.6, 134.1, 130.2, 129.0 (2C), 128.6 (2C), 128.1 (2C), 127.1 
(2C), 114.6, 52.6; IR (CCl4): ν = 2955, 1737, 1509, 1328, 1236, 1151, 1067, 816; [M+H]
+: 343. 
 
 Methyl 1-phenyl-4-(phenylsulfonyl)-1H-pyrazole-3-carboxylate (6’): 
m.p. = 147.3-148.2 oC 1H NMR(300 MHz, CDCl3): δ 8.64–8.66 (s, 1H), 
8.08–8.14 (d, J = 6 Hz, 2H), 7.70-7.77 (d, J = 6 Hz, 2H), 7.40–7.65 (m, 
6H), 3.88–3.90 (s, 3H); 13C NMR (75 MHz, CDCl3): δ  159.8, 141.1, 
140.8, 138.2, 133.3, 133.2, 129.7 (2C), 128.8, 128.6 (2C), 128.1 (2C), 
128.3, 120.2 (2C), 52.6; IR (CCl4): ν = 2955, 1737, 1509, 1328, 1236, 
1151, 1067, 816; [M+H]+: 343.  
 
Methyl 1-(4-nitrophenyl)-5-(phenylsulfonyl)-1H-pyrazole-3-carboxylate (7) and Methyl 1-
(4-nitrophenyl)-4-(phenylsulfonyl)-1H-pyrazole-3-carboxylate (7’): Compounds 7 and 7’ 
were obtained as a off white solids following the general procedure for the 1,3-DC and separated 
by chromatography on silica gel (EtOAc/hexane 2:8). 
 
Methyl 1-(4-nitrophenyl)-5-(phenylsulfonyl)-1H-pyrazole-3-
carboxylate (7): m.p. = 192.7 oC; 1H (300 MHz, CDCl3): δ 8.28–8.35 
(d, J = 9 Hz, 2H), 7.59–7.71 (m, 4H), 7.42–7.53 (m, 3H), 7.25–7.28 (s, 
1H), 3.96–3.99 (s, 3H); 13C NMR (75 MHz, CDCl3): δG160.7, 148.2, 
144.4, 143.8, 142.5, 138.6, 134.7, 129.4 (2C), 128.0 (2C), 127.8 (2C), 
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124.1 (2C), 115.3, 52.8; IR (CH2Cl2): ν = 3970, 2985, 1737, 1531, 1346, 1236; Anal. Calcd for 
C17H13N3O4S:  C, 52.71; H, 3.38; N, 10.85; O, 24.78; S, 8.28. [M+H]
+: 388. 
 
Methyl 1-(4-nitrophenyl)-4-(phenylsulfonyl)-1H-pyrazole-3-
carboxylate (7’): m.p.= 218-219.1 oC; 1H NMR(300 MHz, CDCl3): δ 
8.75–8.79 (s, 1H), 8.39-8.46 (d, J = 9 Hz, 2H), 8.09–8.15 (d, J= 6 Hz, 2H), 
7.96–8.03 (d, J= 9Hz, 2H), 7.52–7.69 (m, 3H), 3.90–3.95 (s, 3H); 13C 
NMR (100 MHz, CDCl3): δ 159.7, 147.5, 142.6, 140.7, 133.9, 133.8, 
133.8, 129.1, 129.0, 128.6 (2C), 125.7 (2C), 120.5 (2C), 53.0; IR (CH2Cl2): 
ν G= 3070, 2985, 1737, 1531, 1346, 1236, 1068. [M+H]+: 388. 
 
Methyl 1-(4-methoxyphenyl)-5-(phenylsulfonyl)-1H-pyrazole-3-carboxylate (8) and Methyl 
1-(4-methoxyphenyl)-4-(phenylsulfonyl)-1H-pyrazole-3-carboxylate (8’): Compounds 8 and 
8’ were obtained as a off white solids following the general procedure for the 1,3-DC and 
separated by chromatography on silica gel (EtOAc/hexane 2:8). 
 
Methyl  1-(4-methoxyphenyl)-5-(phenylsulfonyl)-1H-pyrazole-3-
carboxylate (8): m.p.= 121.3 oC; 1H (300 MHz, CDCl3): δ 7.54–7.61 
(m, 2H), 7.47–7.53 (m, 2H), 7.34–7.43 (t, J = 7.5 Hz, 2H), 7.12–7.18 (d, 
J = 9 Hz, 2H), 6.83-6.89 (d, J = 9 Hz, 2H), 3.94–3.97 (s, 3H), 3.86–3.89 
(s, 3H); 13C NMR (75 MHz, CDCl3): δ 161.2, 160.6, 144.0, 142.5, 
138.8, 134.0, 130.4, 128.9 (2C), 128.4 (2C) , 128.0 (2C), 114.3, 113.6 
(2C), 55.6, 52.5; IR (CCl4): ν = 2919, 1740, 1550, 1520, 1464, 1330, 1251, 1172, 1069; [M+H]
+: 
373. 
 
 Methyl 1-(4-methoxyphenyl)-4-(phenylsulfonyl)-1H-pyrazole-3-
carboxylate  (8’): m.p.= 147-148 oC; 1H (300 MHz, CDCl3): δ 8.51–8.55 
(s, 1H), 8.07–8.14 (d, J= 6Hz, 2H), 7.51–7.67 (m, 5H), 6.97–7.05 (m, 2H), 
3.89–3.90 (s, 3H), 3.86–3.89 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 159.8, 
141.0, 140.8, 133.2, 133.1, 131.7, 128.6 (2C), 128.3, 128.1 (2C), 126.9, 
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121.9 (2C), 114.7 (2C), 55.7, 52.6; IR (CCl4): ν = 2919, 1740, 1550, 1520, 1464, 1330, 1251, 
1172, 1069; [M+H]+: 373. 
 
4-Ethyl 3-methyl-1-phenyl-5-(phenylsulfonyl)-1H-pyrazole-3,4-dicarboxylate and 5-Ethyl 3-
methyl-1-phenyl-4-(phenylsulfonyl)-1H-pyrazole-3,5-dicarboxylate (9 and 9’): Compound 
9/9’ were obtained as a white solids following the general procedure for the 1,3-DC and 
separated by chromatography on silica gel (EtOAc/Light Petroleum 3/7). The two regioisomers 
were further separated by Preperative TLC plates (EtOAc/Light Petroleum 2/3) as yellow oils. 
 
 4-Ethyl 3-methyl-1-phenyl-5-(phenylsulfonyl)-1H-pyrazole-3,4-
dicarboxylate (9): 
1H NMR (400 MHz, CDCl3): δ 7.61-7.49 (m,
 4H), 
7.43-7.35 (m, 4H), 7.14 (d, J = 7.8 Hz, 2H), 4.56 (q, J = 7.2 Hz, 2H), 
3.94 (s, 3H), 1.49 (t, J = 7.2 Hz, 3H) ; 
13C NMR (100.6 MHz, CDCl3): 
δ  162.1, 160.4, 141.0, 139.8, 138.8, 137.2, 134.4, 130.6, 129.1 (2CH), 
128.7 (2CH), 128.4 (2CH), 127.6 (2CH), 122.7, 62.8, 52.7, 14.0; IR (CCl4): ν = 2957, 2931, 
1745, 1504, 1450, 1331, 1222, 1159 cm-1; [M+Na]+: 437. 
 
 5-Ethyl 3-methyl-1-phenyl-4-(phenylsulfonyl)-1H-pyrazole-3,5-
dicarboxylate (9’): 1H NMR (400 MHz, CDCl3,): δ 8.25 (d,
 
J = 8.6 Hz, 
2H), 7.67-7.44 (m, 8H), 4.39 (q, J = 7.2 Hz, 2H), 3.93 (s, 3H), 1.24 (t, J = 
7.2 Hz, 3H); 13C NMR (100.6 MHz, CDCl3): δ 159.8, 158.9, 141.6, 140.7, 
139.5, 137.8, 133.5, 130.0, 129.4 (2CH), 128.7 (2CH), 128.5 (2CH), 124.7, 
124.4 (2CH), 63.7, 52.9, 13.7; IR (CCl4): ν = 2955, 2928, 1746, 1501, 1447, 
1336, 1219, 1163 cm-1; [M+Na]+: 437. 
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4-Ethyl 3-methyl-1-(4-nitrophenyl)-5-(phenylsulfonyl)-1H-pyrazole-3,4-dicarboxylate and 
5-Ethyl 3-methyl-1-(4-nitrophenyl)-4-(phenylsulfonyl)-1H-pyrazole-3,5-dicarboxylate (10 
and 10’): Compound 10/10’ were obtained as white solids following the general procedure for 
the 1,3-DC and separated by preperative TLC plates (EtOAc/Light Petroleum 2/3). 
 
 4-Ethyl 3-methyl-1-(4-nitrophenyl)-5-(phenylsulfonyl)-1H-
pyrazole-3,4-dicarboxylate (10): m.p. = 195.0 °C; 1H NMR (400 
MHz, CDCl3): δ 8.30 (d,
 
J = 8.9 Hz, 2H), 7.68-7.61 (m,
 3H), 7.50-7.40 
(m, 4H), 4.54 (q, J = 7.2 Hz, 2H), 3.95 (s, 3H), 1.48 (t, J = 7.2 Hz, 3H); 
13C NMR (100.6 MHz, CDCl3): δ 161.5, 159.8, 148.6, 141.9, 141.2, 
140.9, 138.6, 134.9, 129.4 (2CH), 128.6 (2CH), 128.1 (2CH), 124.0 
(2CH), 123.3, 63.0, 53.0, 14.1; IR (CHCl3): ν = 2955, 2930, 1745, 1615, 1600, 1539, 1505, 1439, 
1347, 1223, 1164 cm-1; [M+Na]+: 482. 
 
 5-Ethyl 3-methyl-1-(4-nitrophenyl)-4-(phenylsulfonyl)-1H-pyrazole-
3,5-dicarboxylate (10’): m.p.= 208.0 °C; 1H NMR (400 MHz, CDCl3): δ 
8.37 (d, J = 9.1 Hz, 2H), 8.23 (d,
 
J = 7.7 Hz, 2H), 7.75 (d,
 
J = 9.1 Hz, 2H), 
7.68-7.56 (m, 3H), 4.46 (q, J = 7.2 Hz, 2H), 3.95 (s, 3H), 1.34 (t, J = 7.2 Hz, 
3H); 13C NMR (100.6 MHz, CDCl3): δ 159.6, 158.8, 148.1, 142.8, 142.4, 
140.4, 139.5, 133.8, 128.9 (2CH), 128.6 (2CH), 126.1, 125.0 (2CH), 124.9 
(2CH), 64.2, 53.0, 13.7; IR (CHCl3): ν = 2955, 2928, 1747, 1615, 1600, 
1537, 1505, 1436, 1345, 1221, 1164 cm-1; [M+Na]+: 482. 
 
4-Ethyl 3-methyl-1-(4-methoxyphenyl)-5-(phenylsulfonyl)-1H-pyrazole-3,4-dicarboxylate 
and 5-Ethyl 3-methyl-1-(4-methoxyphenyl)-4-(phenylsulfonyl)-1H-pyrazole-3,5-
dicarboxylate (11 and 11’): Compound 11/11’ were obtained as yellow oils following the 
general procedure for the 1,3-DC and separated by chromatography on silica gel (EtOAc/Light 
Petroleum 3/7). The two regioisomers were further separated by preperative TLC plates 
(EtOAc/Light Petroleum 2/8). 
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 4-Ethyl 3-methyl-1-(4-methoxyphenyl)-5-(phenylsulfonyl)-1H-
pyrazole-3,4-dicarboxylate (11): 
1H NMR (400 MHz, CDCl3): δ 7.58 
(t, J = 8.5 Hz, 3H), 7.40 (t,
 
J = 8.0 Hz, 2H), 7.04 (d,
 
J = 8.7 Hz, 2H), 
6.86 (d, J = 8.7 Hz, 2H), 4.55 (q, J = 7.2 Hz, 2H), 3.93 (s, 3H), 3.88 (s, 
3H), 1.48 (t, J = 7.2 Hz, 3H); 13C NMR (100.6 MHz, CDCl3): δ 162.2, 
161.1, 160.4, 146.1, 134.4, 131.9, 129.9, 129.1 (2CH), 128.8 (2CH), 
128.6, 128.4 (2CH), 114.7, 113.7 (2CH), 62.7, 55.6, 52.7, 14.1; IR (CCl4): ν = 2955, 1745, 1510, 
1460, 1441, 1340, 1219, 1163 cm-1; [M+Na]+: 467. 
 
 5-Ethyl 3-methyl-1-(4-methoxyphenyl)-4-(phenylsulfonyl)-1H-
pyrazole-3,5-dicarboxylate (11’): 1H NMR (400 MHz, CDCl3): δ  8.24 (d,
 
J = 7.8 Hz, 2H), 7.67-7.54 (m,
 3H), 7.42 (d, J = 8.6 Hz, 2H), 6.95 (d,
 
J = 8.6 
Hz, 2H), 4.38 (q, J = 7.2 Hz, 2H), 3.92 (s, 3H), 3.85 (s, 3H), 1.26 (t, J = 7.2 
Hz, 3H); 13C NMR (100.6 MHz, CDCl3): δ 160.6, 159.8, 159.0, 141.2, 
140.7, 139.7, 133.5, 130.7, 128.6 (2CH), 128.5 (2CH), 126.0 (2CH), 124.4, 
114.4 (2CH), 63.6, 55.6, 52.8, 13.8; IR (CCl4): ν = 2953, 1743, 1515, 1463, 
1444, 1337, 1219, 1163 cm-1; [M+Na]+: 467. 
 
 Methyl 1-phenyl-5-(phenylthio)-1H-pyrazole-3-carboxylate (12): 
Compound 12 was obtained as a light yellow oil following the general 
procedure for the 1,3-DC and separated by chromatography on silica gel 
(EtOAc/hexane 1/9).  1H NMR(300 MHz, CDCl3): δ 7.48-7.60 (m, 5H), 
7.30–7.40 (m 4H), 7.22–7.29 (m, 1H), 7.12–7.17 (m, 1H), 4.03–4.08 (s, 
3H); 13C NMR (75 MHz, CDCl3): δ 161.4, 143.3, 137.9, 134.9, 132.8, 
128.9 (2C), 128.7 (2C), 128.2, 128.1 (2C), 126.9, 124.9 (2C), 115.2, 51.5; IR (CCl4): ν = 2919, 
1726,1229,1011; [M+H]+: 311. 
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 Methyl 1-(4-nitrophenyl)-5-(phenylthio)-1H-pyrazole-3-carboxylate 
(13): Compound 13 was obtained as a light yellow solid following the 
general procedure for the 1,3-DC and separated by chromatography on 
silica gel (EtOAc/hexane 1/9). m.p.= 89.7-91.1 oC. 1H (300 MHz, CDCl3): 
δ 8.36-8.44 (m, 2H), 7.85–7.92 (m, 2H), 7.36–7.42 (m, 3H), 7.24–7.30 (m, 
2H), 7.19–7.20 (s, 1H), 4.06–4.09 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 
161.6, 147.0, 145.0, 143.2, 136.0, 132.5, 129.6 (2C), 129.5 (2C), 127.9, 125.8 (2C), 124.2 (2C), 
117.0, 52.5; IR (CCl4): ν = 2919, 1730,1531, 1345, 1233,1125, 1009, 854 ; [M+H]
+: 356. 
 
 Methyl 1-(4-methoxyphenyl)-5-(phenylthio)-1H-pyrazole-3-
carboxylate (14): Compound 14 was obtained as a light yellow solid 
following the general procedure for the 1,3-DC and separated by column 
chromatography on silica gel (EtOAc/Light Petroleum 1/9).  m.p.= 83.7 
oC;  1H (300 MHz, CDCl3): δ  7.43-7.47 (m, 2H), 7.32–7.40 (m, 3H), 7.23-
7.27 (m, 2H), 7.14–7.15 (s, 1H), 6.98–7.04 (m, 2H), 4.04-4.06 (s, 3H), 
3.94–3.95 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 162.5, 160.1, 143.9, 
136.0, 133.9, 131.9, 129.8 (2C), 129.6 (2C), 127.7, 127.3 (2C), 115.9, 114.1 (2C), 55.7, 52.3; IR 
(CCl4): ν = 2956, 1745, 1726, 1512, 1247, 1225, 1126, 1011; [M+H]
+: 341. 
 
 4-Ethyl 3-methyl-1-phenyl-5-(phenylthio)-1H-pyrazole-3,4-
dicarboxylate (15): Compound 15 was obtained as a light yellow oil 
following the general procedure for the 1,3-DC and separated by 
chromatography on silica gel (EtOAc/Light Petroleum 1/6). 1H NMR 
(400 MHz, CDCl3): δ 7.39-7.28 (m,
 5H), 7.15-7.09 (m, 3H), 7.04-6.99 
(m, 2H), 4.31 (q, J = 7.2 Hz, 2H), 3.92 (s, 3H), 1.26 (t, J = 7.2 Hz, 3H); 
13C NMR (100.6 MHz, CDCl3): δ 162.3, 161.5, 142.5, 138.0, 135.7, 133.0, 129.4 (2CH), 129.3, 
129.0 (2CH), 128.7 (2CH), 127.3, 126.0 (2CH), 122.3, 61.5, 52.4, 13.8; IR (CCl4): ν = 3065, 
2928, 2843, 1731, 1586, 1498, 1472, 1363, 1285, 1212, 1186 cm-1; [M+Na]+: 405. 
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 4–Ethyl 3-methyl-1-(4-nitrophenyl)-5-(phenylthio)-1H-pyrazole-3,4-
dicarboxylate (16): Compound 16 was obtained as a yellow oil 
following the general procedure for the 1,3-DC and separated by 
chromatography on silica gel (EtOAc/Light Petroleum 1/3).  1H NMR 
(400 MHz, CDCl3): δ  8.24 (d,
 
J = 9.1 Hz, 2H), 7.64 (d, J = 9.1 Hz, 2H), 
7.20-7.16 (m, 3H), 7.06-7.03 (m, 2H), 4.36 (q, J = 7.2 Hz, 2H), 3.97 (s, 
3H), 1.31 (t, J = 7.2 Hz, 3H); 13C NMR (100.6 MHz, CDCl3): δ 161.8, 
161.1, 147.5, 143.6, 142.7, 136.0, 132.3, 129.4 (2CH), 129.2 (2CH), 127.7 (2CH), 126.6 (2CH), 
124.1, 123.5, 61.7, 52.7, 13.9; IR (CCl4): ν = 3065, 29545, 1734, 1653, 1533, 1347, 1203, 1127, 
1079 cm-1; [M+Na]+: 450. 
 
 4-ethyl 3-methyl 1-(4-methoxyphenyl)-5-(phenylthio)-1H-pyrazole-
3,4-dicarboxylate (17): Compound 14c was obtained as a white oil 
following the general procedure for the 1,3-DC and separated by 
chromatography on silica gel (EtOAc/Light Petroleum 3/7). 1H NMR 
(400 MHz, CDCl3): δ  7.26-7.14 (m,
 5H), 7.06-7.02 (m, 2H), 6.84 (d, J = 
9.0 Hz, 2H), 4.31 (q, J = 7.2 Hz, 2H), 3.94 (s, 3H), 3.80 (s, 3H), 1.27 (t, J 
= 7.2 Hz, 3H); 13C NMR (100.6 MHz, CDCl3): δ 162.3, 161.5, 160.0, 
142.3, 135.7, 133.2, 130.9, 129.3 (2CH), 129.0 (2CH), 127.4 (2CH), 127.2, 122.1, 113.7 (2CH), 
61.5, 55.4, 52.4, 13.9; IR (CCl4): ν = 3063, 2955, 2839, 1734, 1515, 1478, 1365, 1287, 1253, 
1212, 1183 cm-1; [M+Na]+: 435. 
 
2-mercapto-1-phenylethanone: A solution of thiolacetic acid (5.6 g, 73.6 mmol) 
in dry pyridine (40 mL) was added to a solution of phenacyl chloride (10 g, 65.0 
mmol) and resultant reaction mixture was maintained at 85oC for 1.5-2 h. After cooling to RT, 
chloroform (200 mL) was added to orange reaction mixture, which was washed with 10% HCl 
(150 mL), and extracted with 10% NaOH (150 mL). The organic layer was dried over MgSO4, 
filtered and solvent was evaporated in vacuo. The crude product was purified by flash column 
chromatography using 1-2% EtOAc/hexane as eluent to afford phenacyl thiolacetate (10.2 g, 
80% yield).  1H NMR (400 MHz, CDCl3): δ 7.98-8.02 (m,  2H), 7.58-7.64 (tt, J = 6 Hz and 1.5 
Hz, 1H), 7.47-7.53 (m, 2H), 4.41 (s, 2H), 2.42 (s, 3H). 
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A solution of phenacyl thiolacetate (10.2 g, 52.5 mmol) in ether (60 mL) was stirred 
vigorously while aq. 2N NaOH solution (58 mL, 120 mmol) was added. This mixture was stirred 
for 2 h, and then separated. The aqueous layer was cooled to 0 oC and acidified. This was 
extracted with DCM (2 x 100 mL). Combined organic layers were dried over MgSO4 and 
evaporated in vacuo. The crude product 2-mercapto-1-phenylethanone was purified by flash 
column chromatography using 5% EtOAc/hexane as eluent to afford pure product as yellow oil 
(7.3 g, 91% yield). 1H NMR (400 MHz, CDCl3): δ 7.93-7.99 (m, 2H), 7.56-7.63 (m, 1H), 7.45-
7.52 (m, 2H), 3.94-3.98 (d, J= 8 Hz, 2H), 2.11-2.15 (t, J = 8 Hz, 1H). 
 
2,2'-disulfanediylbis(1-phenylethanone) (18): To a stirred 
solution of 2-mercapto-1-phenylethanone (5 g, 32.9 mmol) in 
EtOAc (30 mL) was added NaI (49.5 mg, 0.33 mmol) and 30% 
H2O2 (3.38 mL, 32.9 mmol) and mixture was stirred at RT for 1 h. Saturated aq. Na2S2O3 (100 
mL) was then added and resulting mixture was extracted with EtOAc (3 x 50 mL) .The 
combined organic extracts were washed with brine and dried over anhydrous Na2SO4. The 
solvent was evaporated in vacuo. Crude product was purified with flash column chromatography 
using 5% EtOAc/Hexane as eluent to get off white solid. (4.65 g, 93% yield).1H NMR (300 
MHz, CDCl3): δ 7.88-7.99 (d, J = 6 Hz,  4H), 7.55-7.63 (tt, J = 7.5 and 1.5, 2H), 7.42-7.51 (t, J = 
7.5, 4H), 4.20 (s, 4H). 
 
 1,2-bis((2-phenyl-1,3-dioxolan-2-yl)methyl)disulfane (19): A solution 
of 2,2'-disulfanediylbis(1-phenylethanone) 18 (4.65 g, 15.4 mmol), 
ethylene glycol (5.9 g, 92.4 mmol), triethyl orthoformate (11.58 mL, 61.6 
mmol) and PTSA (0.3 g, 1.57 mmol) in toluene was heated to 60oC for 3 
h. After completion reaction mixture was cooled and diluted with EtOAc 
(30 mL) then washed with aq.K2CO3 and brine. Organic layer was then dried over anhydrous 
Mg2SO4 and evaporated. The crude solid product was purified by column chromatography using 
1-5% EtOAc/hexane to give light yellow solid as product (4.9 g, 81% yield). 1H NMR (300 
MHz, CDCl3): δ 7.45-7.53 (m, 4H), 7.25-7.38 (m, 6H), 4.03-4.18 (m, 4H), 3.77-3.89 (m, 4H), 
3.33 (s, 4H).  
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 Trimethyl (((2-phenyl-1,3-dioxolan-2-yl)methylthio)ethynyl)silane 
(20): Trimethylsilylethyne (0.5 g, 5.1 mmol) was dissolved in dry THF 
(10 mL) at 0oC. n-BuLi solution (1.6 M in Hexane, 3.8 mL, 6.1 mmol) 
was then added dropwise with stirring under argon. After 45 min. a solution of 1,2-bis((2-
phenyl-1,3-dioxolan-2-yl)methyl)disulfane (2 g, 6.6 mmol) in THF ( 20 mL) was introduced at 
0oC and stirring was continued for 1-2 h. Then reaction mixture was quenched with sat. NH4Cl 
solution (15 mL). The mixture was then extracted with ether (3 x 15 mL) and organic layer was 
washed with water (2 x 15mL) and brine. The ether layer was then dried dried over anhydrous 
Mg2SO4 and evaporated in vacuo. The residue was purified by flash column chromatography 
using n-hexane as eluent to give colourless oil (1.2 g, 80% yield). 1H NMR (300MHz, CDCl3): δ 
G7.45-7.55 (m, 2H), 7.30-7.44 (m, 3H), 4.02-4.22 (m, 2H), 3.78-3.93 (m, 2H), 3.34 (s, 2H), 0.14 
(s, 9H). 
 
 2-(ethynylthiomethyl)-2-phenyl-1,3-dioxolane (21): To a stirred solution of 
trimethyl(((2-phenyl-1,3-dioxolan-2-yl)methylthio)ethynyl)silane (0.5 g, 1.71 
mmol) in THF (10 mL) at 0oC was added dropwise a solution of TBAF-hydrate 
( 0.5 g, 1.91 mmol) dissolved in THF (5 mL). The reaction was then vigorously stirred at 0°C for 
1-2 h. After completion, sat. NH4Cl (15 mL) was added and mixture was extracted with diethyl 
ether (3 x 10 mL). The combined ether extracts were washed with water (2 x 15 mL) and brine. 
The ether layer was then dried dried over anhydrous Mg2SO4 and evaporated in vacuo to give 2-
(ethynylthiomethyl)-2-phenyl-1,3-dioxolane as a brown solid (351 mg, 93% yield). 1H NMR 
(300 MHz, CDCl3): δ 7.49-7.57 (m, 2H), 7.32-7.44 (m, 3H), 4.17-4.25 (m, 2H), 3.88-3.94 (m, 
2H), 3.34 (s, 2H), 2.70 (s, 1H).  
 
 Methyl 4-formyl-1-phenyl-5-((2-phenyl-1,3-dioxolan-2-
yl)methylthio)-1H-pyrazole-3-carboxylate (22a): To a solution of 2-
(ethynylthiomethyl)-2-phenyl-1,3-dioxolane (0.1 g, 0.43 mmol) in dry 
THF (5 mL) at 78°C was added dropwise a solution of 1M LiHMDS in 
THF (0.47 mL, 0.47 mmol) and resulting mixture was stirred for 20 
min at same temperature. After 20 min. freshly distilled HMPA (0.37 mL, 2.15 mmol) was added 
to reaction and reaction was allowed to warm slowly to 35 °C  in 2 h. After that reaction was 
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again cooled to -78 °C and dry DMF (0.06 mL, 0.86 mmol) was added. Reaction was allowed to 
warm to -35 °C in 2 h and kept at same temperature for further 1.5 h. After that reaction was 
quenched at -35 °C with sat. NH4Cl (5 mL) and extracted with diethyl ether (3 x 10 mL). The 
combined ether extracts were washed with water (2 x 10 mL) and brine. Organic layer was then 
dried over anhydrous MgSO4 and evaporated in vacuo. The crude product was used as it is for 
further reaction without purification. 
Compound (22a) was obtained as a light yellow oil following the general procedure for 
the 1,3-DC and separated by chromatography on silica gel using 10-20% EtOAc/Hexane. Yield: 
126 mg, (66% overall yield);  1H NMR (400 MHz, CDCl3): δ 7.41-7.66 (m, 5H),  7.16-7.33 (m, 
5H), 4.00 (s, 3H), 3.58-3.68 (m, 4H), 3.38 (s, 2H). 13C NMR (100 MHz, CDCl3): δ 186.3, 162.1, 
144.9, 142.5, 140.8, 138.4, 129.7, 129.1, 128.6, 128.4, 126.7, 125.8, 124.8,108.9, 65.4, 52.9, 
45.3; [M+Na]+: 447.  
 
 Methyl 4-formyl-1-(4-nitrophenyl)-5-((2-phenyl-1,3-dioxolan-2-
yl)methylthio)-1H-pyrazole-3-carboxylate (22b): Compound (22b) 
was obtained as a yellow oil following the general procedure for the 
1,3-DC and separated by chromatography on silica gel using 10-20% 
EtOAc/Hexane. Yield:  60 mg, 42%; 1H NMR (300 MHz, CDCl3): δ 
10.54 (s, 1H), 8.35 – 8.41 (d, J = 9 Hz, 2H), 7.82 – 7.87 (d, J = 9 Hz, 
2H), 7.18 – 7.28 (m, 5H), 4.02 – 4.05 (s, 3H), 3.65 – 3.75 (m, 4H), 3.46 – 3.50 (s, 2H); 13C NMR 
(75 MHz, CDCl3): δ 186.0, 161.6, 147.9, 145.6, 143.0, 142.8, 140.3, 128.9, 128.5 (s), 127.4 (s), 
125.8 (s), 125.6, 124.4 (s), 108.8, 65.3 (s), 53.1, 45.6; IR (CCl4): ν = 2956, 1729, 1686, 1598, 
1541, 1533, 1347, 1254, 1141, 1011 cm-1;  [M+Na]+: 492. 
 
 Methyl 4-formyl-1-(4-methoxyphenyl)-5-((2-phenyl-1,3-dioxolan-2-
yl)methylthio)-1H-pyrazole-3-carboxylate (22c): Compound (22c) 
was obtained as a yellow oil following the general procedure for the 
1,3-DC and separated by chromatography on silica gel using 10-20% 
EtOAc/Hexane. Yield: 57.7 mg, 43 %;1H NMR (300 MHz, CDCl3): 
δ 10.53 (s, 1H), 7.44 – 7.48 (d, J = 6 Hz, 2H), 7.21 – 7.25 (m, 5H), 6.97 
– 7.02 (d, J = 6 Hz, 2H), 3.99 – 4.02 (s, 3H), 3.87 – 3.89 (s, 3H), 3.62 – 3.72 (m, 4H), 3.36 – 
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3.39 (s, 2H); 13C NMR (75 MHz, CDCl3): δ 186.4, 162.3, 160.5, 144.7, 142.5, 140.8, 131.4, 
128.6, 128.4 (s), 127.9 (s), 127.3, 125.8 (s), 114.2 (s), 108.8, 65.4 (s), 55.9, 52.9, 45.1; IR (CCl4): 
ν= 3065, 2955, 2892, 1726, 1682, 1612, 1515, 1475, 1253, 1172,1142, 1040 cm-1;  [M+Na]+: 
477. 
 
 Methyl-5-benzoyl-1-phenyl-1H-thieno[2,3-c]pyrazole-3-carboxylate 
(23a) : To a stirred solution of (22a) (100 mg, 0.23 mmol) in acetone 
(5mL) was added 30% TFA in water (10 mL). The resulting mixture was 
then heated at 65°C for overnight. After completion, reaction was cooled 
to room temperature and then acetone was removed carefully under 
reduced pressure. The aqueous layer was then extracted with CHCl3 (3 x 
10 mL). The combined organic layers were washed with water till neutral and then with brine. 
Organic layer was dried over anhydrous MgSO4 and evaporated in vacuo to give crude product. 
This crude product was then purified by preparative TLC plates to give desired product (23) as a 
off white solid (17 mg, 20% overall yield). 1H NMR (400 MHz, CDCl3): δ 7.88-7.97 (m, 4H), 
7.87 (s, 1H), 7.62-7.69 (t, J=16 Hz, 1H), 7.51-7.62 (quartet, J=12 Hz, 4H), 7.37-7.46 (t, J = 16 
Hz, 1H), 4.03 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 189.7, 162.0, 145.6, 144.8, 138.9, 138.0, 
137.4, 132.9, 132.1, 130.0, 129.3, 128.9, 127.9, 125.5, 119.3, 52.8. [M+Na]+: 385.  
 
 Methyl 5-benzoyl-1-(4-nitrophenyl)-1H-thieno[2,3-c]pyrazole-3-
carboxylate (23b): To a stirred solution of (22b) (40 mg, 0.08 mmol) in 
acetone (3mL) was added 50% TFA in water (3 mL). The resulting 
mixture was then heated at 65 °C for overnight. After completion, 
reaction was cooled to room temperature and then acetone was removed 
carefully under reduced pressure. The aqueous layer was then extracted 
with EtOAc (3 x 5 mL). The combined organic layers were washed with 
water till neutral and then with brine. Organic layer was dried over anhydrous MgSO4 and 
evaporated in vacuo to give crude product. This crude product was then purified by preparative 
TLC plates to give desired product (23b) as a yellow solid (9 mg, 26% yield). m.p.= 223.2 °C. 
1H NMR (300 MHz, CDCl3): δ 8.45 -8-49 (d, J = 9 Hz, 2H), 8.09 – 8.13 (d, J = 9 Hz, 2H), 7.90 
– 7.96 (dt, J = 9 and 1.5 Hz, 2H), 7.88 - 7.90 (s, 1H), 7.64 – 7.72 (tt, J = 7.5 and 1.5 Hz, 1H), 
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7.53 – 7.62 (tt, J = 7.5 and 1.5 Hz, 2H), 4.05 – 4.07 (s, 3H); 13C NMR (75 MHz, CDCl3): δ 
189.3, 161.5, 146.3, 145.9, 145.7, 143.2, 139.5, 137.0, 133.2, 132.8, 129.3 (s), 129.0 (s), 125.9 
(s), 125.1, 119.3 (s), 53.1; IR (CCl4): ν = 2927, 1752, 1727, 1640, 1597, 1532, 1508, 1341, 1285, 
1204, 1144, 1085 cm-1; [M+Na]+: 430.  
 
 Methyl-5-benzoyl-1-(4-methoxyphenyl)-1H-thieno[2,3-c]pyrazole-3-
carboxylate (23c): To a stirred solution of (22c) (50 mg, 0.11 mmol) in 
acetone (3mL) was added 50% TFA in water (3 mL). The resulting 
mixture was then heated at 65°C for overnight. After completion, 
reaction was cooled to room temperature and then acetone was removed 
carefully under reduced pressure. The aqueous layer was then extracted 
with EtOAc (3 x 5 mL). The combined organic layers were washed with 
water till neutral and then with brine. Organic layer was dried over anhydrous MgSO4 and 
evaporated in vacuo to give crude product. This crude product was then purified by preparative 
TLC plates to give desired product (23b) as a off white solid (10 mg, 23% yield). m.p.= 191.5 
°C. 1H NMR (400 MHz, CDCl3): δ 7.88 -7.93 (d, J = 6 Hz, 2H), 7.84 -7.86 (s, 1H), 7.80 – 7.84 
(d, J = 6 Hz, 2H), 7.62 – 7.68 (tt, J = 6 and 1.5 Hz, 1H), 7.52 – 7.58 (t, J = 6 Hz, 2H), 7.05 – 7.09 
(d, J = 9 Hz, 2H), 4.00 – 4.03 (s, 3H), 3.87 – 3.90 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 189.7, 
162.1, 159.3, 145.4, 144.7, 137.5, 132.8, 132.4, 132.0, 129.3(s), 128.9 (s), 125.6, 123.0, 121.0 
(s), 115.1 (s), 55.9, 52.7; IR (CCl4): ν = 3005, 2954, 2839, 2361, 1748, 1723, 1638, 1543, 1518, 
1466, 1392, 1287, 1252, 1204, 1144, 1091 cm-1; [M+Na]+: 415. 
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Chapter 3 
1,3-Dipolar Cycloaddition of Nitrile Imines with α-β-Unsaturated 
Cyclic Enones. 
 
3.1  Introduction: 
 As discussed in earlier chapters, ring-fused pyrazole derivatives displays broad spectrum 
of biological activities and are synthetically challenging. Much work has been directed towards 
the design and the synthesis of complex pyrazoles giving particular relevance to the 
functionalization of the scaffold in different regions and in particular to the synthesis of ring-
condensed structures. Indeed, the preparation of pyrazole-fused ring derivatives seems to be very 
important and challenging from the synthetic point of view. Following our interest in 1,3-DC 
reaction for direct access to ring-fused pyrazoles, we have developed a protocol through 1,3-DC 
between cyclic enones and nitrile imines which on further oxidation can lead to the formation of 
ring-fused pyrazole. This is a direct and simplest route with and advantage of having high regio 
and stereocontrol in the reaction which is due to the presence of carbonyl group next to the 
double bond in α- position. 
 
3.2 Recent literature on synthesis and biological importance: 
There are few literature references available on cycloaddition reaction of cyclic enones 
with various 1,3-dipoles. Owing to its importance in synthesis and biological evolution thereafter 
we decided to investigate a direct and simple route for the synthesis of ring fused pyrazoles 
starting from various cyclic enones and the nitrile imines.  
In 2004 Jack Baldwin et.al.1 have reported regio- and stereospecific [3+2] cycloaddition 
of a nitrone derived from N-hydroxy-2-pyridone with medium ring enones which occurred with 
moderate to good yield. In this they found that these cycloadditions were highly regiocontrolled 
and the products formed with high retention of alkene geometry (Sheme 3.1).  They also found 
that 2-cyclopentenone and 2-cyclohexenone were not reactive in this type of cycloaddition.  
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Scheme 3.1: Reported work by Jack Baldwin et.al. 
 
 
In 2007 Ying-Chun Chen et.al.2 reported a enantioselective 1,3-DC of cyclic enones and 
a cyclic azomethine imine in the presence of cinchona alkaloids to give a tricyclic product with 
excellent diastereoselectivity. They have found the additional and synergistic hydrogen bonding 
interaction of catalyst and 1,3-dipole is essential for enantioselectivity and stereoselectivity in 
this type of reaction (Scheme 3.2). 
 
Scheme 3.2: Enantioselective 1,3-DC of cyclic enones and a cyclic azomethine imine. 
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In 2008, Juan Carretero et.al.3 used azomethine ylides in the reaction with cyclic α,β-
unsaturated ketones. The reaction of N-benzylidene glycine methyl ester with 2-cyclopentenone 
catalyzed by chiral Cu(I)-Fe-sulphos complexes afforded a bicyclic pyrrolidine with high endo- 
and enantioselectivity (Scheme 3.3), whereas a very low conversion was observed in the reaction 
with 2-cyclohexenone. 
 
Scheme 3.3: 1,3-DC between azomethine ylide and cyclopentenone. 
 
Furthermore D. Bonnet-Delpon et.al.4 performed the reaction of an azomethine ylide 
generated from N-(trimethylsilylmethyl)-N-(pentoxymethyl)-benzylamine with CF3-substituted 
2-cyclohexenone (Hagemann’s ester) to give a bicyclic perhydroindolone in moderate yield 
(Scheme 3.4). In this case CF3 group acts as an activating group in the reaction, which 
significantly lower the LUMO energy in order to facilitate the cycloaddition reaction. 
 
Scheme 3.4: Ring fused perhydroindolone reported by D. Bonnet-Delpon et.al. 
 
 
The reaction of diphenylnitrilimine with cycloalken-2-enone lead to regiomeric mixtures 
of 4-acyl and 5-acyl derivatives.5 The synthesis of biologically active pyrrolo[3,4-c]pyrazole-4,6-
dione derivatives from diarylnitrilimines and N-arylmaleimides has been reported by Nada 
Abunada et.al.6  in 2008 (Scheme 3.5). They have tested these compounds for their antimicrobial 
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activity against gram negative bacteria Eschercia coli and  gram positive bacteria Staphylococcus 
aureus and antifungal activity against Asperagillus flavus and Candida albicans.  
 
Scheme 3.5: The synthesis of biologically active pyrrolo[3,4-c]pyrazole-4,6-dione. 
 
 
3.3  Present work strategy: 
With the aim to extend the scope of nitrile imines cycloaddition for the synthesis of fused 
heterocycles of pharmaceutical interest, we have tried the 1,3-DC of C-carboxymethyl-N-aryl-
nitrile imines with α,β-unsaturated cyclic enones. The further aromatization of the initially 
formed fused and strained pyrazolines A and B in situ, would offer a direct method for the 
synthesis of these bicyclic compounds. (Figure 3.1).  
 
Figure 3.1: Generic protocol for obtaining the ring fused pyrazoles. 
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In particular the use of 2-cyclohexenone as dipolarophile would lead directly to the 7-
oxo-tetrahydroindazoles, that are scaffolds for the synthesis of more complex 4,5-dihydro-1H-
pyrazolo [4,3-h]quinazolines) which are very promising as kinase inhibitors.7  
 
3.4  Result and discussion: 
The reaction of 5-, 6-, 7- membered ring enones 2-4 with C-carboxymethyl-N-aryl nitrile 
imines, generated in situ from hydrazonoyl chlorides 1a-c (Scheme 3.6), were carried out in dry 
dioxane at 80 °C for 18 h, using Ag2CO3 or Et3N (TEA) as bases in order to investigate their 
influence on the yield and the regioisomeric ratio.  
 
Scheme 3.6: General scheme for the 1,3-dipolar cycloaddition followed by CAN oxidation. 
 
In the literature a different mechanisms for generation of nitrile imines are reported, 
specifically from hydrazonoyl chlorides in the presence of Ag2CO3 or TEA. In the former case 
the first step is a silver ion promoted dehalogenation to give an intermediate nitrilium- like 
carbocation,8 with TEA the deprotonation occurs first followed by the loss of halide ion.9 
All the reactions were also performed in the presence of catalytic amount of Sc(OTf)3. 
This Lewis acid was found to affect the regiochemistry of 1,3-DC of nitrile imines with 
functionalized acetylenes10 as shown in earlier chapter. In all the reactions GCMS analysis and 
1HNMR data revealed a partial aromatization of the initially formed pyrazolines to pyrazoles. 
For example in the reaction of both cyclohexenone 3 and 1a with Ag2CO3 or TEA about 50% of 
aromatized product was found at the end of the reaction (entry 4, Table 3.1); the reaction of 3 
with 1b gave 90% of aromatization with TEA (entry 5, Table 3.1). With cyclic enones 2 and 4 
the aromatized product was found in minor amount at the end of the reaction. The aromatization 
was then completed by treatment of the reaction crude with an oxidizing agent, CAN 
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(cerium(IV)ammonium nitrate). After purification by column chromatography, the structural 
assignment of the separated regioisomers 5-7a-c (5-acyl-pyrazoles) and 5-7a’-c’ (4-
acylpyrazoles) was done based on 1HNMR and X-ray analysis. The yield (calculated on 
separated products) and the regioisomeric ratio of 5-acyl and 4-acyl derivatives in the reaction 
performed with the two bases and without or with Sc(OTf)3 are reported in Table 3.1.  
 
Table 3.1: 1,3-DC of nitrile imines 1a-c with α,β-Unsaturated Cyclic Enones 2-4 
Sr. 
No. 
Nitrile 
imine 
Cyclic 
enones 
Cycloadducts Yield  
(%) 
Regioisomeric 
Ratio 
Yield  
(%) 
Regioisomeric 
Ratio 
* ** * ** *** **** *** **** 
1 1a 2 5a-5a’ 32 14 78:22 76:24 27 43 62:38 70:30 
2 1b 2 5b-5b‘ 49 26 77:23 83:17 43 65 19:81 20:80 
3 1c 2 5c-5c’ – – – –     
4 1a 3 6a-6a’ 42 19 82:18 99:1 72 60 99:1 99:1 
5 1b 3 6b-6b’ 65 34 80:20 99:1 88 62 90:10 99:1 
6 1c 3 6c-6c’ 17 11 60:40 99:1     
7 1a 4 7a-7a’ 36 28 99:1 99:1 82 64 86:14 83:17 
8 1b 4 7b-7b’ 53 38 99:1 99:1 63 69 63:27 79:21 
9 1c 4 7c-7c’ – – – –   – – 
[*]: Ag2CO3 without Sc(OTf)3 [**] Ag2CO3 with Sc(OTf)3 [***]: TEA without Sc(OTf)3 [****] TEA with Sc(OTf)3 
 
Some aspects of this reaction deserve specific comments as outlined from above Table 3.1.  
1. The reactivity of C-carboxymethyl-N-p-NO2-phenyl nitrile imine (1c) with these alkenes 
is very low. No cycloadducts are formed with 2-cyclopentenone 2 and 2-cycloheptenone 
4 and only 17% yield of a balanced mixture of the adducts 6c-c’ has been obtained with 
2-cyclohexenone 3.  
2. The C-carboxymethyl-N-p-OCH3-phenyl nitrile imine is more reactive than the 
unsubstituted phenyl analogue and better yields of cycloadducts were obtained by using 
either Ag2CO3 or TEA (compare entries 2, 5, 8 with 1, 4, 7 in Table3. 1).  
3. As far as the influence of the bases and the size of cyclic enones are concerned, in general 
better yields were obtained by using TEA as a base and with 6- and 7-membered ring 
enones. The yields of 6b-b’ and 7a-a’ with TEA were 88% and 82% respectively. The 
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lower yields obtained with 2 might be the result of an increased tendency for 2-
cyclopentenone enolization.  
4. 2-Cyclohexenone and 2-cycloheptenone generally exhibit a high degree of 
regioselectivity with the prevalent formation of 5-acyl derivative: isomeric ratios from 
80:20 to 99:1 in the presence of Ag2CO3 and from 63:27 to 99:1 with TEA were obtained 
with nitrile imines originated from 1a and 1b. 
5. The addition of a catalytic amount of Sc(OTf)3 in the reaction performed by using 
Ag2CO3 increased the ratio 5-acyl / 4-acyl to 99:1 (entries 4-8 Table 3.1), but with a 
drastic reduction of the yields.  
6. The influence of Sc(OTf)3 on the isomeric ratio was not so important when TEA was 
used as a base and the yields of the reaction remained acceptable. A deviant result was 
found for p-MeO-phenyl substituted 1,3-dipole (1b) with 2-cyclopentenone in the 
presence of TEA. In this reaction a ratio 19:81 and 20:80 in favour of the 4-acyl 
derivative was obtained without and with Sc(OTf)3 respectively.  
 
All these trends can be explained by using a theoretical model (Computational study) by 
doing some molecular calculations and X-ray studies. 
 
3.4.1 Analysis of the Global and Local Reactivity Indexes at the Ground State of reagents.  
The reactivity indexes were evaluated on the dipole and dipolarophile reagents with the 
aim of describing the experimentally observed regioselectivity. The most interesting effect 
occurred when an inversion on the regioselectivity was found for p-MeO-phenyl substituted 1,3-
dipole (1b) with 2-cyclopentenone in the presence of TEA. In order to theoretically evaluate the 
TEA contribution on the regioselectivity, following intermediate conformation that could 
participate in the reaction was proposed (Figure 3.2).  
 
 
 
 
 
 
65 
 
Figure 3.2: Models for the dipoles used in 1,3-dipolar cycloaddition. 
 
In Table 3.2 the electronic chemical potential µ, chemical hardness η, global 
electrophilicity index ω, and global nucleophilicity index N are displayed for the dipole and 
dipolarophile reagents. The electronic chemical potentials, µ, of the dipoles 1a (-0.1399 a.u.) and 
1b (-0.1293 a.u.) were higher than those for the dipolarophiles, which have values between -
0.1409  and -0.1429.  Therefore, the charge transference (CT) at these 1,3-DC reactions will take 
place from the dipole to the dipolarophiles in a normal-electron demand (NED) fashion.  On the 
contrary, in the case of dipole 1c, the electronic chemical potential (µ = -0.1693a.u.) was lower 
compared with those found for the dipolarophiles. Therefore, the CT at these 1,3-DC reactions 
will take place from the dipolarophile to the dipole in an inverse-electron demand (IED) fashion. 
This change in the reactivity pattern of the p-nitro derivative (1c) may be responsible for the low 
reactivity of this system.    
In Table 3.2, the dipoles are classified as strong electrophiles and the dipolarophiles as 
moderate electrophiles, according to the absolute scale of electrophilicity based on the ω index 
reported by Domingo.11 In this scale the simple nitrilimine (NI) is classified as marginal 
electrophile11 (ω=0.28 eV), but our calculations at the ground state, using the same level of 
theory, classify it as moderate electrophile (ω=1.07 eV). The global electrophilicity values 
predict the charge transfer from dipolarophile to dipole in an IED 1,3-DC reactions, which is in 
disagreement with the chemical potential µ prediction, but we considered the chemical potential 
as the index which determines the direction of the electronic flux along the cycloaddition. 
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Table 3.2: Global properties and global electrophilicity for nitrile imines dipole 
and cycloalkenones involved in the 1,3-dipolar cycloaddition reactions. 
  HOMO LUMO µ (a.u.) η (a.u.) ω (eV) N (a.u) 
Dipole  1a -0.2169 -0.0629 -0.1399 0.1541 1.73 0.7831 
 
M-I 1b -0.2018 -0.0568 -0.1293 0.1450 1.57 0.7982 
  1c -0.2394 -0.0991 -0.1693 0.1404 2.78 0.7606 
 
M-II 
      
1a -0.1664 -0.0204 -0.0934 0.1460 0.81 0.8336 
1b -0.1582 -0.0164 -0.0874 0.1418 0.73 0.8418 
1c -0.1875 -0.0654 -0.1265 0.1222 1.78 0.8125 
        
  NI
a -0.2381 -0.0224 -0.1303 0.2158 1.07 0.7618 
Dipolarophile  
       
2 -0.2376 -0.0443 -0.1409 0.1933 1.40 0.7624 
3 -0.2363 -0.0483 -0.1423 0.1881 1.46 0.7637 
4 -0.2377 -0.0481 -0.1429 0.1897 1.46 0.7623 
a Values obtained in this work for dipole model of nitril imine used by Domingo.11 
 
As we see in Table 3.2, the µ and ω indexes properly reflect the substituent effect over 
the p-position at the dipole phenyl group.  The electron withdrawing group (EWG), NO2 
increases the global electrophilicty and decreases the chemical potential, and, therefore, increases 
the electronegativity of the system. On the other hand, the electron donating group (EDG), MeO 
decreases the global electrophilicty and increases the chemical potential making the system less 
electronegative. As expected electrophilic (ω) and nucleophilic indexes (N) present inverse 
reactivity trends (Table 3.2). In the case of the dipolarophiles, contrary to what is expected from 
the bonding strength in the small ring, cyclopentenone 2 is the less reactive in terms of the global 
electrophilicity compared with the other used dipolarophiles, and all of them are in the range of 
moderate electrophiles.  
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Studies of the regioselectivity on Diels Alder (DA) reactions have shown that the analysis 
of the local electrophilicity,	

, at the electrophile, together with the analysis of the nucleophilic 
Fukui functions, 
, at the nucleophile,12 allows the prediction of the regioselectivity in these 
competitive cycloadditions. In his work Domingo et. al.13 extended this methodology to describe 
the regioselectivity of some 1,3-DC. In Table 3.3 the electrophilic, 
, and nucleophilic, 
, 
Fukui functions contributions to the respective atomic centres are summarized. The arrows 
represent the electronic flux directions in the cycloaddition reactions following the chemical 
potential predictions (µ values in Table 3.2).  
As is represented in Figure 3.1, the interaction between N1 and C3 at the dipole with C5 
and C4 at the dipolarophile, respectively, will be favoured to give the experimentally major 
product, in almost all reactions. As we can see in Table 3.3 and Figure 3.2, the adequate 
analysis of the corresponding Fukui functions correctly predicts the experimentally observed 
regioselectivity in these kinds of reactions. As discussed previously, the 1c dipole will react in an 
IED fashion. Contrary to 1a and 1b dipoles, 1c will be electrophile in the 1,3 DC reactions. The 
experimental results showed that this dipole reacts only with cyclohexenone 3 with low yields 
and with the same regioselectivity as that of other dipoles (Table 3.1, entry 6). In Table 3.2 and 
Table 3.3, we observed that not only the global reactivity changes in 1c dipole but also the 
electrophilic local reactivity. Therefore, the final regioselectivity description in terms of these 
descriptors is in total agreement with the experimental evidence. Additionally, as mentioned in 
Table 3.3, the 
index predicts low reactivity at the 1c reactive atoms (N1=0.01 and C3=0.09) 
which accounts for little or null experimental yield when this dipole is used. 
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Table 3.3: Eletrophilic, 
, and nucleophilic, 
, Fukui functions integrate over the respective 
atomic centers. The atomic numbers are according to the Scheme 3.1. 
 
Dipole 
 
Dipolarophile 
1a 1b 1c k 2 3 4 
M-I 
 
0.12 
0.10 
0.12 
0.12 
0.09 
0.11 
0.01 
0.06 
0.09 
0.24 
0.10 
0.20 
0.07 
0.20 
0.04 
 
0.14 
0.00 
0.18 
0.12 
0.00 
0.14 
0.14 
0.00 
0.17 
0.10 
0.05 
0.10 
0.03 
0.11 
0.03 
0.11 
0.00 
0.12 
0.11 
0.00 
0.12 
0.14 
0.01 
0.11 
M-II  
 
As was previously noted, the activations of dipoles by TEA reverses the regioselectivity 
when dipole 1b is used in the reaction. To evaluate the TEA influence in the reactions, the 
reactivity descriptors were calculated over the intermediate nitrilimine-TEA (M-II in Scheme 
3.2). The intermediate (M-II) will act as nucleophile against dipolarophiles from chemical 
potential (µ) prediction (Table 3.2). Interestingly, the most nucleophilic intermediate is the 
corresponding to 1b dipole (N=0.8418 a.u., Table 3.2). Considering that the intermediates 
(described by model II) have relatively short half-life, it is expected that only the most reactive 
one is more likely to react with the dipolarophiles, which could justify that only 1b intermediate 
reacts. To evaluate the regioselectivity, nucleophilic Fukui functions ( 
) were calculated for 
the intermediates. The total atomic contributions of this function are reported in Table 3.3. These 
values are in disagreement with the experimentally observed regioselectivity. As described in the 
computational details, we have evaluated the Fukui functions topologically, obtaining basins 
(regions) around the maximum of this function with chemical interpretation. 
the Fukui functions basins and their corresponding condensed values. Reactive atom (N1) has 
two asymmetrical basins, one of them, the less reactive, is protected by the TE
while the high nucleophilic basin is exposed to possible reactions, i.e. with cyclic enones. 
Therefore, the analysis of local reactivity in terms of the Fukui function condensed over its own 
basins, is in total agreement with the observed 
TEA. Finally, the experimental evidence that the inverse product is only obtained when 2
cyclopentenone is used in the reaction, could be explained by the steric effects of the TEA ethyl 
substituent when the complex intermediate 
favour the reaction. 
 
Figure 3.3: Local Fukui function prediction of the most probable interaction between 
and dipolarophile 2, using the M-
when react with all the studied dipolarophiles (
values are placed over its respective basins
 
 
 
 
 
 
 
Figure 3.3
regioselectivity when 1b dipole is activated by 
M-II is forming then, only a small dipolarophile will 
I to the dipole. The same reaction pattern will follows 
Table 3.2 and Table 3.3). The Fukui condensed 
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 shows 
A and the other, 
-
1a dipole 
1b dipole 
Figure 3.4: Local Fukui function prediction of the most probable interacti
intermediate (M-II) and dipolarophile 
respective basins. 
 
3.5 Conclusions: 
In conclusion we developed a regiocontrolled one pot synthesis of cycloalkenones fused 
with pyrazoles through 1,3-dipolar cycloaddition of 
α,β-unsaturated cyclic ketones. The effect of the substituent in para
dipole, the size of the dipolarophiles and their effect on yields and regiochemistry have been 
investigated. These results shows
reactivity could give count of the experimental observations in these kind of reactions. To 
explain the inversion on regioselectivity when 
that an intermediate prior to the dipole formation could be the reactive species, and the use of the 
topological analysis of the Fukui functions allows a theoretical description of the local reactivity 
in agreement with the experiment
 
 
 
 
 
 
 
 
 
on between 
2, The Fukui condensed values are placed over its 
C-carboxymethyl-N-aryl nitrilimines and 
-position of the aryl on the 
 that adequate use of global and local theoretical descriptors of 
1b dipole is activated by TEA, we have proposed 
al results. 
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3.6 Experimental Section: 
 
3.6.1 Material and Methods:  
1H NMR and 13C NMR spectra were recorded using CDCl3 or CD3OD or DMSO-d6 
solutions at 300, 400 and 600 MHz for 1H and 75.46, 100.6 and 150.92 MHz for 13C. Chemical 
shifts (δ) are reported in ppm relative to CHCl3 (δ = 7.26 for 
1H and δ = 77.0 for 13C ). J values 
are given in Hz. 1H NMR and 13C NMR spectral assignments were made by DEPT, gCOSY and 
gHSQC experiments. IR spectra were recorded in solvent as specified. Mass spectra (MS) were 
obtained with an electrospray ionization source (ESIMS). All the ESIMS spectra were performed 
using MeOH as the solvent. High Resolution Mass Spectra (HRMS) were recorded on a 
micromass LCT spectrometer using electrospray (ES+) ionisation techniques. Reactions were 
conducted in oven-dried (120 °C) glassware under a positive Ar atmosphere. Transfer of 
anhydrous solvents or mixtures was accomplished with oven-dried syringes/septum techniques. 
THF was distilled from sodium/benzophenone just prior to use and stored under Ar. Toluene was 
distilled from sodium. Et2O was distilled from phosphorus pentoxide. CH2Cl2 was passed 
through basic alumina and distilled from CaH2 prior to use. Other solvents were purified by 
standard procedures. Light petroleum ether refers to the fraction with bp 40-60°C. The reactions 
were monitored by TLC performed on silica gel plates (Baker-flex IB2-F). Column 
chromatography was performed with Merck silica gel 60 (70-230 mesh). Preparative thick layer 
chromatography was carried out on glass plates using a 1 mm layer of Merck silica gel 60 Pf 
254. All chemicals were used as obtained or purified by distillation as needed. 
 
3.6.2 General Procedure for 1,3 dipolar cycloaddition:  
To a stirred solution of alkene (1 eq.) and 1,3-dipole (1 eq.) in freshly distilled dioxane (5 
ml) base (2.5 eq.) was added under N2 atmosphere. Reaction was heated at reflux for overnight. 
After completion, reaction mixture was allowed to cool and filtered through bed of celite and 
washed with DCM (5 ml). The filtrate was then evaporated in vacuo to give dark red crude oil. 
The crude product was then dissolved in DCM and washed with water and then with brine. The 
combined organic layers were dried over MgSO4 and then evaporated in vacuo to give the crude 
product. This crude product was then directly used in next step for oxidation. 
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3.6.3 General Procedure for CAN oxidation of cycloadducts:  
The crude cycloaddition product was suspended in THF:H2O (1:1, 10 ml) at 0°C. Then 
cerium (IV) ammonium nitrate (2 eq.) was added slowly in portions. After completion of 
addition, reaction was allowed to stir at 0°C for further 1-2 h. After completion THF was 
evaporated at vacuo and the aqueous layer was extracted with ethyl acetate (3 x 10 ml). The 
organic layer was then washed with water (15 ml) and brine. The combined organic layers were 
dried over MgSO4 and then evaporated in vacuo. The crude residue was purified with column 
chromatography to give the corresponding title compounds. 
 
3.6.4 Analysis of cycloadducts and final compounds: 
 
Methyl 6-oxo-1-phenyl-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxylate (5a) and 
methyl 4-oxo-1-phenyl-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxylate (5a’): 
Compounds (5a) and (5a’) were obtained as solids following the general procedure for 1,3-DC 
followed by the oxidation with CAN. The two products were separated by column 
chromatography using 20–30% EtOAc/ Hexane mixture as eluent.  
 
 Methyl 6-oxo-1-phenyl-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-
carboxylate (5a): M.P.= 176-177 °C; Yellow solid;  1H NMR (400 MHz, 
CDCl3) δ 3.10 – 3.21 (m, 4H), 3.99 (s, 3H), 7.33 – 7.41 ( t, J = 6Hz, 1H), 7.44 
– 7.53 ( t, J = 6Hz, 2H), 8.08 – 8.14 (d, J = 6Hz, 2H); 13C NMR (100MHz, 
CDCl3) δ 19.1, 43.8, 52.5, 121.0 (2C), 128.4, 129.5 (2C), 138.4, 138.8, 144.9, 
151.5, 162.0, 188.0; IR (CCl4): ν = 2955, 2361, 1720, 1592, 1547, 1502, 1254, 1126,1011, 823 
cm-1 
 Methyl 4-oxo-1-phenyl-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-
carboxylate (5a’): M.P.= 156-157 °C; Yellow solid;  1H NMR (300 MHz, 
CDCl3) δ 3.15 – 3.29 (m, 4H), 4.00 (s, 3H), 7.39 – 7.46 (t, J = 7.5Hz, 1H), 7.48 
– 7.56 (t, J = 7.5Hz, 2H), 7.69 – 7.74 (d, J = 6Hz, 2H); 13C NMR ( 75MHz, 
CDCl3) δ 22.0, 43.5, 52.9, 121.0 (2C), 128.4, 128.6, 129.9 (2C), 138.4, 138.6, 
161.3, 165.3 191.4; IR (CCl4): ν = 2955, 2361, 1720, 1592, 1547, 1502, 1254, 1126,1011, 823 
cm-1  
N
N
O
O
O
N
N
O
O
O
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Methyl 1-(4-methoxyphenyl)-6-oxo-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxylate 
(5b) and methyl 1-(4-methoxyphenyl)-4-oxo-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-
carboxylate (5b’): Compounds (5b) and (5b’) were obtained as solids following the general 
procedure for 1,3-DC followed by the oxidation with CAN. The two products were separated by 
column chromatography using 20–30% EtOAc/ Hexane mixture as eluent.  
 
 Methyl 1-(4-methoxyphenyl)-6-oxo-1,4,5,6-
tetrahydrocyclopenta[c]pyrazole-3-carboxylate (5b): M.P.= 174-175°C; 
Yellow solid; 1H NMR (300 MHz, CDCl3) δ 3.06 – 3.21 (m, 4H), 3.84 (s, 
3H), 3.97 (s, 3H), 6.92 – 7.02 (d, J = 9Hz, 2H), 7.96 – 8.05 (d, J = 9Hz, 
2H); 13C NMR ( 75MHz, CDCl3) δ 19.1, 43.8, 52.6, 55.7, 114.5 (2C), 122.5 
(2C), 132.3, 137.9, 144.5, 151.0, 159.8, 162.1, 189.2; IR (CCl4): ν = 2920, 
1677, 1590, 1422, 1323, 1291, 1277, 1181, 1010, 934 cm-1  
 
 Methyl 1-(4-methoxyphenyl)-4-oxo-1,4,5,6-
tetrahydrocyclopenta[c]pyrazole-3-carboxylate (5b’): M.P. = 165-166°C; 
Brown solid;  1H NMR (300 MHz, CDCl3) δ 3.15 – 3.20 (m, 4H), 3.86 (s, 3H), 
4.00 (s, 3H), 6.98 – 7.04 (d, J = 9Hz, 2H), 7.57 – 7.63 (d, J = 9Hz, 2H); 13C 
NMR ( 75MHz, CDCl3) δ 21.7, 43.5, 52.9, 55.8, 115.0 (2C), 122.8 (2C), 128.0, 
131.8, 138.0, 159.7, 161.5, 165.0, 191.4; IR (CCl4): ν = 2920, 1677, 1590, 
1422, 1323, 1291, 1277, 1181, 1010, 934 cm-1.  
 
Methyl 7-oxo-1-phenyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate (6a) and methyl 4-
oxo-1-phenyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate (6a’): Compounds (6a) and (6a’) 
were obtained as solids following the general procedure for 1,3-DC followed by the oxidation 
with CAN. The two products were separated by column chromatography using 10–30% EtOAc/ 
Hexane mixture as eluent.  
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 Methyl 7-oxo-1-phenyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate 
(6a): M.P. = 199-200°C; Yellow solid; 1H NMR (400 MHz, CDCl3): δ 2.09 – 
2.18 (quintet, J = 6Hz, 2H), 2.50 – 2.57 (t, J = 6Hz, 2H), 3.05 – 3.11 (t, J = 
6Hz, 2H), 3.90 (s, 3H), 7.36 – 7.47 (m, 5H); 13C NMR (75 MHz, CDCl3) 
δ 22.1, 24.3, 39.8, 52.3, 125.8 (2C), 128.8 (2C),129.7, 134.8, 136.4, 139.7, 
140.3, 162.7, 188.0; IR (CCl4): ν = 2954, 1724, 1697, 1548, 1496, 1253, 1202, 1132, 993, 810 
cm-1.  
 
 Methyl 4-oxo-1-phenyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate 
(6a’): M.P.= 100-101°C; Brown solid; 1H NMR (300 MHz, CDCl3) δ 2.12 - 
2.22 (quintet, J = 6Hz, 2H), 2.56 -2.65 (t, J = 6Hz, 2H), 2.91 - 2.99 (t, J = 6Hz, 
2H), 3.98 (s, 3H), 7.45 – 7.54 (m, 5H); 13C NMR (75 MHz, CDCl3) δ 23.4, 
23.6, 39.0, 52.9, 119.0, 124.6 (2C), 129.3, 129.7 (2C), 138.2, 142.6, 151.0, 
162.3, 191.1; IR (CCl4): ν = 2954, 1724, 1697, 1548, 1496, 1253, 1202, 1132, 993, 810 cm
-1.  
 
Methyl 1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate (6b) and 
methyl 1-(4-methoxyphenyl)-4-oxo-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate (6b’): 
Compounds (6b) and (6b’) were obtained as solids following the general procedure for 1,3-DC 
followed by the oxidation with CAN. The two products were separated by column 
chromatography using 10–30% EtOAc/ Hexane mixture as eluent.  
 
 Methyl 1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-indazole-3-
carboxylate (6b):M.P. = 144-145°C; Brown solid; 1H NMR (300 MHz, 
CDCl3) δ 2.14 −2.25 (quintet, J = 6Hz, 2H), 2.55 – 2.63 (t, J = 6Hz, 2H), 3.10 
– 3.17 (t, J = 6Hz, 2H), 3.85 (s, 3H), 3.96 (s, 3H), 6.91 – 6.97 (d, J = 6Hz, 2H), 
7.38 – 7.43 (d, J = 6Hz, 2H); 13C NMR (75 MHz, CDCl3) 
δ 22.1, 24.3, 39.8, 52.2, 55.7, 113.8 (2C), 127.0 (2C), 132.8, 134.5, 136.3, 
139.9, 160.1, 162.6, 188.0; IR (CCl4): ν = 2954, 1723, 1696, 1548, 1516, 1252, 1203, 1133, 
1038, 988 cm-1. 
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 Methyl 1-(4-methoxyphenyl)-4-oxo-4,5,6,7-tetrahydro-1H-indazole-3-
carboxylate (6b’): M.P.= 127-128°C; Brown solid; 1H NMR (300 MHz, 
CDCl3) δ 2.10 − 2.21 (quintet, J = 6Hz, 2H), 2.55 – 2.62 (t, J = 6Hz, 2H), 2.85 
– 2.92 (t, J = 6Hz, 2H), 3.86 (s, 3H), 3.97 (s, 3H), 6.97 – 7.02 (d, J = 9Hz, 2H), 
7.37 – 7.43 (d, J = 9Hz, 2H); 13C NMR ( MHz, CDCl3) δ 23.4 (2C), 39.0, 52.8, 
55.8, 114.7 (2C), 118.8, 126.1 (2C), 131.1, 142.2, 151.0, 160.2, 162.3, 191.1;  
IR (CCl4): ν = 2954, 1723, 1696, 1548, 1516, 1252, 1203, 1133, 1038, 988 cm
-1. 
 
Methyl 8-oxo-1-phenyl-1,4,5,6,7,8-hexahydrocyclohepta[c]pyrazole-3-carboxylate (7a) and 
methyl 4-oxo-1-phenyl-1,4,5,6,7,8-hexahydrocyclohepta[c]pyrazole-3-carboxylate (7a’): 
Compounds (7a) and (7a’) were obtained as solids following the general procedure for 1,3-DC 
followed by the oxidation with CAN. The two products were separated by column 
chromatography using 10–30% EtOAc/ Hexane mixture as eluent.  
 
 Methyl 8-oxo-1-phenyl-1,4,5,6,7,8-hexahydrocyclohepta[c]pyrazole-3-
carboxylate (7a): M.P.= 205-206°C; White solid; 1H NMR (300 MHz, 
CDCl3) δ 1.83 – 1.98 (m, 4H), 2.67 – 2.78 (t, J = 6Hz, 2H), 3.19 – 3.29 (t, J = 
6Hz, 2H), 3.89 (s, 3H), 7.28 – 7.42 (m, 5 H); 13C NMR ( 75MHz, CDCl3) 
δ 22.1, 23.3, 25.7, 43.1, 52.2, 126.0 (2C), 128.9 (2C), 129.0, 131.0, 140.4, 
140.6, 140.6, 163.0, 192.7; IR (CCl4): ν = 2905, 1722, 1686, 1588, 1548, 1320, 1179, 1012 cm
-1 
 
 Methyl 4-oxo-1-phenyl-1,4,5,6,7,8-hexahydrocyclohepta[c]pyrazole-3-
carboxylate (7a’): M.P. = 166-167°C; Yellow solid; 1H NMR (400 MHz, 
CDCl3) δ 1.91 – 2.03 (m, 4H), 2.79 – 2.85 (t, J = 6Hz, 2H), 2.88 – 2.94 (t, J = 
6Hz, 2H), 3.95 (s, 3H), 7.39 – 7.44 (m, 2H), 7.46 – 7.55 (m, 3H); 13C NMR ( 
75MHz, CDCl3) δ 1.88 – 2.03 (m, 4H), 2.77 – 2.85 (t, J = 6Hz, 2H), 2.86 – 
2.94 (t, J = 6Hz, 2H), 3.93 (s, 3H), 7.37 – 7.44 (m, 2H), 7.45 – 7.55 (m, 3H); IR (CCl4): ν = 
2905, 1722, 1686, 1588, 1548, 1320, 1179, 1012 cm-1 
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Methyl 1-(4-methoxyphenyl)-8-oxo-1,4,5,6,7,8-hexahydrocyclohepta[c]pyrazole-3-
carboxylate (7b) and methyl 1-(4-methoxyphenyl)-4-oxo-1,4,5,6,7,8-
hexahydrocyclohepta[c]pyrazole-3-carboxylate (7b’): Compounds (7b) and (7b’) were 
obtained as solids following the general procedure for 1,3-DC followed by the oxidation with 
CAN. The two products were separated by column chromatography using 10–30% EtOAc/ 
Hexane mixture as eluent.  
 
 Methyl 1-(4-methoxyphenyl)-8-oxo-1,4,5,6,7,8-
hexahydrocyclohepta[c]pyrazole-3-carboxylate (7b): ): M.P. = 141-141°C; 
Yellow solid; 1H NMR (300 MHz, CDCl3) δ 1.86 - 1.99 (m, 4H), 2.69 – 2.78 
(t, J = 6Hz, 2H), 3.22 – 3.30 (t, J = 6Hz, 2H), 3.81 (s, 3H), 3.92 (s, 3H), 6.87 
– 6.93 (d, J = 9Hz, 2H), 7.21 – 7.27 (d, J = 9Hz, 2H); 13C NMR ( 75MHz, 
CDCl3) δ 22.1, 23.2, 25.6, 43.1, 52.2, 55.7, 114.0 (2C), 127.3 (2C), 130.9, 
133.5, 140.3, 140.6, 160.0, 163.0, 192.7;  IR (CCl4): ν = 2952, 1723, 1686, 1516, 1250, 1177, 
1126, 833 cm-1. 
 
 Methyl 1-(4-methoxyphenyl)-4-oxo-1,4,5,6,7,8-
hexahydrocyclohepta[c]pyrazole-3-carboxylate (7b’): M.P. = 108-109°C; 
Yellow solid; 1H NMR (300 MHz, CDCl3) δ 1.90 - 2.01 (m, 4H), 2.77 – 2.89 
(m, 4H), 3.86 (s, 3H), 3.94 (s, 3H), 6.96 – 7.01 (d, J = 9 Hz, 2H), 7.29 – 7.34 
(d, J = 9 Hz, 2H); 13C NMR ( 75MHz, CDCl3) δ 23.1, 25.3, 26.9, 43.7, 52.8, 
55.8, 114.7 (2C), 122.7, 127.5 (2C), 131.2, 144.0, 146.7, 160.4, 163.4, 
195.9; IR (CCl4): ν = 2952, 1723, 1686, 1516, 1250, 1177, 1126, 833 cm
-1. 
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3.6.5 Theoretical and computational method:  
To rationalize the reactivity of the studied systems we have used some global descriptors 
of reactivity which have been defined within the context of the density functional theory. The 
global electrophilicity power measures the capability of a system to acquire electronic charge 
from the environment, and is calculated by the following simple expression,14 
  , where 
µ and η are the electronic chemical potential and chemical hardness of the ground state of atoms 
and molecules, respectively. While µ describes the charge transfer pattern in the system in its 
ground state geometry, η describes the resistance to this charge transference. Both quantities 
could be approached in terms of the one electron energies of the frontier molecular orbital 
HOMO and LUMO,  and , as      and     , respectively.
15,16 As 
nucleophilicity (N) descriptor we have used the ionization energy, approached following the 
Koopmans’ theorem17 and the Kohn-Sham scheme18 as the negative of the highest occupied 
molecular orbital (HOMO) energy; but to recover the direct proportionality of the index and 
nucleophilicity we expressed N as,     . A similar expression has been 
previously successfully used to study the reactivity of captodative ethylenes in polar 
cycloaddition reactions.19 As local descriptor of reactivity to evaluate the regioselectivity, we 
have used the Fukui function; these local quantities were obtained from a topological analysis of 
the Fukui function, using the same topological tools proposed  by Bader almost three decades 
ago to analyze the gradient field of the electron density to give a definition of an atom in a 
molecule.20 For a detailed revision of this methodology see the following references.21,22 
The molecular geometries have been optimized using the B3LYP density functional method23 in 
conjunction with the 6-31G(d) basis set.  All electronic structure calculations were done at the 
same level of theory using the Gaussian 03 program,24 the topological analysis of the scalar 
functions and the calculation of the condensed Fukui function were done with the DGrid 4.4 set 
of programs.25  
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3.7 X-Ray Analyses:  
The diffraction experiments were carried out at room temperature (with the exception of 
compound 6a for which data were collected at 100 K) and performed on a Bruker ApexII 
iffractometer equipped with a CCD detector, by using graphite monochromated MoKα radiation 
(λ = 0.71073 Å). An empirical absorption correction was applied on all structures by using 
SADABS.26 They were solved by using SHELXS-97 and refined by full-matrix least-squares 
based on F2 using SHELXL-97. All non-hydrogen atoms were refined anisotropically, while 
hydrogen atoms were set geometrically and given fixed isotropic thermal parameters. 
 
3.7.1 X-Ray structure of 5a: 
 The unit cell of 5a contains eight molecules, two of which constitute the independent 
unit. Although being chemically identical, the two are not equivalent from a crystallographic 
point of view and the analysis of their structural parameters shows that they are, in fact, two 
conformational isomers, only detectable in the solid state. As a matter of fact, while their bond 
lengths and angles do not significantly differ, some of the torsion angles considerably diverge 
(Table 3.4). As shown in Figure 3.5, if the plane defined by the pyrazolic unit is taken as a 
reference, in molecule A the 5-member ring is practically coplanar (C(2)-C(3)-N(7)-C(14) = 
0.78°) while in molecule B the correspondent torsion angle is 1.74°. More notably, while the 
phenyl ring in molecule A is slightly rotated counter-clockwise (C(3)-N(7)-C(14)-C(15) = -4.82° 
and N(8)-N(7)-C(14)-C(19) = -5.44°), in molecule B the rotation is clockwise and much larger 
(C(23)-N(27)-C(34)-C(35) = 11.80°, N(28)-N(27)-C(34)-C(39) = 11.76°). The same, but to a 
lesser extent, also happens with the carboxyl groups (N(8)-C(9)-C(10)-O(12) = 178.41 in 
molecule A, N(28)-C(29)-C(30)-O(32) = 175.66 in molecule B). The solid packing is held only 
by rather weak intermolecular hydrogen interactions involving the oxygen atoms of the carbonyl 
groups and the carbon atoms of the 5-member or phenyl rings, with distances varying from 3.055 
(O(1)...H-C(13_a)) to 3.611 (O(11)...H-C(13)) Å. 
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Figure 3.5: Crystal Structure of 5a with 30% ellipsoid probability (hydrogen atoms have been 
omitted for clarity). 
 
 
(A)                                                (B) 
 
Table 3.4: List of the torsion angles for Structure 5a. 
Isomer A atoms Angles (°)  Isomer B Atoms Angles(°) 
O(1) C(2) C(3) C(4) −179.21  O(21) C(22) C(23) C(24) 179.23 
O(1) C(2) C(3) N(7) −0.06  O(21) C(22) C(23) N(27) −2.08 
C(6) C(2) C(3) C(4) −0.08  C(26) C(22) C(23) C(24) 0.11 
C(6) C(2) C(3) N(7) 179.06  C(26) C(22) C(23) N(27) 178.8 
O(1) C(2) C(6) C(5) 179.61  O(21) C(22) C(26) C(25) −179.56 
C(3) C(2) C(6) C(5) 0.43  C(23) C(22) C(26) C(25) −0.4 
C(2) C(3) C(4) C(5) −0.32  C(22) C(23) C(24) C(25) 0.23 
C(2) C(3) C(4) C(9) 178.97  C(22) C(23) C(24) C(29) 179.78 
N(7) C(3) C(4) C(5) −179.76  N(27) C(23) C(24) C(25) −178.9 
N(7) C(3) C(4) C(9) −0.47  N(27) C(23) C(24) C(29) 0.65 
C(2) C(3) N(7) N(8) −178.6  C(22) C(23) N(27) N(28) −179.16 
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C(2) C(3) N(7) C(14) 0.78  C(22) C(23) N(27) C(34) 1.74 
C(4) C(3) N(7) N(8) 0.57  C(24) C(23) N(27) N(28) −0.45 
C(4) C(3) N(7) C(14) 179.94  C(24) C(23) N(27) C(34) −179.55 
C(3) C(4) C(5) C(6) 0.56  C(23) C(24) C(25 C(26) −0.46 
C(9) C(4) C(5) C(6) −178.34  C(29) C(24) C(25) C(26) −179.76 
C(3) C(4) C(9) N(8) 0.23  C(23) C(24) C(29) N(28) −0.65 
C(3) C(4) C(9) C(10) −178.8  C(23) C(24) C(29) C(30) 177.55 
C(5) C(4) C(9) N(8) 179.18  C(25) C(24) C(29) N(28) 178.68 
C(5) C(4) C(9) C(10) 0.14  C(25) C(24) C(29) C(30) −3.11 
C(4) C(5) C(6) C(2) −0.58  C(24) C(25) C(26) C(22) 0.51 
C(3) N(7) N(8) C(9) −0.41  C(23) N(27) N(28) C(29) 0.04 
C(14) N(7) N(8) C(9) −179.88  C(34) N(27) N(28) C(29) 179.26 
C(3) N(7) C(14) C(15) −4.82  C(23) N(27) C(34) C(35) 11.8 
N(8) N(7) C(14) C(15) 174.51  N(28) N(27) C(34) C(35) −167.24 
N(8) N(7) C(14) C(19) −5.44  N(28) N(27) C(34) C(39) 11.76 
N(7) N(8) C(9) C(4) 0.11  N(27) N(28) C(29) C(24) 0.38 
N(7) N(8) C(9) C(10) 179.26  N(27) N(28) C(29) C(30) −178.05 
C(4) C(9) C(10) O(11) 176.6  C(24) C(29) C(30) O(31) 178.05 
C(4) C(9) C(10) O(12) −2.62  C(24) C(29) C(30) O(32 −2.42 
N(8) C(9) C(10) O(11) −2.36  N(28) C(29) C(30) O(31) −3.87 
N(8) C(9) C(10) O(12) 178.41  N(28) C(29) C(30) O(32) 175.66 
C(9) C(10) O(12) C(13) 178.47  C(29) C(30) O32) C(33) −179.64 
O(11) C(10) O(12) C(13) −0.76  O31) C(30) O32) C(33) −0.1 
N(7) C(14) C(15) C(16) −179.49  N(27) C(34) C(35) C(36) 177.7 
C(19) C(14) C(15) C(16) 0.45  C(39) C(34) C(35) C(36) −1.28 
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N(7) C(14) C(19) C(18) 178.64  N(27) C(34) C(39) C(38) −176.97 
C(15) C(14) C(19) C(18) −1.31  C(35) C(34) C(39) C(38) 2.03 
C(14) C(15) C(16) C(17) 0.41  C(34) C(35) C(36) C(37) −0.19 
C(15) C(16) C(17) C(18) −0.4  C(35) C(36) C(37) C(38) 0.9 
C(16) C(17) C(18) C(19) −0.47  C(36) C(37) C(38) C(39) −0.14 
C(17) C(18) C(19) C(14) 1.32  C(37) C(38) C(39) C(34) −1.32 
 
 
3.7.2 X-Ray structure of 5b: 
 The unit cell of 5b contains four identical molecules generated by the one constituting the 
independent unit (Figure 3.6). As seen for 5a, the MeO-substituted phenyl ring is not perfectly 
coplanar with the pyrazolic fragment but has a torsion angle of -10.55°, probably for steric 
reasons due to the presence of the methoxy group. The solid packing is held by weak 
intermolecular hydrogen interactions involving the oxygen atoms of the methoxy and carboxyl 
groups and the carbon atoms of the methyl groups, whose distances vary from 3.331(1) 
(O(20)...H-C(21_a)) to 3.543(2) (O(11)...H-C(13_a)) Å, and intermolecular π interactions 
between the phenyl and the pyrazolic rings. Both drive the solid arrangement in such a way that 
the molecules are disposed in a parallel fashion, clearly visible along the b axis (Figure 3.7), and 
the distance between planes is about 3.41 Å, slightly longer than the one found in the α and β 
graphite (3.354 Å). 
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Figure 3.6: Crystal Structure of 5b with 30% ellipsoid probability (hydrogen atoms have been 
omitted for clarity). 
 
 
 
 
 
Figure 3.7: Crystal Packing of 5a viewed along the b axis. 
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3.7.3 X-Ray structure of 5b’: 
 The 5b’ compound crystallizes in a chiral group and the unit cell contains four molecules, 
while only one constitutes the independent unit. Similarly to the previous structures, there is a 
torsion angle of 13.18° between the pyrazolic and the phenyl fragments which makes them non 
co-planar. Again, there are weak intermolecular hydrogen bonds of lengths between 3.161(0) 
(O(1)...H-C(18_a)) and 3.543 (O(11)...H-C(16_a)) Å within the molecules laying on the same 
plane, and π interactions between the ones laying on parallel planes (3.55 Å distant), giving the 
solid state packing the same type of the arrangement than the one seen for 5b’. Its crystal 
structure is shown in Figure 3.8. 
 
Figure 3.8: Crystal Structure of 5b’ with 30% ellipsoid probability (hydrogen atoms have been 
omitted for clarity). 
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3.7.4 X-ray structure of 6a: 
 The unit cell of 6a contains four identical molecules generated by the one constituting the 
independent unit, which is shown in Figure 3.9. The phenyl ring is strongly rotated (44.62º) with 
respect to the plane where the pyrazole ring lies, probably owing to the large steric hindrance of 
the CO-substituted 6-member ring. As for the hydrogen bonds, the stronger one is 2.976(3) Å 
long between the oxygen of the carboxyl group, O(10) and the carbon atom of the methyl unit of 
the neighbour molecule, C(14)_a. 
 
Figure 3.9: Crystal Structure of 6a with 30% ellipsoid probability (hydrogen atoms have been 
omitted for clarity). 
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3.7.5 X-ray structure of 7a: 
 The unit cell of 7a contains four molecules and only one in the asymmetric unit, which is 
shown in Figure 3.10. As seen in the structure of 6a, the phenyl ring is strongly rotated (54.81º) 
with respect to the plane where the pyrazole ring lies, for the same reason stated above. As for 
the hydrogen bonds, the stronger one is intermolecular (3.265(1) Å long) and can be found 
between the oxygen of the CO group on the 7-member ring (O(1)) and one carbon atom of the 
neighbour phenyl group (C(17_a)).  
 
Figure 3.10: Crystal Structure of 7a with 30% Ellipsoid probability (hydrogen atoms have been 
omitted for clarity). 
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Table 3.5: Summary of Crystal Data for 5a, 5b, 5b’, 6a and 7a. 
Compound 
C15H14N2O3 
(6a) 
C14H12N2O3 
5a 
C15H14N2O4 
5b 
C16H16N2O3 
7a 
C15H14N2O4 
5b’ 
Fw 270.28 256.26 286.28 284.31 286.28 
T, K 97(2) 296(2) 296(2) 296(2) 296(2) 
λ, Å 0.71073 0.71073 0.71073 0.71073 0.71073 
Crystal system Monoclinic Monoclinic Monoclinic Monoclinic Orthorhombic 
Space group P21/n P21/n P21/c P21/n P212121 
a, Å 9.9364(18) 10.7675(12) 19.296(3) 9.202(2) 7.0473(5) 
b, Å 7.6127(14) 7.1185(8) 8.4029(15) 8.0227(18) 10.7862(8) 
c, Å 17.248(3) 31.632(4) 8.4244(15) 18.832(4) 18.1206(14) 
α, ° 90 90 9 90 90 
β, ° 95.645(2) 91.4820(10) 101.301(2) 94.205(3) 90 
γ, ° 90 90 90 90 90 
Cell Volume, Å3 1298.3(4) 2423.7(5) 1339.5(4) 1386.5(5) 1377.41(18) 
Z 4 8 4 4 4 
Dc, g cm
-3 1.383 1.405 1.420 1.362 1.381 
µ, mm-1 0.098 0.101 0.105 0.095 0.102 
F(000) 568 1072 600 600 600 
Crystal size, mm 
0.25 x 0.20 x 
0.15 
0.25 x 0.15 x 
0.08 
0.15 x 0.12 x 
0.08 
0.25 x 0.20 x 
0.10 
0.22 x 0.20 x 
0.10 
θ limits, ° 2.37 to 25.00 1.29 to 25.00 1.08 to 25.00 2.17 to 24.98 2.20 to 24.97 
Index ranges 
-11 ≤ h ≤ 11, -
9 ≤ k ≤ 9, -20 
≤ l ≤ 20 
-12 ≤ h ≤ 12, -8 
≤ k ≤ 8,-37 ≤ l ≤ 
37 
-22 ≤ h ≤ 22, -9 
≤ k ≤ 9, -10 ≤ l 
≤ 10 
-10 ≤ h ≤ 10, 
-9 ≤ k ≤ 9, 
-22 ≤ l ≤ 22 
-8 ≤ h ≤ 8, -12 ≤ 
k ≤ 12, -21 ≤ l ≤ 
21 
Reflections 
collected 
11937 22300 12339 12782 13215 
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Independent 
reflections 
2287 [R(int) = 
0.0225] 
4269 [R(int) = 
0.0321] 
2346 [R(int) = 
0.0350] 
2438 [R(int) = 
0.1668] 
2424 [R(int) = 
0.0268] 
Completeness to θ 
= 25.00° 
99.9 % 99.9 % 100.0 % 99.9 % 100.0 % 
Data / restraints / 
parameters 
2287 / 0 / 182 4269 / 0 / 345 2346 / 0 / 193 2438 / 0 / 192 2424 / 0 / 193 
Goodness on fit 
on F2 
1.025 1.029 1.062 0.993 1.065 
R1 (I > 2σ(I)) 0.0306 0.0393 0.0375 0.0609 0.0303 
wR2 (all data) 0.0777 0.1101 0.1098 0.1606 0.0783 
Largest diff. peak 
and hole, e Å-3 
0.226 &-0.162  0.167 & -0.187 0.170 & -0.142 0.171 & -0.209 0.151 & -0.131 
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Chapter 4 
1,3-Dipolar Cycloaddition of Nitrile Imines with α,β-Unsaturated 
Lactones, Thiolactones and Lactams 
 
4.1 Introduction and recent literature: 
The synthetic utility of the 1,3-dipolar cycloaddition reaction stems from the wide scope 
and from the relevance of numerous targets achievable by this chemistry1 especially 
heterocycles,  since many 1,3-dipolar species are readily available and react with a variety of 
dipolarophiles containing heteroatoms. Pyrazoles fused with lactone, lactum and thiolactone 
rings are scarcely reported in literature. These bicyclic heterocycles can be important for 
applications in the agrochemical and pharmaceutical industries. These types of bicyclic systems 
are still very much challenging by the synthetic point of view.2 
As shown in earlier chapters, following our interest in the 1,3-DC3 we have reported the 
synthesis of pyrazoles using in the 1,3-DC methodology of nitrile imines and functionalized 
acetylenes,4a and we have developed a protocol based on intramolecular cyclization starting from 
a sulphur-substituted acetylene, to obtain a ring-fused thieno-pyrazole.4b Also a regiocontrolled 
one pot synthesis of cycloalkenones fused with pyrazoles through 1,3-DC of cyclic α,β-
unsaturated ketones has been reported by us.5 On the other hand lactones, lactums and 
thiolactones have been studied as the dipolarophile. Although few references does exists that 
uses these compounds as one of the partner element in cycloaddition reaction but 1,3-DC’s 
involving nitrile imine and these dipolarophiles are not that much explored.  
In 2009, G. Ruano et.al.6 have reported a 1,3 dipolar cycloaddition between enatiopure 
sulfinyllactones as dipolarophile and diazomethane to yield a mixture of isomeric bicyclic 
pyrazolines (Scheme 4.1). The stereochemistry in 1,3-DC was found to be controlled by the 
presence of lewis acid in the reaction. Use of Yb(OTf)3 was found to be the effective lewis acid 
in this case. The predominant isomer was found to be with exo stereochemistry.  
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Scheme 4.1: 1,3 DC between sulfinyllactones and diazomethane. 
 
2(5H)-Furanone and 1H-pyrrol-2(5H)-one has attracted considerable attention from 
organic chemists which is attributed to their frequent occurrence in the biologically active natural 
and non-natural compounds as a key fragment.7 Jinzing Ye et.al.8 described use of 2(5H)-
furanone and 1H-pyrrol-2(5H)-one for the synthesis of ring fused compounds. In this case they 
used α,β-unsaturated lactum and α,β-unsaturated lactones and α,β-unsaturated enones in a 
tandem Michael-Michael type of reaction which was catalysed by using bifuctional thiourea 
catalyst (Scheme 4.2).  
 
Scheme: 4.2: Tandem Michael-Michael reaction involving 2(5H)-Furanone and 1H-pyrrol-
2(5H)-one and cyclic α,β-unsaturated enones. 
 
 Raman Alibes and Marta Figueredo et.al.9 studied the [2+2] photochemical cycloaddition 
of 1,4-difunctionalized 2-butenes with 2(5H)-furanones. This reaction delivered ring fused 
1,2,3,4-tetrasubstituted cyclobutanes (Scheme 4.3).  
 
Scheme 4.3: [2+2] photochemical cycloaddition of 1,4-difunctionalized 2-butenes to 2(5H)-
furanones. 
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In 1998, Pedro De March et.al.10 used α,β-unsaturated lactones for first time with nitrile 
ylid. Cycloaddition proceeds effectively with only with electron poor olefins. They discovered 
methylene-γ-butyrolactone with an exocyclic double bond is the most reactive lactone. In all 
cases, exo adducts were obtained as major or exclusive products. 
Another important fragment in biologically active compounds is α,β-unsaturated lactum. 
Menzamine A, is one of the naturally occurring biologically active compound which acts as a 
antitumor11 and antibacterial12 agent. Tohru Hino et.al.13 in 1992 proposed a synthesis of 
menzamine A. The core of menzamine A was synthesized by using a Diels-Alder reaction 
between a α,β-unsaturated lactum and a diene (Scheme 4.4).  
 
Scheme 4.4: Diels-Alder reaction between a α,β-unsaturated lactum and a diene in synthesis of 
menzamine A. 
 
Jennifer Qiao et.al.14a synthesised a library of compounds from 1,3-DC of nitrile imine 
with 3-chloro-5,6-dihydropyridin-2(1H)-one (Scheme 4.5). The series of compounds they tested 
were found FXa inhibitors with high FXa binding afﬁnity (FXa Kof some in the picomolar 
range) and high anticoagulant activity (PT ECi < 3lM) in vitro. A set of compounds, obtained 
from optimization of the R group, were orally bioavailable in dog PK studies. Some compounds 
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obtained in this series were also highly efﬁcacious in the rabbit A-V shunt thrombosis model (E 
Cd50 < 85 nM). 
 
Scheme 4.5: 1,3-DC of nitrile imine with 3-chloro-5,6-dihydropyridin-2(1H)-one. 
 
Among the 1,3-DC reactions of α,β-unsaturated lactones an extensive investigation has 
been dedicated to the reaction with diazoalkanes,15 chiral and achiral nitrones,16,15a-b and nitrile 
oxides.17,15a-b The reaction of α,β unsaturated lactones with nitrile ylids and the cycloaddition of 
chiral butenolides with azomethine ylids18,15a and with azides19 have also been reported.  
No references were found on the 1,3-DC of simple unsaturated lactones and nitrile imines 
and only the reaction of diphenyl nitrile imine with coumarin or its 3-substituted derivatives has 
been performed.20 To our knowledge the use of α,β-unsaturated thiolactones as dipolarophiles in 
1,3-DC has not yet been explored. An α,β-unsaturated lactam is a structural motif that is often 
found in bioactive molecules.21 The use of such olefins as dipolarophiles in 1,3-DC for the 
production of bicyclic compounds of biological interest is not very extensive. As a dipole 
partners the following 1,3-dipoles have been used: diazomethane,22 nitrones,23 nitrile oxides24 
and aryl azides.19 The nitrile imines were the more studied 1,3-dipoles for the synthesis of potent 
inhibitors of blood coagulation factor Xa (FXa). In this case the starting material was a 6-
membered α,β-unsaturated lactam bearing a good leaving group as chlorine or morpholine useful 
for the aromatization.14 
The 1,3-DC of nitrile imines with cyclic α,β-unsaturated lactones, thiolactones and 
lactams could provide, after aromatization of initially formed pyrazoline, a general and direct 
access to pyrazoles fused with these frameworks (Figure 4.1), and indeed the derivatives 
containing the pyrazole dihydropyridone core are targets of utmost importance in the 
pharmaceutical industry.14 
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Figure 4.1: General protocol for the synthesis of ring-fused pyrazoles via 1,3-DC between nitrile 
imine and α,β-unsaturated lactones, thiolactones and lactams. 
 
 
4.2 Result and discussion:  
Compounds 2-4 were commercially available, while 5,6-dihydro-2H-thiopyran-2-one 5, 
unknown in the literature, was prepared (Scheme 4.6) starting from β-
acetylthiopropionaldehyde25 in a three-steps synthetic protocol. The two N-tosyl protected 
lactams 6 and 7 were prepared according to literature procedures.26 
 
Scheme 4.6: Synthesis of 5,6-dihydro-2H-thiopyran-2-one 5. 
 
The Scheme 4.7 illustrates the synthesis of fused pyrazoles. The reaction of α,β-
unsaturated lactones 2, 3, thiolactones 4, 5 and lactams 6, 7 with C-carboxymethyl-N-phenyl and 
N-p-OCH3-phenyl nitrile imines,
5 generated “in situ” from hydrazonoyl chlorides 1a,b, was 
performed in dry dioxane at 80 °C for 18-24 hours, using triethylamine (TEA) for the generation 
of the nitrile imine. In the case of the lactams toluene was used in order to get better yields. 
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Scheme 4.7: 1,3-DC of 2-7 with dipoles from 1a-b. 
 
During the cycloaddition a partial aromatization of the initially formed bicyclic 
pyrazoline was occurred in some cases; the reaction of 6-membered thiolactone 5 with 1a and 1b 
(entries 7 and 8 Table 4.1) afforded fully aromatized products in 24 h, while 5-membered 
thiolactone 4 with both 1a and 1b gave about 10 % of aromatization at the end of cycloaddition. 
The crude cycloadduct  was then subjected to oxidation using cerium(IV) ammonium nitrate 
(CAN) in order to get fully aromatised final pyrazoles. The yield of the products is referred to the 
sum of the two regioisomers 8a-b/13a-b (5-acylpyrazoles) and 8a’-b’/-13a’-b’ (4-
acylpyrazoles). The lower yields obtained with the dipole from 1a showed that the C-
carboxymethyl-N-p-OCH3-phenyl nitrile imine is more reactive than the unsubstituted phenyl 
analogue. Also the size of the ring influenced the yield, lower yields were obtained with 5-
membered lactones, thiolactones and lactams and this might result from an increased tendency 
for the 5-membered ring enolization and from the initially formed strained fused pyrazolines. 
Same observations were observed in the cycloaddition of these nitrile imines with cyclic α,β-
unsaturated ketones.5 
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Table 4.1: 1,3-DC of 2-7 with 1,3-dipoles from 1a-b. 
Entry 1,3-dipole Dipolarophile Cycloadducts Yield % 
Ratio 
5-acyl/4-acyl 
1 1a 2 8a-8a’ 14 70:30 
2 1b 2 8b-8b’ 31 14:86 
3 1a 3 9a-9a’ 47 52:48 
4 1b 3 9b-9b’ 66 87:13 
5 1a 4 10a-10a’ 21 99:1 
6 1b 4 10b-10b’ 36 82:18 
7 1a 5 11a-11a’ 56 81:19 
8 1b 5 11b-11b’ 77 86:14 
9 1a 6 12a-12a’ 38 72:28 
10 1b 6 12b-12b’ 35 61:39 
11 1a 7 13a-13a’ 74 83:17 
12 1b 7 13b-13b’ 68 83:17 
 
All the products were characterized by NMR and GCMS analysis. The regioisomeric 
ratio of 5-acyl/4-acyl pyrazoles was attributed by using 1H-NMR analysis of the purified 
compounds after complete aromatization. On TLC 5-acyl derivative was found to be non-polar 
compared to 4-acyl derivative (Rf difference was ~ 0.3-0.4). This is probably due to an 
intramolecular H-bonding between the carbonyl of ring and the H- of the aromatic ring (Figure 
4.2). 
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Figure 4.2: Possible mode of intramolecular H-bonding in the cycloadducts. 
 
 
 The structural assignment of the regioisomers was based on 1H-NMR signals and X-ray 
diffraction analyses,27 for compounds 8b, 9a’, 11a, 12b, 13a and 13b. Other compounds were 
correlated using the TLC pattern and NMR data. The NMR pattern was a distinguishing factor in 
aromatic region when the 5-membered lactone, lactum, and thiolactone were involved in the 
reaction, whereas aliphatic region was the distinguishing factor when 6-memebred lactone, 
lactum and thiolactones were involved. Incase of reaction between 1b and 2, 8b and 8b’ can be 
distinguished by NMR signals based on the fact that there might exists an intramolecular H-
bonding between the C=O of lactone and H- of aromatic ring, for 8b the signals are 7.03 and 
8.05 ppm and 7.03 and 7.51ppm for 8b’. Similar observations were found with other compounds 
whereas for 8a and 8a’, the multiplates were observed in aromatic region so they were 
distinguished by general TLC pattern. Incase of 6-membered lactone, lactum and thiolactone the 
distinguishing factor was the aliphatic region of the NMR. As to have an intramolecular H-
bonding in these compounds, it involves 7-membered ring, which is disfavoured because of the 
non co-planarity of the 6-membered ring, so we did not observed any significant variations in the 
aromatic region. In reaction between 1a and 3, 9a has signals 3.31 and 3.98 ppm whereas for 9a’ 
they are 3.16 and 4.00 ppm for CH2 next to pyrazole ring respectively on other side aromatic 
region found to have the same signals. Similar observations were found with other compounds as 
well.  
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The X-ray structural data showed that the compounds except 8b and 12b, the pyrazole is 
never coplanar with the the ester function and aryl groups, which is probably due to packing 
efficiency, and torsion angles going from about -18° to -55° are observed. The compound 8b is 
the only one virtually flat, as in 12b the protective N-tosyl group is forced to form a torsion angle 
of 105.77° with the rest of the molecule, therefore the solid packing of the former is arranged in 
parallel sheets along the b axis (Figure 4.9). The crystal structures of two of the major products, 
11a and 12b, are illustrated in Figure 4.3 (a) and (b). 
 
Figure 4.3: X-ray structures of the ring-fused pyrazoles 11a (a) and 12b (b) (ellipsoids are at 
30% probability). 
 
         
 (a) (b) 
 
It appeared from the Table 4.1 that the nitrile imine from 1a gave a large prevalence of 
the 5-acyl derivative with 5-membered lactone 2 (entry 1), thiolactone 4 (entry 5) lactam 6 (entry 
9) and with 6-membered thiolactone 5 (entry 7) and lactam 7 (entry 11). A balanced mixture of 
5- and 4-acyl derivatives has been obtained with 6-membered lactone 3 (entry 3). The nitrile 
imine from 1b gave also the 5-acyl derivative as the major product (entries 4, 6, 8, 10, 12) but a 
deviant result, with inversion of regiochemistry with the 5-membered lactone 2 (entry 2) was 
observed. The regioisomeric ratio is influenced by the X moiety and by the nature of the nitrile 
imine; a very high regioselectivity in favour of the 5-acyl derivative was found when X= S. A 
ratio up to 99:1 was found with α,β-unsaturated 5- and 6-membered thiolactones. The 
regioselectivity in favour of the 5-acylderivative, decreased gradually going from lactams (X=N-
p-Tosyl) to lactones (X= O). 
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The regiochemical results obtained in the 1,3-DC of 5-membered dipolarophiles with p-
MeO dipole are summarised in Figure 4.4, and are compared with the results obtained 
previously when cyclopentenone5 (c-2-one) was used as a dinophile. 
 
Figure 4.4: Summary of the different regiochemistry obtained from different dipolarophiles 2, 4, 
6 and c-2-one with dipole from 1b. 
 
 
 
 
4.2.1 Theoretical Analysis: 
As was previously discussed there are some intriguing and not obvious regioselectivity 
trends in the 1,3 DC studied reactions. Inversion of regioselectivity was previously observed in 
the DC of the nitrile imine from 1b activated by TEA and 2-cyclopentenone (c-2-one). To 
explain it, an intermediate of the p-MeO-dipole with TEA prior to the 1,3-dipole formation as 
reactive intermediate with c-2-one was proposed; this intermediate was labelled as M-II to 
differentiate of the 1,3-dipole which was identified as M-I (Figure 4.5).5 
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Figure 4.5: Models for the dipoles used in 1,3-dipolar cycloaddition. 
 
 
4.2.2 Energies analysis: 
The 1,3-DC has two reactive channels associated with the formation of 5-acyl and 4-acyl 
derivatives. In this study we have considered only the first reaction step (see Figure 4.1) of the 
1,3-dipole (M-I) 1b and the five-member ring dipolarophiles (c-2-one, 2, 4, 6) to produce 
pyrazoline intermediates. Therefore, four transition state (TS) pairs (TS/TS’) and the 
corresponding cycloadducts have been localized and characterized in the potential energy surface 
(PES).with dipole 1b (M-I) according to scheme 4.7. The computed activation barrier energies 
for 1b + c-2-one reaction in the formation of 5-acyl (1b + c-2-one→TS-14b) derivatives (7.6 
kcal-mol-1) is smaller than the activation barrier involved in the formation of the 4-acyl (1b + 2-
c-one→TS-14b’) derivative (10.9 kcal-mol-1), as reported in Table 4.2. When the dipolarophiles 
are 2 and 4, the activation barriers associated to the 5-acyl derivatives are almost 3.3 kcal.mol-1 
smaller than the barrier energies associated with the 4-acyl derivatives, and when dipolarophile is 
6 (X=N-p-Tosyl) this barrier difference is lower by 0.9 kcal.mol-1. Therefore, if 1b (M-I) reacts 
with dipoles: c-2-one, 2, 4 and 6, the 5-acyl derivative should be the preferred product due to its 
lower barrier energies compared with the 4-acyl derivatives. In all cases the 5-acyl derivatives 
are the thermodynamic preferred products (most negative ones) compared with the 4-acyl 
derivatives. The reactions involving 1a dipole presents almost the same trend shown by 1b. 
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Table 4.2: B3LYP/6-31G(d) total energies (E, in au). Activation, ∆E≠, and reaction, ∆E0, (in kcal 
mol-1) energies involved in the formation of the non-aromatized products. 
System E 
c-2-one -269.25098 
2 -305.18927 
4 -628.16360 
6 -1104.12910 
1a -607.47671 
1b -721.96653 
Ts-14b -991.29339 
Ts-14b’ -991.29217 
Ts-8b -1027.23428 
Ts-8b’ -1027.21135 
Ts-10a -1235.71493 
Ts-10a’ -1235.71493 
Ts-10b -1350.20369 
Ts-10b’ -1350.19100 
Ts-12b -1826.17376 
Ts-12b’ -1826.17185 
Reactions E
≠ 
E
0
 
   
1b + c-2-one → Ts-14b → 14b  7.6 -47.6 
Ts-14b’ 14b’ 10.9 -46.9 
1b + 2 → Ts-8b → 8b 6.7 -49.3 
Ts-8b’ 8b’ 11.4 -34.9 
1a + 4 → Ts-10a → 10a 7.7 -46.8 
Ts-10a’ 10a’ 12.2 -38.9 
1b + 4 → Ts-10b → 10b 7.4 -46.2 
Ts-10b’ 10b’ 12.0 -38.2 
1b + 6 → Ts-12b → 12b 6.3 -49.0 
Ts-12b’ 12b’ 7.2 -47.8 
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The energies associated with dipole 1a and dipolarophile 4, as well as all the other 
reaction energies, are reported in Table 4.2. The PES analysis predicts that in all evaluated 
reactions the 5-acyl derivatives should be the major regioisomer product if 1b and 1a react in 
their activated dipole form (M-I) with all five membered rings dipolarophiles, but as was 
previously noted, in some specific cases the 4-acyl derivatives are obtained as the major product. 
Therefore, the PES analysis validates our previous hypothesis,5 that in some cases, intermediate 
forms previously to the formation of the 1,3 dipole and could be the reactive species against 
dipolarophiles in the pyrazole synthesis. 
 
4.2.3 Justification of the intermediate form M-II of dipole as reactive species in these 1,3-
dipolar cycloadditions: 
The analysis of the regioselectivity depending on the experimental conditions allowed us 
to propose some requirements for the intermediate-dipole M-II to be the reactive species in this 
1,3-DC: a) the intermediate M-II must be sufficiently reactive, clearly the intermediate of the p-
MeO-dipole (1b) is the most reactive compared to the intermediate of 1a dipole in terms of the 
global nucleophilicity index (see Table 4.3), b) the dipolarophile should be small due to the 
sterically protective environment around the reactive region in the intermediate-dipole 
(surrounding groups and TEA) and because the M-II is expected to have a short half-life, then, 
any reaction involving it, will be kinetically controlled. Summarizing, only dipole-intermediate 
1b (M-II) could be the reactive species against small dipolarophiles; among the studied 
dipolarophiles, when X = -C2H4- and –C3H6- (with n=1) in our previous work,
5 and X=NTs in 
the present work, the dipolarophile is too large to react with dipole-intermediate 1b form, 
therefore  the 1,3-dipole (M-I) will be the reactive species. However, when X= O and S 
(dipolarophiles 2 and 4), the effect changes as both are comparatively as small as c-2-one, which 
was proposed to react with the dipole-intermediate M-II form. The differences in regiochemistry 
when these two dipolarophiles are used in the reaction will be discussed in the following 
paragraphs in terms of global and local reactivity descriptors. 
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4.2.4 Analysis of the global and local reactivity indexes: 
To gain more insights about reactivity of these systems we have evaluated some 
electronic-based reactivity descriptors. In Table 4.3, the electronic chemical potential, µ, 
chemical hardness, η, global electrophilicity index, ω, and global nucleophilicity index, N, are 
displayed for the dipoles considering both models (M-I and M-II) and the 5-membered set of 
dipolarophile reagents. The electronic chemical potential, µ, of the dipoles are higher than those 
for the dipolarophiles. Therefore, the predicted charge transfer (CT) in these 1,3-DC reactions 
will take place from the dipole to the dipolarophiles in a normal-electron-demand (NED) fashion. 
 
Table 4.3: Global properties and global electrophilicity for nitrile imines dipole and 
cycloalkenes involved in the 1,3-dipolar cycloaddition reactions. 
  HOMO LUMO µ (a.u.) η (a.u.) ω (eV) N (a.u.) 
 M-I 1a -0.2169 -0.0629 -0.1399 0.1541 1.73 0.7831 
 1b -0.2018 -0.0568 -0.1293 0.1450 1.57 0.7982 
Dipole       
 
M-II 1a -0.1664 -0.0204 -0.0934 0.1460 0.81 0.8336 
1b -0.1582 -0.0164 -0.0874 0.1418 0.73 0.8418 
      
 c-2-one -0.2376 -0.0443 -0.1409 0.1933 1.40 0.7624 
 2 -0.2851 -0.0478 -0.1664 0.2373 1.59 0.7149 
Dipolarophile 4 -0.2539 -0.0575 -0.1557 0.1964 1.68 0.7461 
 6 -0.2568 -0.0499 -0.1533 0.2070 1.55 0.7432 
 
The question that remains unanswered is why the regiochemistry with dipolarophile 4 is 
different from the one with dipolarophile c-2-one? Figure 4.6, shows the best Fukui predicted 
interaction between reagents, when M-II is proposed in the reactions. The Fukui dipolarophile 
values correspond to the c-2-one; the values for all other dipolarophiles (2, 4 and 6) are almost 
the same therefore are not reported here. The black square encloses the reactive region, while the 
regions presenting substituents that could sterically disfavour or favour the reaction are enclosed 
in red squares. The terminal methyl groups of TEA have been deleted to allow a better view of 
the region of interest. The Fukui topological analysis successfully describes the experimentally 
observed inversion in regioselctivity of dipolarophiles 
that dipolarophile 4 should present the same inversion to give 
product. 
 
Figure 4.6: Local Fukui function predictions of the most probable interaction between the dipole 
from intermediate 1b (M-II) and dipolarophile 
when dipoles 2, 4, and 6 are used in the simulation. Enclosed in a black square is the reactive 
region, and enclosed in red squares are the groups that could favour or disfavour the interactions 
by electrostatic effects. 
 
To explain the different regioselectivity between O a
interaction between S and Cl will be higher than repulsive interaction between O and Cl (see 
Figure 4.6) when both reagents interact. This argument is based on the larger size of the S 
compared to O,  therefore the surroundin
polarisable,  resulting in a high repulsive interaction with the electronic density around the 
chloride. This statement needs further analysis and will be addressed using a methodology which 
allows visualisation of electronic charge density whether excess or deficient around the reactive 
 
c-2-one and 2, but erroneously predicts 
the 4-acyl derivative as the major 
c-2-one (X=CH2). The same trends are presented 
 
nd S we propose that repulsive 
g electronic density in the  former will be most 
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regions of the molecules. This method combines electronic charge density and molecular 
electrostatic potential values (MEP). 
 
4.2.5 Molecular electrostatic analysis: 
To verify the previously proposed hypothesis about repulsive interaction between Cl 
around the dipole and O or S of the dipolarophiles 2 and 4, we have calculated the electrostatic 
potential (V(r)) in both dipolarophiles and in the intermediate reactive species M-II, and mapped 
it over an isodensity surface corresponding to 0.002 a.u. This surface just encloses the Van der 
Waals volumes of the individual atoms in the molecule and is thus a good representation of the 
reactive regions around the molecules.4 The maximum and minimum V(r) values are 0.05 and -
0.05 au respectively. Therefore, regions rich in electronic charge density will present negative 
values of V(r) and regions deficient in electron charge density will present positive values of 
V(r). 
As we can see in Figure 4.7, the electronic charge density is concentrated in small 
regions in dipolarophile 2, whereas in dipolarophile 4 the electronic charge density is distributed 
in a large surface around S. The electron charge density in M-II remains constant in both the 
hypothetic reactions and the interaction with dipole 4 (S) should be the most disfavoured by the 
higher repulsive effects, as indicated in the Figure 4.6. This will be the reason why dipole 4 does 
not react with the intermediate-dipole-1b (M-II) to produce the 4-acyl derivative, whereas dipole 
2 is favoured to react in this form. 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: B3LYP/6-31G(d) 0.002 au isodensity surface with superimposed electrostatic 
potential for (a) interaction between dipole 
interaction between dipole 1b (M
and minimum potential values are 0.05 and 
the colour scale of the MEP are displayed on the left.
 
 
 
 
 
(a)
 (b)
 
 
 
 
 
 
 
1b (M-I) with dipolarophile 2 
-I) with dipolarophile 4 (X=S). In both cases, the maximum 
-0,05 au respectively. The molecular structures and 
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4.2.6: Some insights about isomeric ratio: 
Finally, another important experimental result that deserves to be discussed is the higher 
isomeric ratio in favour of the 5-acylderivative (99:1) for the reaction between 1a with 4. From 
our previously discussed results we summarized some important remarks: only the intermediate 
dipole 1b (M-II) is enough reactive (higher nucleophilicity) to react against small dipoles, like 
five-member 2-cyclopentenone and 5-member lactone, which do not present appreciable steric 
effects; in all other cases the 1,3-dipole 1b (M-I) is expected to be the prevailing reagent, and 
1,3-dipole 1a (M-I) should be the unique reagent. Therefore, the product distribution could be 
analyzed in terms of activation and reaction energies reported in Table 4.2. Because the 
concentration of negative charge around S compared with O is only slightly larger, it is possible 
to say that in small quantity the intermediate 1b (M-II) could react with 4, to gives small 
amounts of the 4-acylderivative, justifying the 82:18 experimental ratio. When the reaction is 
between 1a with 4, the 5-acylderivative is the kinetic and thermodynamic preferred product and 
there is not the presence of an intermediate reactive form of dipole, which agrees very well with 
the 99:1 experimental ratios. It is interesting to note that higher regioselectivity of this 
dipolarophile is in agreement with their higher reactivity (ω=1.68, in Table 4.3). Making the 
same analysis to the reaction with dipolarophile 6, the 5-acylderivative is only 0.9 and 1.2 
kcal/mol kinetically and thermodynamically more favoured than 4-acylderivative, therefore it is 
reasonable to expect the possible presence of 4-acylderivatives, in agreement with the 72:28 
experimental observed ratio.  
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4.3     Conclusion: 
In conclusion, we have developed a simple one-pot two-step method for the 
regiocontrolled synthesis of pyrazoles fused with lactones, thiolactones and lactams based on the 
1,3-DC of nitrile imines with the corresponding α,β-unsaturated dipolarophiles. In all the cases 
examined the 5-acyl substituted pyrazole is the major product, with ratio 5-acyl/4-acyl up to 
99:1, except with the 5-membered α,-β-unsaturated lactone (ratio 5-acyl/4-acyl 14:86). The 
effect of the substituent in the para-position of the aryl on the dipole, the nature and size of the 
dipolarophiles and their effect on yields and regiochemistry have been investigated. To 
rationalize the experimental results a theoretical model including the possibility of reactive 
intermediate forms of dipole, the size of the dipolarophile and the electrostatic interactions 
between the reactive forms has been developed.  
The reported methodology appears to be suitable for the control of the regiochemistry of 
this 1,3-DC and could be potentially useful for applications in medicinal chemistry. Computer-
assisted syntheses of ring-fused pyrazoles of this type are currently being investigated as 
multikinase inhibitors.  
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4.4      Experimental: 
 
4.4.1 Material and Methods:  
1H NMR and 13C NMR spectra were recorded using CDCl3 or CD3OD or DMSO-d6 
solutions at 300, 400 and 600 MHz for 1H and 75.46, 100.6 and 150.92 MHz for 13C. Chemical 
shifts (δ) are reported in ppm relative to CHCl3 (δ = 7.26 for 
1H and δ = 77.0 for 13C ). J values 
are given in Hz. 1H NMR and 13C NMR spectral assignments were made by DEPT, gCOSY and 
gHSQC experiments. IR spectra were recorded in solvent as specified. Mass spectra (MS) were 
obtained with an electrospray ionization source (ESIMS). All the ESIMS spectra were performed 
using MeOH as the solvent. High Resolution Mass Spectra (HRMS) were recorded on a 
micromass LCT spectrometer using electrospray (ES+) ionisation techniques. Reactions were 
conducted in oven-dried (120 °C) glassware under a positive Ar atmosphere. Transfer of 
anhydrous solvents or mixtures was accomplished with oven-dried syringes/septum techniques. 
THF was distilled from sodium/benzophenone just prior to use and stored under Ar. Toluene was 
distilled from sodium. Et2O was distilled from phosphorus pentoxide. CH2Cl2 was passed 
through basic alumina and distilled from CaH2 prior to use. Other solvents were purified by 
standard procedures. Light petroleum ether refers to the fraction with bp 40-60°C. The reactions 
were monitored by TLC performed on silica gel plates (Baker-flex IB2-F). Column 
chromatography was performed with Merck silica gel 60 (70-230 mesh). Preperative TLC was 
carried out on glass plates using a 1 mm layer of Merck silica gel 60 Pf 254. All chemicals were 
used as obtained or purified as needed. 
 
4.4.2 Synthesis of 5,6-dihydro-2H-thiopyran-2-one (5): 
A solution of NaH (0.4 g, 10.0mmol, 60% dispersion in mineral oil) in dry THF (15 ml) 
was cooled to 0°C and methyl 2-(dimethoxyphosphoryl)acetate (1.68 g, 9.2 mmol) was added 
slowly for 5 min. The resulting mixture was stirred at 0°C for further 20 min, then S-3-oxopropyl 
ethanethioate26 (1 g, 8.4 mmol) dissolved in dry THF was introduced and the resulting mixture 
was stirred at room temperature for further 1-2 h. After completion, water was added and 
extracted with EtOAc (3 x 20 ml). Combined organic layers were washed with brine, dried over 
MgSO4 and evaporated in vacuo. The (E)-methyl 5-(acetylthio)pent-2-enoate (1.4 g, 93 %) was 
directly used for next step. 1H NMR (300 MHz, CDCl3): δ 2.34 (s, 3H), 2.44-2.54 (qd, J = 7.1 
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and 1.6 Hz, 2H), 2.98 (t, J = 7.1 Hz, 2H), 3.74 (s, 3H), 5.87 (dt, J = 15.6 and 1.5 Hz, 1H), 6.90 
(dt, J = 15.6 and 6.54 Hz, 1H). 
(E)-methyl 5-(acetylthio)pent-2-enoate (1.4g, 7.4 mmol) was dissolved in MeOH (10 ml) 
then 10% NaOH (10 ml) was added. The resulting reaction mixture was then stirred at room 
temperature for overnight. After completion, reaction mixture was extracted with EtOAc (3 x 20 
ml). Combined organic layers were washed with brine, dried over MgSO4 and evaporated in 
vacuo to give (E)-5-mercaptopent-2-enoic acid (0.87 g, 88 %) as oil which was directly used for 
next step. 
(E)-5-mercaptopent-2-enoic acid (0.8 g, 6.0 mmol) was added to PPA (10 ml) and heated 
to 70°C for 2 h. After completion, ice water was added to reaction and extracted with DCM (3 x 
15 ml). Combined organic layers were washed with water and brine, dried over MgSO4 and 
evaporated in vacuo to give 5,6-dihydro-2H-thiopyran-2-one (5) (0.12 g, 17%) as oil. 1H NMR 
(300 MHz, CDCl3): δ 2.57-2.65 (m, 2H), 3.21 (t, J = 6.3 Hz, 2H), 6.11 (dt, J = 10.8, 1.8 Hz, 1H), 
6.91 (dt, J = 10.9, 4.8 Hz, 1H). 
 
4.4.3  General Procedure for 1,3 dipolar cycloaddition:  
To a stirred solution of dipolarophiles 2-7 (1 eq) and 1a or 1b (1 eq. for 2-5 and 2 eq. for 
6 and 7) in freshly distilled dioxane (5 mL for 2-5) or toluene (5 mL for 6 and 7) under argon 
atmosphere was added triethylamine (2.5 eq. for 2-5 and 5 eq. for 6 and 7). Reaction was heated 
at 80 °C overnight. After completion, reaction mixture was allowed to cool and filtered through 
bed of celite and washed with DCM (5 mL). The filtrate was then evaporated in vacuo to give 
dark red crude oil. The crude product was directly used in the oxidation stage. 
 
4.4.4  General Procedure for CAN oxidation of cycloadducts:  
The crude cycloaddition product was suspended in THF:H2O (6:8, 10 ml) at 0°C. Then 
cerium (IV) ammonium nitrate (CAN) (2.5 eq.) was added slowly in portions. After completion 
of addition, reaction was allowed to stirr at 0°C for further 1-2 h. After completion, THF was 
evaporated at vacuo and the aqueous layer was extracted with ethyl acetate (3 x 10 ml). The 
organic layer was then washed with water (15 ml) and brine. The combined organic layers were 
dried over MgSO4 and then evaporated in vacuo. The crude residue was purified with column 
chromatography to give the corresponding title compounds. 
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4.4.5 Cycloadducts and their analysis: 
Methyl 6-oxo-1-phenyl-4,6-dihydro-1H-furo[3,4-c]pyrazole-3-carboxylate and Methyl 4-
oxo-1-phenyl-4,6-dihydro-1H-furo[3,4-c]pyrazole-3-carboxylate (8a and 8a’): Compounds 
8a and 8a’ were obtained as a yellow oil following the general procedure for the 1,3-DC 
followed by the oxidation with CAN and separated by chromatography on silica gel (10-50% 
EtOAc/hexane). The two regioisomers were further separated by preparative TLC plates (50 % 
EtOAc/hexane). 
 
 Methyl 6-oxo-1-phenyl-4,6-dihydro-1H-furo[3,4-c]pyrazole-3-carboxylate 
(8a): 1H NMR (300 MHz, CDCl3): δ 4.00 (s, 3H), 5.41 (s, 2H), 7.31-8.30 (m, 
5H); 13C NMR (100 MHz, CDCl3): δ 52.9, 65.8, 120.7 (2C), 127.3, 128.9, 
129.8 (2C), 136.1, 138.3, 142.5, 158.4, 161.1; [M]+ = 258; IR (CCl4): ν = 
3068, 2953, 1780, 1725, 1576, 1436, 1374, 1276, 1138, 1032, 984 cm-1. 
 
 Methyl 4-oxo-1-phenyl-4,6-dihydro-1H-furo[3,4-c]pyrazole-3-carboxylate 
(8a’): 1H NMR (300 MHz, CDCl3): δ 4.04 (s, 3H), 5.45 (s, 2H), 7.36-7.78 (m, 
5H); 13C NMR (100 MHz, CDCl3): δ 53.1, 64.1, 119.6 (2C), 125.8, 129.3, 
130.3 (2C), 130.6, 137.9, 139.2, 158.2, 160.5; [M]+ = 258; IR (CCl4): ν = 
3068, 2953, 1780, 1725, 1576, 1436, 1374, 1276, 1138, 1032, 984 cm-1. 
 
Methyl 1-(4-methoxyphenyl)-6-oxo-4,6-dihydro-1H-furo[3,4-c]pyrazole-3-carboxylate and 
methyl 1-(4-methoxyphenyl)-4-oxo-4,6-dihydro-1H-furo[3,4-c]pyrazole-3-carboxylate (8b 
and 8b’): Compounds 8b and 8b’ were obtained as a solid and yellow oil respectively following 
the general procedure for the 1,3-DC followed by the oxidation with CAN and separated by 
chromatography on silica gel (10-50 % EtOAc/hexane). The two regioisomers were further 
separated by preperative TLC plates (50 % EtOAc/hexane). 
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Methyl 1-(4-methoxyphenyl)-6-oxo-4,6-dihydro-1H-furo[3,4-c]pyrazole-3-
carboxylate (8b): M.P.= 190-191°C; 1H NMR (300 MHz, CDCl3): δ 3.86 (s, 
3H), 3.99 (s, 3H), 5.40 (s, 2H), 7.01 (d, J = 9.1 Hz, 2H), 8.05 (d, J = 9.1 Hz, 
2H); 13C NMR (100 MHz, CDCl3): δ 52.9, 55.8, 65.8, 114.8 (2C), 122.3 (2C), 
131.7, 135.4, 135.6, 142.1, 158.6, 160.0, 161.2; [M]+ = 288; IR (CCl4): ν = 
2954, 2909, 2223, 1755, 1720, 1612, 1559, 1505, 1442, 1254, 1119, 1065, 951 
cm-1. 
 
Methyl 1-(4-methoxyphenyl)-4-oxo-4,6-dihydro-1H-furo[3,4-c]pyrazole-3-
carboxylate (8b’): 1H NMR (300 MHz, CDCl3): δ 3.87 (s, 3H), 4.04 (s, 3H), 
5.39 (s, 2H), 7.03 (d, J = 9.2 Hz, 2H), 7.52 (d, J = 9.2 Hz, 2H); 13C NMR (200 
MHz, CDCl3): δ 53.1, 55.9, 63.9, 155.3 (2C), 117.1, 121.3 (2C), 131.2, 138.8, 
157.7, 160.0, 160.6, 160.7; [M]+ = 288; IR (CCl4): ν = 2954, 2909, 2223, 1755, 
1720, 1612, 1559, 1505, 1442, 1254, 1119, 1065, 951 cm-1. 
 
Methyl 7-oxo-1-phenyl-1,4,5,7-tetrahydropyrano[3,4-c]pyrazole-3-carboxylate and methyl 
4-oxo-1-phenyl-1,4,6,7-tetrahydropyrano[4,3-c]pyrazole-3-carboxylate (9a and 9a’): 
Compounds 9a and 9a’ were obtained as solids following the general procedure for the 1,3-DC 
followed by the oxidation with CAN and separated by chromatography on silica gel (10-50 % 
EtOAc/hexane). The two regioisomers were further separated by preperative TLC plates (50 % 
EtOAc/hexane). 
 
 Methyl 7-oxo-1-phenyl-1,4,5,7-tetrahydropyrano[3,4-c]pyrazole-3-
carboxylate (9a): M.P.= 183-184°C ; 1H NMR (300 MHz, CDCl3): δ 3.31 (t, 
J = 6.0 Hz, 2H), 3.98 (s, 3H), 4.64 (t, J = 6.0 Hz, 2H), 7.44-7.63 (m, 5H); 13C 
NMR (100 MHz, CDCl3): δ 22.1, 52.5, 69.1, 125.3 (2C), 129.0 (2C), 129.3, 
129.6 (2C), 138.8, 139.6, 156.6, 162.1; [M]+ = 272; IR (CCl4): ν = 2997, 
2955, 1751, 1724, 1599, 1509, 1439, 1367, 1265, 1240, 1139,c1101, 1003, 948 cm-1. 
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Methyl 4-oxo-1-phenyl-1,4,6,7-tetrahydropyrano[4,3-c]pyrazole-3-
carboxylate (9a’): M.P.= 141-142 °C ; 1H NMR (300 MHz, CDCl3): δ 3.16 (t, 
J = 5.9 Hz, 2H), 4.00 (s, 3H), 4.52 (t, J = 5.9 Hz, 2H), 7.46-7.57 (m, 5H); 13C 
NMR (100 MHz, CDCl3): δ 23.4, 53.0, 66.4, 110.5, 123.9 (2C), 129.5, 129.9 
(2C), 137.6, 144.1, 146.5, 159.5, 161.3; [M]+ = 272; IR (CCl4): ν = 2997, 
2955, 1751, 1724, 1599, 1509, 1439, 1367, 1265, 1240, 1139,c1101, 1003, 948 cm-1. 
 
Methyl 1-(4-methoxyphenyl)-7-oxo-1,4,5,7-tetrahydropyrano[3,4-c]pyrazole-3-carboxylate 
and methyl 1-(4-methoxyphenyl)-4-oxo-1,4,6,7-tetrahydropyrano[4,3-c]pyrazole-3-
carboxylate (9b and 9b’): Compounds 9b and 9b’ were obtained as solids following the general 
procedure for the 1,3-DC followed by the oxidation with CAN and separated by chromatography 
on silica gel (10-50 % EtOAc/hexane). The two regioisomers were further separated by 
preperative TLC plates (50 % EtOAc/hexane). 
 
 Methyl 1-(4-methoxyphenyl)-7-oxo-1,4,5,7-tetrahydropyrano[3,4-
c]pyrazole-3-carboxylate (9b): M.P.= 218-219°C ; 1H NMR (300 MHz, 
CDCl3): δ 3.30 (t, J = 6.1 Hz, 2H), 3.86 (s, 3H), 3.98 (s, 3H), 4.63 (t, J = 6.1 
Hz, 2H), 6.97 (d, J = 8.9 Hz, 2H), 7.49 (d, J = 8.9 Hz, 2H); 13C NMR (100 
MHz, CDCl3): δ 22.1, 52.5, 55.7, 69.1, 114.1 (2C), 126.6 (2C), 129.2, 129.3, 
131.9, 139.2, 156.8, 160.4, 162.2; [M]+ = 302; IR (CCl4): ν = 3000, 2954, 
2052, 1755, 1723, 1592, 1559, 1509, 1444, 1391, 1254, 1100, 1065, 951 cm-1. 
 
1-(4-methoxyphenyl)-4-oxo-1,4,6,7-tetrahydropyrano[4,3-c]pyrazole-3-
carboxylate  (9b’): M.P.=113-114 °C ; 1H NMR (300 MHz, CDCl3): δ 3.09 (t, 
J = 6.2 Hz, 2H), 3.86 (s, 3H), 3.99 (s, 3H), 4.51 (t, J = 6.2 Hz, 2H), 7.01 (d, J = 
9.3 Hz, 2H), 7.42 (d, J = 9.3 Hz, 2H); 13C NMR (75 MHz, CDCl3): δ 23.2, 
52.9, 55.9, 66.4, 114.9 (2C), 125.4 (2C), 128.2, 130.6, 143.8, 146.5, 159.6, 
160.4, 161.4; [M]+ = 302; IR (CCl4): ν = 3000, 2954, 2052, 1755, 1723, 1592, 
1559, 1509, 1444, 1391, 1254, 1100, 1065, 951 cm-1. 
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Methyl 6-oxo-1-phenyl-4,6-dihydro-1H-thieno[3,4-c]pyrazole-3-carboxylate (10a): 
Compound 10a was obtained as a solid following the general procedure for the 1,3-DC followed 
by the oxidation with CAN and separated by chromatography on silica gel (20 % 
EtOAc/hexane). 
 
Methyl 6-oxo-1-phenyl-4,6-dihydro-1H-thieno[3,4-c]pyrazole-3-
carboxylate (10a): M.P.= 194°C ; 1H NMR (300 MHz, CDCl3): δ 4.00 (s, 
3H), 4.43 (s, 2H), 7.38-7.53 (m, 3H), 7.79-7.86 (m, 2H); 13C NMR (75 MHz, 
CDCl3): δ 27.2, 52.7, 123.2 (2C), 129.2, 129.4 (2C), 137.8, 138.0, 142.6, 
143.2, 161.6, 182.2; [M]+ = 274; IR (CCl4): ν = 3075, 2957, 2361, 1754, 
1721, 1698, 1501, 1464, 1372, 1294, 1202, 1132, 1048, 881cm-1. 
 
Methyl 1-(4-methoxyphenyl)-6-oxo-4,6-dihydro-1H-thieno[3,4-c]pyrazole-3-carboxylate and 
methyl 1-(4-methoxyphenyl)-4-oxo-4,6-dihydro-1H-thieno[3,4-c]pyrazole-3-carboxylate 
(10b and 10b’): Compounds 10b and 10b’ were obtained as a solid and yellow oil respectively 
following the general procedure for the 1,3-DC followed by the oxidation with CAN and 
separated by chromatography on silica gel (10-50 % EtOAc/hexane). The two regioisomers were 
further separated by preperative TLC plates (50 % EtOAc/hexane). 
 
Methyl 1-(4-methoxyphenyl)-6-oxo-4,6-dihydro-1H-thieno[3,4-
c]pyrazole-3-carboxylate (10b): M.P.= 180-181°C ; 1H NMR (400 MHz, 
CDCl3): δ 3.85 (s, 3H), 3.99 (s, 3H), 4.41 (s, 2H), 6.98 (d, J = 9.1Hz, 2H), 
7.72 (d, J = 9.1 Hz, 2H); 13C NMR (75 MHz, CDCl3): δ 27.1, 52.7, 55.8, 
114.4 (2C), 124.7(2C), 131.2, 137.4, 142.1, 142.9, 160.2, 161.8, 182.3; [M]+ = 
304; IR (CCl4): ν = 2957, 2361, 1753, 1722, 1698, 1594, 1514, 1439, 1255, 
1160, 1132, 1050, 883 cm-1. 
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Methyl 1-(4-methoxyphenyl)-4-oxo-4,6-dihydro-1H-thieno[3,4-c]pyrazole-
3-carboxylate (10b’): 
1H NMR (300 MHz, CDCl3): δ 3.88 (s, 3H), 4.00 (s, 
3H), 4.35 (s, 2H), 7.03 (d, J = 8.8 Hz, 2H), 7.55 (d, J = 8.8 Hz, 2H); 13C NMR 
(100 MHz, CDCl3): δ 27.5, 52.9, 55.9, 115.1(2C), 123.8 (2C), 124.9, 130.4, 
136.9, 157.8, 160.3, 160.8, 182.7; [M]+ = 304; IR (CCl4): ν = 2957, 2361, 
1753, 1722, 1698, 1594, 1514, 1439, 1292, 1255, 1160, 1132, 1050, 883cm-1. 
 
Methyl 7-oxo-1-phenyl-1,4,5,7-tetrahydrothiopyrano[3,4-c]pyrazole-3-carboxylate and 
methyl 4-oxo-1-phenyl-1,4,6,7-tetrahydrothiopyrano[4,3-c]pyrazole-3-carboxylate (11a and 
11a’): Compounds 11a and 11a’ were obtained as solids following the general procedure for the 
1,3-DC and separated by chromatography on silica gel (10-50 % EtOAc/hexane). The two 
regioisomers were further separated by preperative TLC plates (50 % EtOAc/hexane). 
 
Methyl 7-oxo-1-phenyl-1,4,5,7-tetrahydrothiopyrano[3,4-c]pyrazole-3-
carboxylate (11a): M.P.= 206-207°C; 1H NMR (300 MHz, CDCl3): δ 3.35-
3.55 (m, 4H), 3.95 (s, 3H), 7.40-7.50 (m, 5H); 13C NMR (100 MHz, CDCl3): δ 
22.5, 31.6, 52.4, 125.8 (2C), 128.9 (2C), 129.6, 131.3, 134.2, 139.7, 140.0, 
162.4, 180.9; [M]+ = 288; IR (CCl4): ν = 3065, 2954, 1747, 1682, 1601, 1566, 
1501, 1450, 1263, 1149, 1074, 967, 889 cm-1. 
 
Methyl 4-oxo-1-phenyl-1,4,6,7-tetrahydrothiopyrano[4,3-c]pyrazole-3-
carboxylate (11a’): M.P.= 154-155°C ; 1H NMR (300 MHz, CDCl3): δ 3.16-
3.35 (m, 4H), 3.97 (s, 3H), 7.39-7.65 (m, 5H); 13C NMR (100 MHz, CDCl3): δ 
24.2, 29.8, 53.3, 125.1 (2C), 129.7, 129.8 (2C), 137.6, 142.7, 147.8, 162.0, 
183.3; [M]+ = 288; IR (CCl4): ν = 3065, 2954, 1747, 1682, 1601, 1566, 1501, 
1450, 1263, 1149, 1074, 967, 889 cm-1. 
 
Methyl 1-(4-methoxyphenyl)-7-oxo-1,4,5,7-tetrahydrothiopyrano[3,4-c]pyrazole-3-
carboxylate and methyl 1-(4-methoxyphenyl)-4-oxo-1,4,6,7-tetrahydrothiopyrano[4,3-
c]pyrazole-3-carboxylate (11b and 11b’): Compounds 11b and 11b’ were obtained as a solid 
and yellow oil respectively following the general procedure for the 1,3-DC and separated by 
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chromatography on silica gel (10-50 % EtOAc/hexane). The two regioisomers were further 
purified by preperative TLC plates (50 % EtOAc/hexane). 
 
Methyl 1-(4-methoxyphenyl)-7-oxo-1,4,5,7-tetrahydrothiopyrano[3,4-
c]pyrazole-3-carboxylate (11b): M.P.=201-202 °C ; 1H NMR (300 MHz, 
CDCl3): δ 3.35-3.53 (m, 4H), 3.83 (s, 3H), 3.95 (s, 3H), 6.92 (d, J = 8.7 Hz, 
2H), 7.35 (d, J = 8.7 Hz, 2H); 13C NMR (100 MHz, CDCl3): δ 22.6, 31.6, 
52.4, 55.7, 114.0 (2C), 127.0 (2C), 131.1, 132.8, 134.1, 139.7, 160.3, 162.5, 
181.0; [M]+ = 318; IR (CCl4): ν = 3003, 2955, 2837, 1722, 1668, 1593, 1515, 
1438, 1250, 1179, 1131, 1038, 891 cm-1. 
 
Methyl 1-(4-methoxyphenyl)-4-oxo-1,4,6,7-tetrahydrothiopyrano[4,3-
c]pyrazole-3-carboxylate (11b’):
 1H NMR (300 MHz, CDCl3): δ 3.11-3.16 
(m, 4H), 3.87 (s, 3H), 3.97 (s, 3H), 7.01 (d, J = 8.3 Hz, 2H), 7.36 (d, J = 8.3 
Hz, 2H); 13C NMR (100 MHz, CDCl3): δ 24.2, 29.7, 53.0, 55.9, 114.9 (2C), 
126.5 (2C), 130.5, 142.2, 148.0, 156.1, 160.5, 162.1, 183.3; [M]+ = 318; IR 
(CCl4): ν = 3003, 2955, 2837, 1722, 1668, 1593, 1515, 1438, 1250, 1179, 
1131, 1038, 891 cm-1. 
 
Methyl 6-oxo-1-phenyl-5-tosyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-3-carboxylate and 
methyl 4-oxo-1-phenyl-5-tosyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-3-carboxylate (12a 
and 12a’): Compounds 12a and 12a’ were obtained as a yellowish solid and yellow foam 
following the general procedure for the 1,3-DC (in toluene) followed by the oxidation with CAN 
and separated by chromatography on silica gel (1/9 EtOAc/hexane). The two regioisomers were 
further separated by preparative TLC plates (CH2Cl2). 
 
Methyl 6-oxo-1-phenyl-5-tosyl-1,4,5,6-tetrahydropyrrolo[3,4-
c]pyrazole-3-carboxylate (12a): MP.: 184-189 °C, 1H NMR 
(300 MHz, CDCl3): δ 2.44 (s, 3H), 4.00 (s, 3H), 4.96 (s, 2H), 
7.32-7.51 (m, 3H), 7.98-8.12 (m, 4H); 13C NMR (75 MHz, 
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CDCl3): δ  22.0, 45.7, 52.7, 121.3, 128.5, 128.9, 129.7, 130.3, 134.8, 135.2, 137.0, 138.2, 145.9, 
155.3, 161.2; [M]+ = 411; IR (CCl4): ν = 2928, 2855, 1741, 1559, 1467, 1177, 1097cm
-1. 
 
Methyl 4-oxo-1-phenyl-5-tosyl-1,4,5,6-tetrahydropyrrolo[3,4-
c]pyrazole-3-carboxylate (12a’): 1H NMR (400 MHz, CDCl3): δ 
2.43 (s, 3H), 3.98 (s, 3H), 5.10 (s, 2H), 7.34 (d, J = 8.6 Hz, 2H), 
7.45 (tt, J = 7.3 and 1.2 Hz, 2H), 7.55 (tt, J = 7.3 and 1.7 Hz, 2H), 
7.64 (dt, J = 7.3 and 1.4 Hz, 2H), 8.02 (d, J = 8.2 Hz, 2H); 13C 
NMR (75 MHz, CDCl3): δ  21.9, 45.9, 53.1, 120.1, 120.7, 121.5, 128.6, 129.1, 129.7, 130.1, 
130.3, 135.9, 137.9, 145.6, 150.9, 157.6, 160.5; [M]+ = 411; IR (CCl4): ν = 2928, 2855, 1741, 
1559, 1467, 1177, 1097cm-1. 
 
Methyl 1-(4-methoxyphenyl)-6-oxo-5-tosyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-3-
carboxylate and methyl 1-(4-methoxyphenyl)-4-oxo-5-tosyl-1,4,5,6-tetrahydropyrrolo[3,4-
c]pyrazole-3-carboxylate (12b and 12b’): Compounds 12b and 12b’ were obtained as a white 
solid and white foam following the general procedure for the 1,3-DC (in toluene) followed by the 
oxidation with CAN and separated by chromatography on silica gel (1/9 EtOAc/hexane). The 
two regioisomers were further separated by preparative TLC plates (CH2Cl2). 
  
Methyl 1-(4-methoxyphenyl)-6-oxo-5-tosyl-1,4,5,6-
tetrahydropyrrolo[3,4-c]pyrazole-3-carboxylate (12b): m.p.: 
213-218 °C, 1H NMR (400 MHz, CDCl3): δ 2.43 (s, 3H), 3.88 
(s,3H), 4.00 (s, 3H), 4.98 (s, 2H), 6.93-9.97 (d, J = 8.5 Hz, 2H), 
7.35 (d, J = 8.0 Hz, 2H), 7.94-8.10 (m, 4H); 13C NMR (100 MHz, 
CDCl3): δ 22.0, 45.5, 52.9, 55.8, 114.7, 122.7, 128.5, 130.2, 
131.6, 134.4, 135.2, 136.5, 137.2, 145.8, 155.4, 160.0, 161.2; [M]+ = 441, found [M+23]+ = 464; 
IR (CCl4): ν = 3071, 2954, 1944, 1725, 1600, 1264, 1098 cm
-1. 
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Methyl 1-(4-methoxyphenyl)-4-oxo-5-tosyl-1,4,5,6-
tetrahydropyrrolo[3,4-c]pyrazole-3-carboxylate (12a’): 1H 
NMR (400 MHz, CDCl3): δ 2.43 (s, 3H), 3.87 (s, 3H), 3.98 (s, 
3H), 5.04 (s, 2H), 7.03(d, J = 8.9 Hz, 2H), 7.34 (d, J=8.0 Hz, 2H), 
7.54 (d, J = 9.0 Hz, 2H), (d, J = 8.2 Hz, 2H); 13C NMR (100 
MHz, CDCl3): δ 21.9, 45.7, 53.1, 55.9, 115.3, 119.9, 121.9, 
128.5, 130.1, 131.2, 135.4, 139.2, 145.6, 150.5, 157.8, 160.0, 160.7; [M]+ = 441; IR (CCl4): ν = 
3071, 2954, 1944, 1725, 1600, 1264, 1098 cm-1. 
 
Methyl 7-oxo-1-phenyl-6-tosyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-
carboxylate and Methyl 4-oxo-1-phenyl-5-tosyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-
c]pyridine-3-carboxylate (13a and 13a’): Compounds 13a and 13a’ were obtained as a white 
solid and yellow foam following the general procedure for the 1,3-DC (in toluene) followed by 
the oxidation with CAN and separated by chromatography on silica gel (1/9 EtOAc/hexane). The 
two regioisomers were further separated by preparative TLC plates (CH2Cl2). 
 
Methyl 7-oxo-1-phenyl-6-tosyl-4,5,6,7-tetrahydro-1H-
pyrazolo[3,4-c]pyridine-3-carboxylate (13a): M.P.: 195-198 
°C, 1H NMR (300 MHz, CDCl3): δ 2.41 (s, 3H), 3.29 (t, J = 6.8 
Hz, 3H), 3.95 (s, 3H), 4.34 (t, J = 6.8 Hz, 2H), 7.29 (d, J = 8.4 
Hz, 2H), 7.38-7.41 (m, 5H), 7.89 (d, J = 8.4 Hz, 2H); 13C NMR 
(100 MHz, CDCl3): δ 21.9, 22.1, 46.8, 52.5, 125.6, 128,7, 128,9 (2C), 129.5, 129.8, 132.1, 136.0, 
139.1, 139.4, 145.2, 155.7, 162.2; [M]+ = 425, found [M+23]+ = 448; IR (CCl4): ν = 2984, 2360, 
1710, 1559, 1264, 1174 cm-1. 
 
Methyl 4-oxo-1-phenyl-5-tosyl-4,5,6,7-tetrahydro-1H-
pyrazolo[4,3-c]pyridine-3-carboxylate (13a’): 1H NMR (400 
MHz, CDCl3): δ 2.43 (s, 3H), 3.16 (t, J = 6,3 Hz, 3H), 3.95 (s, 3H), 
4.29 (t, J = 6,3 Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H), 7.44-7.57 (m, 5H), 
7.92 (d, J = 8.2 Hz, 2H); 13C NMR (100 MHz, CDCl3): δ 21.9, 24.0, 
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45.1, 53.0, 123.9, 128,8, 129.6, 129.8, 129.9 (2C), 134.0, 136.3, 137.6, 145.0, 146.7, 158.3, 
165.6; [M]+ = 425; IR (CCl4): ν = 2984, 2360, 1710, 1559, 1264, 1174 cm
-1 . 
 
Methyl 1-(4-methoxyphenyl)-7-oxo-6-tosyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-
3-carboxylate and Methyl 1-(4-methoxyphenyl)-4-oxo-5-tosyl-4,5,6,7-tetrahydro-1H-
pyrazolo[4,3-c]pyridine-3-carboxylate (13b and 13b’): Compounds 13b and 13b’ were 
obtained as a white solid and yellow foam following the general procedure for the 1,3-DC (in 
toluene) followed by the oxidation with CAN and separated by chromatography on silica gel (1/9 
EtOAc/hexane). The two regioisomers were further separated by preparative TLC plates 
(CH2Cl2). 
 
Methyl 1-(4-methoxyphenyl)-7-oxo-6-tosyl-4,5,6,7-
tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate (13b): 
M.P.: 167-172 °C, 1H NMR (300 MHz, CDCl3): δ 2.41 (s, 3H), 
3.28 (t, J = 6,3 Hz, 3H), 3.83 (s, 3H), 3.95 (s, 3H), 4.34 (t, J = 
6,3 Hz, 2H), 6.89 (d, J = 9.1 Hz, 2H), 7.29 (d, J = 8.5 Hz, 2H), 
7.36 (d, J = 9.1 Hz, 2H), 7.90 (d, J = 8.5 Hz, 2H); 13C NMR 
(100 MHz, CDCl3): δ 21.9, 22.1, 46.952.4, 55.8, 114.1, 126.9, 128.8, 128.9, 129.5, 129.8, 132.0, 
132.3, 136.1, 139.1, 145.2, 155.8, 160.3, 162.2; [M]+ = 455, Found [M+23]+ = 478; IR (CCl4): ν 
= 2928, 2856, 2360, 1726, 1576, 1516, 1465, 1263 cm-1. 
  
Methyl 1-(4-methoxyphenyl)-4-oxo-5-tosyl-4,5,6,7-tetrahydro-
1H-pyrazolo[4,3-c]pyridine-3-carboxylate (13b’): 1H NMR (300 
MHz, CDCl3): δ 2.41 (s, 3H), 3.10 (t, J = 6,3 Hz, 3H), 3.87 (s, 3H), 
3.93 (s, 3H), 4.28 (t, J = 6,3 Hz, 2H), 7.01 (d, J = 9.0 Hz, 2H), 7.32 
(d, J = 8.2 Hz, 2H), 7.36 (d, J = 9.1 Hz, 2H), 7.90 (d, J = 8.4 Hz, 
2H); 13C NMR (100 MHz, CDCl3): δ  21.9, 23.8, 45.2, 53.1, 55.8, 
114.9, 125.7, 128.8, 128.9, 129.5, 130.6, 136.4, 143.8, 144.9, 146.7, 158.4, 160.4, 161.6; [M]+ = 
455; IR (CCl4): ν = 2928, 2856, 2360, 1726, 1576, 1516, 1465, 1263 cm
-1. 
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4.4.6 Theoretical and computational method: 
  To rationalize the reactivity of the studied systems we have used some global descriptors 
of reactivity which have been defined within the context of the density functional theory. The 
global electrophilicity power measures the capability of a system to acquire electronic charge 
from the environment, and is calculated by the following simple expression,28 
  
 
!
, where µ 
and η are the electronic chemical potential and chemical hardness of the ground state of atoms 
and molecules, respectively.29,30 While µ describes the charge transfer pattern in the system in its 
ground state geometry, η describes the resistance to this charge transference. Both quantities 
could be approached in terms of the one electron energies of the frontier molecular orbital 
HOMO and LUMO,  and , as      and     , respectively. As 
nucleophilicity (N) descriptor we have used the ionization energy, approached following the 
Koopmans’ theorem31 and the Kohn-Sham scheme32 as the negative of the highest occupied 
molecular orbital (HOMO) energy; but to recover the direct proportionality of the index and 
nucleophilicity we expressed N as,     . A similar expression has been 
previously successfully used to study the reactivity of captodative ethylenes in polar 
cycloaddition reactions.33 As local descriptor of reactivity to evaluate the regioselictivity, we 
have used the Fukui function; these local quantities were obtained from a topological analysis of 
the Fukui function, using the same topological tools proposed  by Bader almost three decades 
ago to analyze the gradient field of the electron density to give a definition of an atom in a 
molecule.34 For a detailed revision of this methodology see the following references.35,36 To 
evaluate the possible electrostatic interactions we have computed the electrostatic potentials on 
the surfaces of a series of selected systems. For this purpose, we taking the molecular surface to 
be the 0.002 au contour of the molecule’s electronic density ρ(r), as proposed by Bartolotti et 
al.
27 The electrostatic potential V(r) that is produced at any point r by the nuclei and electrons of 
the molecule is given by:37  
 "#  $ %&
'(&)'
*  +
,-)′./)′
0)′)0
 
ZA is the charge on nucleous A, located at RA. Regions where V(r) is negative are attractive to 
cations and repulsive to anions; regiosn where V(r) is positive are attractive to anions and 
repulsive to cations. The molecular geometries have been optimized using the B3LYP density 
functional method38 in conjunction with the 6-31G(d) basis set.39  All calculations were carried 
121 
 
out with the Gaussian 03suite of programs,40 the topological analysis of the scalar functions and 
the calculation of the condensed Fukui function were done with the DGrid 4.4 set of programs.41 
 
4.5 X-ray Analysis: 
The diffraction experiments were carried out at room temperature on a Bruker ApexII 
diffractometer equipped with a CCD detector, by using graphite monochromated MoKα radiation 
(λ = 0.71073 Å). An empirical absorption correction was applied on all structures by using 
SADABS.42 They were solved by Direct Methods and refined by full-matrix least-squares based 
on F2 using SHELXL97.43 All non-hydrogen atoms were refined anisotropically while hydrogen 
atoms were set geometrically and given fixed isotropic thermal parameters. Crystal data and 
details of the data collection and refinement are given in Table 2-SI. 
 
4.5.1 X-ray structures of 8b, 9a’, 11a, 12b, 13a and 13b: 
 The unit cell of 8b contains four molecules, one of which constitutes the independent unit 
(Figure 4.8). In this case, unlike most of the others that will follow, the pyrazole is practically 
coplanar with the acyl and the p-methoxy-phenyl groups, the torsion angles being only 1.70(1) 
(N8-C9-C10-O11) and 1.5381)° (C5-C9-C10-O12) for the former, -4.94(1)° (N8-N7-C14-C19) 
and -4.69(1)° (C6-N7-C14-C15) for the latter (see Figure 4). As a result the whole molecule is 
virtually flat and arranges in parallel units in the solid state, as illustrated in Figure 4.9 (view 
along the b axis). The packing is held by some intermolecular hydrogen bonds involving the 
oxygen and nitrogen atoms, whose lengths are comprised between 3.063(1) (O20...H-C13_a) and 
3.588(3) Å (N8...H-C4_b). 
 
Figure 4.8: X-ray structure of 8b (ellypsoids are at 30% probability). 
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Figure 4.9: Crystal packing of 8b. View along the b axis. 
 
 
 The unit cell of 9a’ contains four molecules, one of which represents the independent 
unit. As shown in Figure 4.10, with respect to the pyrazolic plane both the acyl and phenyl 
groups are tilted, probably due to packing efficiency, and their torsion angles are -18.20(26)° 
(C4-C3-C17-O18) and -23.4(2)° (N2-C3-C17-O19) for the acyl, -33.83(23)° (C5-N1-C11-C12) 
and -30.03(19)° (N2-N1-C11-C16) for the phenyl ring. The solid state packing shows only weak 
intermolecular hydrogen bonds involving the oxygen and nitrogen atoms, ranging between 
3.367(2) (O8...H-C16_a) and 3.562(3) Å (O19...C7_b).  
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Figure 4.10: Crystal structure of 9a’ (ellypsoids at 30% probability). 
 
 
  
 The unit cell of 11a contains 4 molecules, one of which constitutes the independent unit 
(see Figure 4.3 (a)). Similarly to the previous structure the phenyl ring is tilted with regard to the 
pyrazole plane by 56.90(1)° (N8-N9-C20-C15) and 53.47(2)° (C3-N8-C15-C20), while the acyl 
group is nearly coplanar as it only deviates by 3.25° (N9-C10-C11-O12) and 4.94° (C4-C10-
C11-O13). The solid state arrangement only shows weak intermolecular hydrogen bonds 
involving the oxygen atoms, whose distances vary from 3.193(1) (O7...H-C16_a) to 3.507(2) Å 
(O13...H-C20_b).  
 The unit cell of 12b is made of two molecules of which one represents the asymmetric 
unit (see Figure 4.3(b)). Without considering the protective N-tosyl group, whose position is 
determined by the N1-S1-C4 angle of 105.77°, the rest of the molecule appears almost flat, 
similarly to what seen for compound 8b, and the torsion angles between the pyrazole plane and 
the p-methoxy-phenyl and acyl groups are 2.12(2)° (N18-N17-C24-C29) and 3.43(2) (C14-N17-
C24-C25) for the former, 1.27(2)° (N18-C19-C20-O21) and 3.63(2)° (C13-C19-C20-O22) for 
the latter. The distance of 2.888(1) Å between the oxygen atoms O2 and O16 is close to the sum 
of their Van der Waals radii (2.80Å). Some intermolecular hydrogen bonds involving both 
oxygen and nitrogen atoms are present and they vary between 3.047(4) Å (O16...H-C23_a) to 
3.581(3) Å (N18...H-C23_b). 
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 The compound 13a crystallizes in a chiral space group (flack parameter 0.0235) and its 
unit cell contains four molecules, one of which forms the independent unit (Figure 4.11). In the 
solid state the pyrazolic unit is not coplanar neither with the phenyl ring (torsion angles of -
52.49(20)° (N18-N19-C20-C21) and -55.07(24)° (C12-N19-C20-C25)) nor with the acyl group 
(torsion angles: -11.64(23)° (N18-C17-C26-O28) and -11.15(27)° (C13-C17-C26-O27)), most 
likely to achieve a more efficient space filling . In terms of connectivity there is an 
intramolecular Van der Waal’s distance of 2.860(2) Å between O2 and O16 and only rather weak 
intermolecular hydrogen bonds involving O and N atoms, spanning between 3.368(2) (O2...H-
C4_a) and 3.511(2) Å (O16...H-C22_b). 
 
Figure 4.11: X-ray structure of 13a (ellypsoids are at 30% probability). 
 
The crystals of 13b had a quite low diffraction power and this accounts for a high R(int) 
value. The unit cell is rather big and contains eight molecules, with just one representing the 
asymmetric unit (Figure 4.12). While the acyl group is laying on the same plane as the pyrazolic 
unit (the torsion angles are 0.43(3)° (N19-C20-C21-O22) and 4.28(3)° (C14-C20-C21-O23), the 
p-methoxy-phenyl fragment is heavily rotated, the torsion angles being 45.58(3)° (C15-N18-
C25-C30) and 50.30(3)° (N19-N18-C25-C26). As seen for the previous species, the distance of 
2.901(1) Å between the oxygen atoms O2 and O17 is close to the sum of their Van der Waal’s 
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radii. In the solid state packing there is one weak intramolecular hydrogen bond of 3.397(1) 
(O17...H-C5) and some intermolecuar ones involving the oxygen atoms, spanning from 3.204(1) 
(O17...H-C24_a) to 3.609(1) (O22...H-C9_b). 
 
Figure 4.12: X-ray structure of 13b (ellypsoids are at 30% probability). 
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Table 4.4: Summary of Crystal Data for compounds 8b, 9a’, 11a, 12b, 13a and 13b.  
Compound 
8b 
C14H12N2O5 
9a’ 
C14H12N2O4 
11a 
C14H12N2O3S 
12b 
C21H19N3O6S 
13a 
C21H19N3O5S 
13b 
C22H22N3O6S 
Fw 288.26 272.26 288.32 441.45 425.45 456.49 
T, K 296(2) 296(2) 296(2) 296(2) 296(2) 296(2) 
λ, Å 0.71073 0.71073 0.71073 0.71073 0.71073 0.71073 
Crystal system Monoclinic Monoclinic Monoclinic Triclinic Orthorhombic Orthorhombic 
Space group P21/c P21/c P21/n P−1 P212121 Pbca 
a, Å 7.8818(9) 11.041(2) 8.9718(16) 7.8255(12) 10.2328(8) 13.864(4) 
b, Å 13.6137(16) 16.332(3) 7.9815(14) 9.6341(14) 10.3945(8) 13.094(4) 
c, Å 12.1658(15) 7.3439(15) 18.569(3) 13.807(2) 18.5732(14) 23.866(7) 
α, ° 90 90 90 91.084(2) 90 90 
β, ° 93.642(2) 101.058(3) 91.571(2) 96.684(2) 90 90 
γ, ° 90 90 90 105.346(2) 90 90 
Cell Volume, Å3 1302.8(3) 1299.7(5) 1329.2(4) 995.7(3) 1975.5(3) 4332(2) 
Z 4 4 4 2 4 8 
Dc, g cm
-3 1.470 1.391 1.441 1.473 1.430 1.400 
µ, mm-1 0.114 0.104 0.252 0.209 0.204 0.194 
F(000) 600 568 600 460 888 1912 
Crystal size, mm 
0.20 x 0.18 x 
0.15 
0.40 x 0.10 x 
0.10 
0.25 x 0.20 x 
0.15 
0.25 x 0.20 x 
0.18 
0.20 x 0.18 x 
0.12 
0.25 x 0.25 x 
0.20 
θ limits, ° 2.25 to 25.00 1.88 to 24.99 2.19 to 24.99 1.49 to 25.00 2.19 to 24.99 1.71 to 25.00 
Index ranges 
−9 ≤ h ≤ 9, 
−16 ≤ k ≤ 16, 
−14 ≤ l ≤ 14 
−13 ≤ h ≤ 13, 
−19 ≤ k ≤ 19, 
−8 ≤ l ≤ 8 
−7 ≤ h ≤ 10, 
−9 ≤ k ≤ 9, 
−21 ≤ l ≤ 16 
−9 ≤ h ≤ 9, 
−11 ≤ k ≤ 11, 
−16 ≤ l ≤ 16 
−12 ≤ h ≤ 12, 
−12 ≤ k ≤ 12, 
−22 ≤ l ≤ 22 
−16 ≤ h ≤ 16, 
−15 ≤ k ≤ 15, 
−28 ≤ l ≤ 27 
Reflections collected 12252 12210 5737 9699 17973 29469 
Independent 2300 [R(int) 2284 [R(int) 2237 [R(int) 3507 [R(int) 3485 [R(int) 3822 [R(int) 
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reflections = 0.0246] = 0.0339] = 0.0297] = 0.0681] = 0.0199] = 0.3017] 
Completeness to θ = 
25.00° 
100.0 % 100.0 % 95.3 % 99.7 % 100.0 % 100.0 % 
Data / restraints / 
parameters 
2300 / 0 / 
193 
2284 / 0 / 
182 
2237 / 0 / 
183 
3507 / 0 / 
283 
3485 / 0 / 273 3822 / 0 / 293 
Goodness on fit on F2 1.051 1.026 1.032 1.034 1.050 0.982 
R1 (I > 2σ(I)) 0.0351 0.0375 0.0355 0.0570 0.0266 0.0698 
wR2 (all data) 0.1047 0.0979 0.0987 0.1424 0.0738 0.2160 
Largest diff. peak and 
hole, e Å-3 
0.178 and 
−0.141 
0.153 and 
−0.227 
0.171 and 
−0.264 
0.214 and 
−0.286 
0.147 and 
−0.298 
0.306 and 
−0.298 
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Chapter 5 
Synthesis of multifunctional Helicene-thiourea catalyst and its 
applications in asymmetric synthesis. 
 
5.1 Introduction: 
Helicenes are polycyclic aromatic compounds with nonplanar screw-shaped skeletons 
formed by ortho-fused benzene or other aromatic rings.1,2 The ﬁrst helicenes A and B (Figure 
5.1) were synthesized by Meisenheimer and Witte in 1903.3 After then little progress was made 
towards helicene synthesis. Figure 5.1 Lists some of the helicene compounds which were 
discovered before 1950. In 1950 Newmann et.al.4 synthesized [6]-helicene such as D in non-
racemic form via a Friedel-Crafts acylation and managed to resolve the resulting charge transfer 
complex. After this discovery the helicene chemistry was significantly expanded. 
 
Figure 5.1: Helicenes prepared before 1950. 
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In the 1990’s, the Diels-Alder synthetic approach after Martin’s photochemical methods 
brought another breakthrough in the preparation of helicenes on a large scale.5 Based on this 
approach, a large number of helicene derivatives were synthesized.6 Since the late 1990s, more 
and more new strategies for the synthesis of helicenes have been developed giving desired 
helicenes in good yields and enantioselectivity. Typically these methods rely on use of 
organometallic chemistry.7 
 
5.2  Helicene properties: 
The deﬁning property of a helicene is its helical structure. Because of the steric hindrance 
of the terminal rings, helicenes can fold in opposite directions and develope a C2-symmetry axis 
along the axis perpendicular to the helical axis (Figure 5.2).8 This property of helicene makes 
them chiral even though they don’t have any asymmetric carbon or chiral centre in it.  
 
Figure 5.2: Ball and stick model of helicene. 
 
As the number of fused rings increases, the helicene spirals up along the helical axis to 
form a cylindrical structure with a constant pitch (in both inner and outer helixes).1d For 
helicenes composed of six-membered aromatic rings like benzene, it takes nearly six rings to 
cover a complete 360° rotation of a screw,9a while four thiophene and three benzene units are 
required for making thiahelicenes.9b The interplanar angles (i.e. angle between) of the two 
terminal rings depend on the lengths of the helicenes and the substituents present. The 
interplanar angles of carbohelicenes increase as the helicenes are elongated from [4]-helicenes 
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(26.7˚) to [6]-helicenes (58.5˚) but decrease with further elongation.10 Thus, even compared with 
phenacenes, helicenes show a greater departure from planarity. As a result of torsional strain, the 
bond lengths in the skeleton are diﬀerent, with diﬀerent C-C bonds having features of a single 
bond or a double bond. In comparison with the bond length of benzene (1.393 Å),11 the average 
bond length of the C-C bonds in the inner helix is lengthened to about 1.430 Å while the average 
length of the ones on the periphery are shortened to about 1.360 Å.1c,d  
Based on helicity, in 1966 Cahn, Ingold and Prelog proposed a IUPAC nomenclature for 
helicenes and they are denoted as plus or minus. The plus isomer is the one in which the helical 
twist is clockwise (right handed) and can be designated as “P ” while the minus isomer is the one 
for which the helical twist is anticlockwise (left handed) and desisgnated as “M ” (Figure 5.3).12 
Furthermore, according to the results of ORD and CD spectroscopy, there is a general 
relationship between the absolute conﬁguration and the chirality: (P)-helicenes are considered as  
dextrorotatory, while (M)-helicenes are as levorotatory. 13 
 
Figure 5.3: Chirality in Helicenes. 
 
 
The racemization of helicenes is another intriguing property of these annulated systems. 
For [n]-helicenes, the free energy barriers to racemisation increase with n and with substitution at 
the inner helical sites. Thus, the free energy barriers (kcal mol-1 at 27 ˚C) for parent [n]-helicenes 
increase in the following order: 24.1 {n = 5}, 36.2 {n = 6}, 41.7 {n = 7}, 42.4 {n = 8} and 43.5 
{n = 9}. Interestingly, introducing two methyl groups at the 1,1’-positions of hexahelicenes, 
increases the half-life of racemisation (t1/2) from 13.4 minutes at 221.7 ˚C, to 444 minutes at 
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270°C. However, substitution at the 2,2’ position did not have a significant effect on 
racemisation. 
 
5.3 Helicene recent literature and synthesis: 
During the last decade, helicene chemistry has grown to become an interesting field of 
research owing to the extraordinary optical and electronic properties associated with this type 
annulated system. The annulation of [n]-helicenes affect both the optical and chiral properties of 
these materials, with larger numbers of aromatic rings (n) forming rigid structures which possess 
large barriers to racemisation, thus, enhancing chirality. There are several methods available to 
synthesize carbohelicenes. However, an ideal synthetic strategy has not been developed yet as 
existing methods are having its own limitations.  Indeed, the most commonly used method for 
helicene synthesis is oxidative photocyclisation. 
 
5.3.1 Photocyclisation: 
In 1967, Martin et.al.14a reported the ﬁrst photoinduced synthesis of heptahelicene 
(Scheme 5.1). Since then, photocyclization has become one of the most important methods for 
the synthesis of many helicene homologues (from [5]- to [14]helicene) and derivatives, because 
the stilbene-type precursors can be easily prepared by Wittig oleﬁnation and the helicenes can be 
obtained in relatively few steps.  
 
Scheme 5.1: First synthesis of heptahelicene via photocyclisation.  
 
Photocyclisation is could be carried out in an inert atmosphere or in presence of air. 
However the two reaction conditions has an effect on both the selectivity and the yield of the 
reaction. In the presence of air, oxidative photocyclisation also produces side reactions which 
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result in further degradation of the reaction product. Similarly, the reactions under inert 
conditions have some disadvantages like, 
1) A stoichiometric amount of iodine is required to affect oxidation;  
2) The by-product of this oxidation (HI) reduces double bonds in the presence of light. 
In order to overcome these disadvantages, Katz et.al.15 developed a new strategy that uses 
stoichiometric amount of iodine and excess propylene oxide to destroy reacting the acid (HI) 
formed during the course of the reaction. In this context propylene oxide prevents the formation 
of a high concentration of acid which lead to some by-products coming from elimination 
reactions of pH-sensitive secondary alcohols. This new set of reaction conditions not only 
enhances the yields greatly compared with the traditional methods for the photocyclization of 
stilbene, but also prevents photoreduction and photooxidative side reactions of the double bonds. 
Up to date this has become the standard procedure for the photocyclization of stilbenoid 
precursors. 
In 1969, in order to optimize the yields and to better direct the cyclization toward the 
desired regioisomer, Martin et.al.14b reported the concept of a ‘‘bromine auxiliary’’ for  
carbohelicene photosyntheses (Scheme 5.2). In this context, bromine substituent acts as a 
directing group for the regioselective formation of the radical species that lead to efficient 
cyclisation. 
 
Scheme 5.2: The ‘‘bromine auxiliary’’ method for controlling the regioselectivity of 
photocyclization. 
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In 2004, de Koning et.al.16 described another type of precursor for the preparation of 
[5]helicene in good yield (Scheme 5.3). The mechanism is believed to involve abstraction of one 
proton of the methyl group by t-BuOK, followed by transformation into the enolate in aldol 
reaction which then undergoes photocyclisatoin through isomerization.  
 
Scheme 5.3: Synthesis of [5]helicene reported by De Koning et.al. 
 
 
5.3.2 Diels-Alder approach: 
 The problems associated with the photooxidative strategy have led to the advancement of 
several new methodologies which provide useful alternatives for the synthesis of carbohelicenes. 
In 1990, Katz and Liu et.al.5 reported a Diels-Alder reaction approach to racemically synthesise 
[5]-helicene bis-quinone from 1,4-divinylbenzene and benzequinone (Scheme 5.4). Interestingly, 
this paper also reported an enzymatic hydrolysis which enabled the authors to obtain optically 
pure [5]-helicene bis-quinone. Moreover, the presence of four carbonyl groups in the resulting 
[5]-helicene allows for convenient functionalization of the terminal rings. 
 
Scheme 5.4: Diels-Alder approach by Katz and Liu et.al.  
 
The work carried out by Katz and co-workers in the early 1990’s enabled the large scale 
preparation of helicenes. Although their Diels Alder approach is thought of as a remarkable 
breakthrough in this field, it yielded rather inert substrates which could not be transformed into 
more useful materials. Almost immediately after publishing his ground-breaking synthesis of [5]-
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helicene, Katz and co-workers began investigating routes to more functionalised [n]-helicenes. 
Preliminary results in this area were published in 199217 and involved the reaction of 
acetophenone enol ethers with benzoquinone to yield functionalised [5]- and [6]-helicenes 
(Scheme 5.5). Following this methodology, functionalised [5]- and [7]-helicenes were also 
synthesised from enol ethers and resulted in good yields. It was observed that further 
functionalization of the aromatic portion of the enol ether resulted in erosion of yield. The 
helicene materials obtained from these reactions were resolved, thus, affording them in their non-
racemic form. 
 
Scheme 5.5: The first synthesis of functionalised [6]-helicenes. 
 
 
5.3.3 Friedel-Craft type of reactions: 
The synthesis of 1,12-dimethylbenzo[c]phanthrene and hexahelicene by double Friedel-
Crafts acylation was ﬁrst reported by Newman et.al.18 As shown in Scheme 5.6, the ketoacid 
prepared by cyclization of malonic acid derivative in the presence of anhydrous hydrogen 
ﬂuoride was reduced to the carboxylic acid and subsequent acylation was accomplished by 
stannic chloride. After the reduction of the ketone and a hydrogen transfer reaction over 
rhodium-on-alumina, the final hexahelicene was obtained in moderate yield. 
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Scheme 5.6: Work by Newman et.al. 
 
Another Friedel-Craft-type cyclisation sequence was described by Ichikawa et.al.19 
(Scheme 5.7). The presence of two ortho-methyl groups is important to facilitate the domino 
cyclization. They not only direct the reaction to form a helical structure but also enhance the 
nucleophilicity of the aromatic moieties. With the help of magic acid (FSO3H.SbF5) and 
Ph3CBF4, double ring closure and dehydrogenation proceeded eﬃciently giving 6,11-
dimethyl[6]helicene in good yield. This methodology gives direct access to tetracyclic core in 
one pot. 
 
Scheme 5.7: Friedel-Crafts-type cyclisation by Ichikawa et.al. 
 
 
5.3.4 Metal catalysed cyclisations: 
Helicenes can be synthesized by metal catalysed cyclisations. Most of the metal catalysed 
cyclisation reactions involve the use of precious metals. These includs cross-coupling reactions 
(Pd, Ru), ring-closing metathesis (Ru), [2 + 2 + 2] cycloaddition (Ru), and [2 + 2 + 2] 
cycloisomerization (Co). These cyclizations are of practical utility not only because of the small 
number of steps (building several rings in one step), relatively high yields, and good functional 
group tolerance, but also because such modular synthesis allows construction of a variety of 
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helicenes (even long helicenes). The [2 + 2 + 2] cycloisomerization, in particular, has been 
accepted as a general synthetic strategy. 
In 2006, Collins et.al.21 reported the synthesis of helicenes in 78-93% yield by the ring-
closing olefin metathesis method (Scheme 5.8). Two different routes, a and b, were utilized. 
Route a is very fast (24 min) but requires a high temperature (100°C) which can result in 
pyrolysis; route b occurs under mild conditions (40°C), accommodating the presence of sensitive 
functional groups, but requires a longer time (24 h). From readily modified 1,1 binaphthyl 
framework, this method—with good tolerance and high efficiency—was found to be a facile way 
to prepare substituted [5]-, [6]-, and [7]helicenes. 
 
Scheme 5.8: Ring closing methathesis for synthesis of helicene reported by Collins et.al. 
 
 
A novel lithium-induced cyclization of tribenzocyclyne was described by Tessier, 
Youngs et.al.22 in 1996. Gingras and Dubois have reported a synthesis of helicenes via  McMurry 
coupling.23The yields in this reactions were not promising. In 1998, they also reported a short 
and scalable approach to [5]-helicenes, which focused on the coupling of aromatic 
bis(bromomethyl) moieties in the presence of excess LiHMDS. This ‘carbenoid coupling’ 
approach to helicenes was high yielding leading to [5]-helicenes in 3 steps (Scheme 5.9). 
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Scheme 5.9: Carbenoid coupling approach to [5]-helicenes. 
 
In 2009, Sehnal et.al.24 have reported a synthesis of long helicenes by organometallic 
approach to the derivatives of undecacyclic helicene, which is based on intramolecular [2 + 2 + 
2] cycloisomerization of aromatic hexaynes under metal catalysis closing 6 new cycles of a 
helicene backbone in a single operation (Scheme 5.10).They have also developed an asymmetric 
version involving cobalt- or nickel-catalyzed cyclization to prepare the nonracemic [11]helicene-
like derivatives in good diastereomeric purity. 
 
Scheme 5.10: Synthesis of helicenes by intramolecular [2 + 2 + 2] cycloisomerisation.  
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5.4 Applications of helicenes:  
Helicenes as interesting compounds that have numerous potential applications in 
chemistry. They could be used as molecular machines like molecular ratchet,25 molecular 
springs26 and molecular switches,27 dyes etc. Recently dye sensitized solar cells (DSSCs) have 
attracted considerable attention due to their low cost processes, high performance, and ease of 
production. Gratzel and O’Regan reported the first DSSCs in 1991. Because of the high expense 
of the Ru dyes involved, several environmentally friendly, easily prepared organic donor-
acceptor π−conjugated (D−π−A) dyes have been investigated as alternatives.28 Harima and co-
workers synthesized a series of  D−π−A dyes using a heterohelicene as a building block taking 
advantage of its conjugation framework and helical backbone (Figure 5.4).29 
  
Figure 5.4: Organic D−π−A dyes. 
 
Katz et.al. described the first synthesis of two novel ladder polymers bearing 
heptahelicene connected by nickel salophen units in which the square planar geometry made the 
π-conjugation extend from the helicenes to the whole polymer.30 Recently another novel type of 
ladder polymer forming a one dimensional wire, constructed from fused benzothiophene rings 
was reported by Nishide et.al. 31 Besides the above ladder polymers which have helical skeletons 
themselves, helicene units can be introduced into macromolecules by either directly synthesizing 
helicenes or utilizing helicene monomers. Similarly helicenes are used used in molecular 
recognition techniques.32 
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5.4.1 Biological applications of helicenes: 
Telomerase inhibition has been considered as a new method of cancer therapy. Sugiyama 
and co-workers described the ﬁrst example using a bridged helicene as a chiral wedge to 
eﬀectively block the access of telomerase to telomeres by association with higher order G-
quadruplex structures.33 In 2002, Yamaguchi and co-workers ﬁrst disclosed the chiral recognition 
between the helicenediamine  H and B-DNA (Figure 5.5).34 The apparent changes in the UV and 
CD spectra caused by adding calf thymus DNA to the solutions of (P)- and (M)-730 suggested 
that DNA-helicene complexes were formed. According to isothermal titration calorimetry, the 
binding constant of (P)-helicene is slightly larger than that of its enantiomer, whereas the chiral 
recognition whereby (P)-730 favors right-handed helicity is probably driven by entropy. 
 
Figure 5.5: Helicenes used in biological applications. 
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Sugiyama et.al.35 reported that (P)-helicene I can bind Z-DNA selectively and convert B-
DNA into Z-DNA. Also recently, Latterini et.al.36 reported counterion eﬀects in the binding 
between helicenes and DNA using the same organic azahelicenium moiety J with diﬀerent 
anions (I- , NO3
-and CF3CO2
-). 
 
5.4.2:  Helicenes in asymmetric catalysis: 
As helicenes are inherently chiral compounds they can be useful in asymmetric synthesis. 
As a consequence, helical carbohelicenes of C2-symmetry were promising candidates for further 
innovations. Several features would position them favorably with a large chiral polyaromatic 
template which could favor some eﬃcient and long range chiral inductions and some secondary 
binding interactions to the substrate by π−stacking. Additionally, reactions at higher 
temperatures 
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might be possible without racemizing the helicene ligand ([6]helicenes or higher helicenes). It 
would be an advantage compared to a lower-energy thermal racemization of many binaphthyl 
ligands.37 Martin et.al. have utilized substituted [7]helicenes as chiral auxiliaries or chiral 
reagents in ﬁve diﬀerent diastereoselective reactions, including reduction of α-keto esters,38 
hydroxyamination39 and epoxidation40 of oleﬁns, synthesis of atrolactic ester,41 and the ene 
reaction42 (Figure 5.6). 
 
Figure 5.6: Use of [7]helicenes as chiral auxiliaries or chiral reagent. 
 
 
Among the first catalyzed asymmetric reactions involving a carbohelicene a catalytic 
enantioselective epoxidation of E-stilbene with the use of (P)-(+)-2-cyano-[7]helicene in the 
presence of H2O2 (92%; 99.8% ee). Similarly, α-methylstyrene afforded excellent results with (-
)-2-cyano-[7]helicene (84%; 97.6% e.e.) 40, 41 (Scheme 5.11). 
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Scheme 5.11: Highly enantioselective epoxidation of E-stilbene and styrene. 
 
There are numerous examples showing, helicenes as a chiral lingands. Until present the 
use of helicene as a organocatalyst is not extensively explored. However, a few examples were 
reported by using a series of 1-aza-helicene N-oxides as chiral organocatalysts in heterohelicene 
chemistry.42 Aza helicenes were synthesized from a Pd-catalyzed ring closure involving 
dihalogenated stilbene type substrates and (Me3Sn)2. N-oxidization with m-CPBA was achieved 
and the final helicenes were resolved by chiral HPLC. They were then tested in a catalytic 
enantioselective desymmetrization of some meso epoxides (Scheme 5.12). 
 
Scheme 5.12: Organocatalytic asymmetric desymmetrization of meso epoxides. 
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Keeping in mind the catalytic systems involving helicenes have not been explored we 
decided to synthesize the bifucntional helicene-thiourea catalysts. To the best of our knowledge 
this type of system has never been applied to any asymmetric synthesis. Recently, we reported 
the first enantioselective Michael addition of sodium bisulfite to a range of α,β-unsaturated 
systems (Scheme 5.13). Bifunctional aminothiourea derivates of cinchona alkaloids were used to 
catalyse this reaction. We found that this asymmetric reaction worked best affording products in 
excellent yields with 90-99% ee (for aromatic substrates). The mechanism of this reaction was 
investigated and we assume that the thiourea moiety is hydrogen bonded to the carbonyl group of 
the Michael adduct, thus locking it in place. We expect that the amino group belonging to the 
cinchona alkaloid also plays a key role in the reaction; activating the sodium bisulfite 
nucleophile and delivering it stereospecifically to one face of the Michael adduct. 
 
Scheme 5.13: Enantioselective Michael addition catalysed by bifunctional aminothiourea 
catalyst. 
 
We anticipate that aminothiourea derivatives of (P)- and (M)-[6]- and [7]-helicenes 
would behave in a similar manner in the organcatalytic reaction to that of aminothiourea derived 
cinchona alkaloid catalysts. The structures of our first generation helicene based aminothiourea 
catalysts are outline in Figure 5.7. The aminothiourea derivative of [6]-helicene K is based on 
the parent molecule; however, we intend to further substitute this molecule in order to enhance 
its stability. As only part of the molecule is utilized for organocatalysis the potential exist to 
further functionalise its backbone and carry out secondary and even tertiary operations there. 
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Figure 5.7: Proposed helicene-thiourea organocatalyst. 
 
The aminothiourea functionalised [6]-helicenes K-N (Figure 5.7) are also based on the 
parent molecule. Again the potential exists to further functionalise this catalyst allowing for 
stabilization or further participation of the molecule in a secondary or tertiary catalytic cycle. 
The first catalyst K which incorporates the amino functionality into the backbone of the helicene 
structure can have the potential to bind substrates in a more locked manner, therefore enhancing 
selectivity. The potential (as with any catalyst/ligand system) exists to tailor these catalysts for 
specific reactions. Due to the many available binding sites on the helicene backbone, it seems 
plausible that the catalyst can be substituted in such a manner as to stabilize the intermediates of 
certain reactions, thus, mimicking nature. 
 
 
 
 
 
150 
 
5.5 Retrosynthesis for helicene thiourea catalyst: 
 Due to structural interest, the catalyst of type L was taken in to consideration. The 
structures M and N were excluded for the convenience as the catalytic site lie on the periphery of 
helicene (3,3’ position) which can exert very little or negligible catalytic effect on the reaction in 
consideration. In case of catalyst K and L, as the catalytic site lie on the core of helicene (2,2’ 
position) they can serve as the catalyst suitable for the primary study. To start we decided to 
synthesize the catalyst of type L as it can be easily accessible. With some structural 
modifications based on commercially available starting materials we proposed following 
retrosynthetic pathway (Scheme 5.14). 
 
Scheme 5.14: Retrosynthesis for helicene-thiourea catalyst 14. 
 
 In first instance the catalyst 14 can be obtained from 2-aminohexahelicene 13. The 
Buchawald-Hartwig cross coupling reaction on triflate derivative of compound 12 with 
phthalimide followed by phthalimide deprotection of the obtained product will lead to the 
formation of the 2-aminohexahelicene 13. The phenanthrene 10 and vinyl-naphthalene 5 can be 
treated in a heck reaction to get an alkene which can be subjected to the photocyclisation to give 
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compound 12. The phenathrene 10 can be synthesized with the classical method of Wittig 
reaction between 6 and 9 followed by a simple photocyclisation reaction. Whereas the compound 
5 can be vinylated by following a sequence of reactions involving esterification of naphthoic acid 
followed by its reduction, then bromination and Wittig salt formation. The Wittig salt thus 
obtained, on treatment with paraformaldehyde will lead to formation of vinyl-naphthalene 5. 
 
5.6 Result and discussion: 
In the beginning the plan was to synthesize the helicene derivative bearing two methyl 
groups at 1,1’ positions in the inner helix of helicene (Catalyst L in Figure 5.7). Then due to 
difficulties in the synthesis of those properly substituted compounds we decided to synthesize 
compound 14 bearing only one methyl group in inner helix which is still enough to reduce the 
recemisation of helicene. 
 In the synthesis of helicene-thiourea catalyst 14 two building blocks viz. vinyl-
naphthelene 5 and phenanthrene 10 were the key intermediates. Synthesis of vinyl-naphthalene 5 
is outlined in the Scheme 5.15. The synthesis was started with the dibenzylation of 3-hydroxy-7-
methoxy-2-naphthoic acid 1.  
 
Scheme 5.15: Synthesis of 2-(benzyloxy)-6-methoxy-3-vinylnaphthalene 5. 
 
 The dibenzylation of 3-hydroxy-7-methoxy-2-naphthoic acid 1 was carried out with 
benzylbromide, potassium carbonate in dry DMF. The benzyl ester thus obtained was 
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transesterified by hydrolysis using 2M NaOH followed by the treatment with thionyl chloride in 
methanol to give methyl ester 2. The ester was then reduced using LAH in THF:toluene mixture 
to give (3-(benzyloxy)-7-methoxynaphthalen-2-yl)methanol 3 in 79% yield. The alcohol 3 was 
then brominated using phosphorus tribromide in dichloromethane to yield bromo-compound in 
90% yield which was subsequently converted to a Wittig salt 4 by treatment with triphenyl 
phosphine in toluene with the yield of 92%. The Wittig reaction between the Wittig salt 4 and 
paraformaldehyde in presence of 2M NaOH, gave vinyl-naphthalene 5 in 60% yield.  
 The other intermediate phenanthrene 10 was synthesized from 4-bromobenzaldehyde 6 
(Scheme 5.16). The 4-bromobenzaldehyde 6 was converted to (4-bromobenzyl)-bromide 7 by 
reduction using NaBH4/EtOH followed by a treatment with phosphorus tribromide in usual 
reaction conditions. The (4-bromobenzyl)-bromide 7 was then converted to a Wittig salt 8 using 
triphenylphosphine in toluene in 85% yield. The Wittig salt 8 was then treated with 4-methoxy-
2,5-dimethylbenzaldehyde in presence of 2M NaOH to give stilbene derivative 9 as a cis-trans 
isomeric mixture in the ratio 40:60 confirmed by 1HNMR. The stilbene derivative 9 thus 
obtained was subjected to the photocyclisation using I2 in cyclohexane in 40 % yield. The 
bromo,methoxy-phenanthrene was then subjected to hydrolysis using borontribromide to give 6-
bromo-1,4-dimethylphenanthren-3-ol 10.  
 
Scheme 5.16: Synthesis of phenanthrene 10. 
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During the photocyclisation step we observed the addition/reduction product as well. 
Attempts of using propylene oxide to overcome formation of side product failed and overall 
degradation of the product was observed when the reaction was kept for longer times under light 
whereas the reaction without the use of any additives gave reasonable yield (40%) under normal 
reaction conditions of photocyclisation together with addition/reduction impurity. 
After the synthesis of the two key intermediates (5 and 10) the next step was to couple 
them. They were coupled as shown in Scheme 5.17. The coupling was done in presence of 
Pd(OAc)2 / TEA / DMF at 100°C for overnight. The crude product showed the formation of the 
coupled product however the yield was very low. This step needs to be optimized. The following 
sequence is in progress.  
 
Scheme 5.17: Synthesis of helicene-thiourea catalyst 14. 
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5.7 Conclusion and future work: 
 In all until now we have developed a route towards the helicene synthesis which can be 
elaborated for synthesis of diversely substituted helicenes. The final product although not in hand 
seems to be a promising catalyst for the asymmetric reactions. The next plan will be to finish the 
synthesis and the application of this novel helicene-thiourea catalyst for the asymmetric 
reactions. The advancement will be synthetic elaboration for making rest of the model helicen-
thiourea catalyst of type K, M, N (Figure 5.7) and some more helicene-thiourea derived catalyst 
from the core of these molecules. 
 
5.8 Experimental: 
Material and Methods:  
1H NMR and 13C NMR spectra were recorded using CDCl3 or CD3OD or DMSO-d6 
solutions at 300, 400 and 600 MHz for 1H and 75.46, 100.6 and 150.92 MHz for 13C. Chemical 
shifts (δ) are reported in ppm relative to CHCl3 (δ = 7.26 for 
1H and δ = 77.0 for 13C). J values 
are given in Hz. 1H NMR and 13C NMR spectral assignments were made by DEPT, gCOSY and 
gHSQC experiments. IR spectra were recorded in solvent as specified. Mass spectra (MS) were 
obtained with an electrospray ionization source (ESIMS). All the ESIMS spectra were performed 
using MeOH as the solvent. High Resolution Mass Spectra (HRMS) were recorded on a 
micromass LCT spectrometer using electrospray (ES+) ionisation techniques. Reactions were 
conducted in oven-dried (120°C) glassware under a positive Ar atmosphere. Transfer of 
anhydrous solvents or mixtures was accomplished with oven-dried syringes/septum techniques. 
THF was distilled from sodium/benzophenone just prior to use and stored under argon. Toluene 
was distilled from sodium. Et2O was distilled from phosphorus pentoxide. CH2Cl2 was passed 
through basic alumina and distilled from CaH2 prior to use. Other solvents were purified by 
standard procedures. Light petroleum ether refers to the fraction with bp 40-60°C. The reactions 
were monitored by TLC performed on silica gel plates (Baker-flex IB2-F). Column 
chromatography was performed with Merck silica gel 60 (70-230 mesh). Preperative TLC was 
carried out on glass plates using a 1 mm layer of Merck silica gel 60 Pf 254. All chemicals were 
used as obtained or purified as needed. 
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 Methyl 3-(benzyloxy)-7-methoxy-2-naphthoate (2): To a solution of 
3-hydroxy-7-methoxy-2-naphthoic acid 1(5 g, 21.7 mmol) and K2CO3 
(9.01 g, 62.2 mmol) in dry DMF (50 mL) was added benzyl bromide 
(9.29 g, 54.3 mmol). The reaction was then stirred at 100°C overnight. After completion, water 
was added to reaction mixture and extracted with CHCl3 (2 X 50mL). The organic layer was 
then washed with water (50 mL), brine and dried in vacuo to give benzyl 3-(benzyloxy)-7-
methoxy-2-naphthoate as a gray-yellow solid. The crude product was used as it for the next 
step. Yield: 9.0 g, 98%, 1H NMR (CDCl3, 400 MHz) δ 3.91 (s, 3H), 3.97 (s, 3H), 5.26 (s, 2H), 
7.14 (d, J = 2.4 Hz, 1H), 7.20 (dd, J = 2.4 and 9.2 Hz, 1H), 7.24 (s, 1H), 7.33 (t, J = 7.44 Hz, 
1H), 7.41 (t, J = 7.8 Hz, 2H), 7.55 (d, J = 7.6 Hz, 2H), 7.63 (d, J = 8.8 Hz, 1H), 8.25 (s, 1H). 
Benzyl 3-(benzyloxy)-7-methoxy-2-naphthoate (7.65 g, 19.22 mmol) was then dissolved 
in ethanol (50 mL) and 2M NaOH (2 g, 23.1 mmol, 11.5 mL) was added to it. The reaction 
mixture was stirred at RT for 2 h. After completion, ethanol was partially evaporated at vacuo 
and was extracted with ethyl acetate (3 X 30 mL). Combined organic layer was evaporated in 
vacuo to give brown solid which was recrystallised with absolute ethanol to give 3-(benzyloxy)-
7-methoxy-2-naphthoic acid as brown needles. Yield 3.8 g, 64%. 
3-(benzyloxy)-7-methoxy-2-naphthoic acid (2.3 g, 7.46 mmol) was then suspended in dry 
methanol (20 mL) under inert atmosphere and cooled to 0 °C. The solution of thionyl chloride 
(4.45 g, 37.4 mmol) was then added dropwise and reaction was refluxed for 2-3 h. After 
completion the reaction was cooled to room temperature and the solvent was evaporated at vacuo 
to give a crude sticky yellow oil which was recrystallised from ethanol to give the final product 
methyl 3-(benzyloxy)-7-methoxy-2-naphthoate (2) as light brown needles. Yield: 1.35 g, 56%. 
1H NMR (CDCl3, 400 MHz) δ 3.91 (s, 3H), 5.26 (s, 2H), 7.14 (d, J = 2.4 Hz, 1H), 7.20 (dd, J = 
9.2 and 2.8 Hz, 1H), 7.24(s, 1H), 7.33 (t, J = 7.4 Hz, 1H), 7.42 (t, J = 7.4 Hz, 2H), 7.56 (d, J = 
7.2 Hz, 2H), 7.64 (d, J = 9.2 Hz, 1H). 
 
(3-(benzyloxy)-7-methoxynaphthalen-2-yl)methanol (3): The solution 
of methyl 3-(benzyloxy)-7-methoxy-2-naphthoate 2 (1.34 g, 4.17 mmol) 
in dry THF:toluene (20:10 mL) was cooled to 0 °C under nitrogen and 
powdered LAH (0.89 g, 23.5 mmol) was slowly added. The reaction was then heated to 100 °C 
for 3 - 4 h. After completion, reaction was cooled to 0 °C and ethyl acetate (10 mL) was added 
O
O
OBn
O
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slowly. The reaction mixture was then extracted with ethyl acetate (3 X 15 mL).  Combined 
organic layers were washed with water (20 mL) and brine. The organic layer was then 
evaporated in vacuo to give crude oil which was then purified by flash chromatography to give 
(3-(benzyloxy)-7-methoxynaphthalen-2-yl)methanol 3 as a colorless oil. Yield: 1 g, 82%, 1H 
NMR (CDCl3, 400 MHz) δ 3.91 (s, 3H), 4.87 (s, 2H), 5.21 (s, 2H), 7.12(s, 1H), 7.14 (d, J = 2.4 
Hz, 1H), 7.19 (s, 1H), 7.34 – 7.40 (m, 1H), 7.43 (td, J = 0.8 and 7.8 Hz, 2H), 7.48 (d, J = 6.8 Hz, 
2H), 7.64 (d, J = 9.2 Hz, 1H), 7.67 (s, 1H). 
 
 ((3-(benzyloxy)-6-methoxynaphthalen-2-yl)methyl)triphenyl phosphonium 
bromide (4): To the solution of (3-(benzyloxy)-7-methoxynaphthalen-2-
yl)methanol 3 (1 g, 3.40 mmol) in DCM (10 mL) was added slowly a solution of 
PBr3 (2.85 g in 2 mL DCM) at 0 °C and reaction was left for stirring at 0 °C for 
2 h. After completion reaction mixture was cooled to 0 °C and sat. NaHCO3 (20 
mL) was added slowly. The reaction mixture was then extracted with DCM (3X 
10 mL). Combined organic layer was washed with sat. NaHCO3, water, brine and evaporated in 
vacuo to give crude oil which on flash column chromatography gives 2-(benzyloxy)-3-
(bromomethyl)-6-methoxynaphthalene as yellow oil. Yield: 1.2, 99 %, 1H NMR (CDCl3, 400 
MHz) d 4.76 (s, 3H), 5.25 (s, 2H), 7.14 (dd, J = 2.8 and 8.8 Hz, 1H), 7.17 (s, 1H), 7.36 (t, J = 7.6 
Hz, 2H), 7.43 (t, J = 7.4 Hz, 2H), 7.57 (d, J = 7.2 Hz, 2H), 7.62 (d, J = 9.2 Hz, 1H), 7.76 (s, 1H). 
 To the clear solution of 2-(benzyloxy)-3-(bromomethyl)-6-methoxynaphthalene (1.2 g, 
3.36 mmol) in dry toluene (10 mL) was added triphenylphosphine (0.89 g, 3.4 mmol). The 
reaction was then heated overnight at 100°C. After completion the white precipitate was filtered 
and washed with cold toluene (10 mL). The white precipitate was dried under vacuo to give ((3-
(benzyloxy)-6-methoxynaphthalen-2-yl)methyl)triphenyl phosphonium bromide 4. Yield: 1.23, 
59 %. 
 
 2-(benzyloxy)-6-methoxy-3-vinylnaphthalene (5): ((3-(benzyloxy)-7-
methoxynaphthalen-2-yl)methyl)bromotriphenyl phosphorane 4 (1.23 g, 
1.89 mmol) and paraformaldehyde (0.1 g, 3.33 mmol) were suspended in 
DCM (15 mL) and to the resulting solution 50% NaOH (0.4 g, 10 mmol) was added dropwise. 
After stirring the reaction at RT for 2 h, it was extracted with DCM (3 X 10 mL). The combined 
OBn
O
PPh3
Br-
OBn
O
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organic layer was evaporated in vacuo to give a crude oil which was on purification with flash 
chromatography afforded 2-(benzyloxy)-6-methoxy-3-vinylnaphthalene 5 as a white solid. Yield 
%, 1H NMR (CDCl3, 400 MHz) d 4.10 (s, 3H), 5.25 (s, 2H), 5.65 (d, J = 12.4 Hz, 1H), 6.15 (d, J 
= 18.0 Hz, 1H), 7.25(s, 1H), 7.30 (dd, J = 2.8 and 9.2 Hz, 1H), 7.45 (t, J = 9.0 Hz, 1H), 7.52 (t, J 
= 7.8 Hz, 1H), 7.58 (t, J = 7.2 Hz, 2H), 7.64 – 7.70 (m, 3H), 7.75 (d, J = 8.8 Hz, 1H), 8.37 (s, 
1H). 
 
1-Bromo-4-(bromomethyl)benzene (7): To a solution of 4-bromobenzaldehyde 6 (1 g, 
5.46 mmol) in ethanol (10 mL) was added NaBH4 (0.32 g, 8.2 mmol) at 0 °C. After 
addition, reaction was slowly warmed and sirred at RT for 2 h. After completion, 
ethanol was evaporated at rotavapour and the residue was extracted with DCM (3 X 15 
mL). The combined organic layer was then dried in vacuo to give the 4-bromobenzyl alcohol as 
white needles. Yield: 934 mg, 92.4%, 1H NMR (CDCl3, 400 MHz) δ 4.65 (s, 2H), 7.24 (d, J = 
8.29 Hz, 2H), 7.49 (d, J = 8.24 Hz, 2H). 
 To the solution of 4-bromobenzyl alcohol (934 mg, 4.99 mmol) in DCM (5 mL) was 
added slowly a solution of PBr3 (2.70 g, 9.48 mmol, in 5 mL DCM) at 0 °C and reaction was left 
for stirring at 0 °C for 2 h. After completion reaction mixture was cooled to 0 °C and sat. 
NaHCO3 (10 mL) was added slowly. The reaction mixture was then extracted with DCM (3 X 10 
mL). Combined organic layer was washed with sat. NaHCO3, water, brine and evaporated in 
vacuo to give crude oil which was purified by  flash column chromatography to give 1-Bromo-4-
(bromomethyl)benzene 7  as a white needles. Yield: 975 mg, 78%, 1H NMR (CDCl3, 400 MHz) 
δ 4.44 (s, 2H), 7.27 (d, J = 8.40 Hz, 2H), 7.48 (d, J = 8.38 Hz, 2H). 
 
 (4-Bromobenzyl)triphenylphosphonium bromide (8): To the clear solution of 1-
Bromo-4-(bromomethyl)benzene 7 (973 mg, 0.38 mmol) in dry toluene (5 mL) was 
added triphenylphosphine (1.01g, 0.39 mmol). The reaction was then heated 
overnight at 100°C. After completion the white precipitate was filtered and washed 
with cold toluene (5 mL). The white precipitate was dried under vacuo to give (4-
Bromobenzyl)triphenylphosphonium bromide 8 as a white solid. Yield %, 1H NMR (CDCl3, 400 
MHz) d 5.59 (d, J = 15.14 Hz, 2H), 7.03 – 7.13 (m, 2H), 7-14 – 7.25 (m, 2H), 7.54 – 7.67 (m, 
6H), 7.70 – 7.86 (m, 9H). 
Br
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1-(4-Bromostyryl)-4-methoxy-2,5-dimethylbenzene (9): (4-
Bromobenzyl)triphenylphosphonium bromide 8 (749 mg, 1.46 mmol) and 
4-methoxy-2,5-dimethylbenzaldehyde (200 mg, 1.21 mmol) were 
suspended in chloroform (5 mL) and to the resulting solution 50% NaOH 
(58.5 mg, 1.46 mmol) was added dropwise. After stirring the reaction at RT for 1 - 2 h, it was 
extracted with DCM (3 X 5 mL). The combined organic layer was evaporated in vacuo to give a 
crude oil which was on purification with flash chromatography afforded 1-(4-Bromostyryl)-4-
methoxy-2,5-dimethylbenzene 9 as a white solid with 60:40 trans:cis ratio. Yield: 290 mg, 75%,  
 
6-Bromo-1,4-dimethylphenanthren-3-ol (10): The solution of Iodine (80 
mg, 0.63 mmol) and 1-(4-Bromostyryl)-4-methoxy-2,5-dimethylbenzene 9 
(100 mg, 0.31 mmol) in cyclohexane was irradiated with light for 12 h at 
RT. After completion, the solvent was evaporated in vacuo and the residue 
was directly purified by flash chromatography to give 6-bromo-3-methoxy-1,4-
dimethylphenanthrene as a white solid. Yield: 40 mg, 40 %. 
 6-bromo-3-methoxy-1,4-dimethylphenanthrene (150 mg, 0.49 mmol) was then dissolved 
in DCM (5 mL)  and a solution of BBr3 (245 mg, 0.98 mmol in DCM) was added dropwise at 0 
°C. The reaction was then stirred at RT for 1.5 h. After completion reaction mixture was cooled 
to 0 °C and cold water was slowly added. The reaction mixture was then extracted with DCM 
and evaporated in vacuo. The crude product was then purified using flash chromatography to 
give 6-bromo-1,4-dimethylphenanthren-3-ol 10 as a white solid. Yield 70 mg, 49%. 
 
2-(benzyloxy)-14-methoxy-9,12-dimethylhexahelicen-11-ol (12): To 
the solution of 2-(benzyloxy)-6-methoxy-3-vinylnaphthalene 5 (100mg, 
0.34 mmol) and 6-bromo-1,4-dimethylphenanthren-3-ol 10 (103 mg, 
0.34 mmol) in dry DMF (5 mL) under nitrogen was added triethylamine 
(52.1 mg, 0.51 mmol) followed by Pd(OAc)2 (7.6 mg, 0.034 mmol). The 
reaction was then heated at 100 °C overnight. After completion reaction was diluted with ethyl 
acetate (5 mL) and filtered through a pad of celite. The filtrate was then concentrated at vacuo to 
give crude 2-(benzyloxy)-14-methoxy-9,12-dimethylhexahelicen-11-ol 12 as a brown oil.  
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